Compositions and methods for treating cancer with anti-bcma immunotherapy

ABSTRACT

Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/888,020, filed May 29, 2020, which claims priority to U.S. Provisional Patent Application Ser. No. 62/854,574, filed on May 30, 2019, the entire contents of which are hereby incorporated by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 28, 2020, is named Sequence_Listing.txt and is 146 kilobytes in size.

FIELD OF THE DISCLOSURE

This application relates to the field of cancer, particularly to B-cell maturation antigen (BCMA) antigen binding domains and chimeric antigen receptors (CARs) containing such BCMA antigen binding domains and methods of use thereof.

BACKGROUND

Cancer is one of the most deadly threats to human health. In the U.S. alone, cancer affects nearly 1.3 million new patients each year, and is the second leading cause of death after cardiovascular disease, accounting for approximately 1 in 4 deaths. Solid tumors are responsible for most of those deaths. Although there have been significant advances in the medical treatment of certain cancers, the overall 5-year survival rate for all cancers has improved only by about 10% in the past 20 years. Cancers, or malignant tumors, metastasize and grow rapidly in an uncontrolled manner, making treatment extremely difficult.

Multiple myeloma (MM) the second most common blood cancer in the US (after non-Hodgkin's lymphoma), with overall 5-year survival rate of approximately 50%, whereas types of genetic abnormalities determine the aggressiveness of MM, and older age at diagnosis, higher disease stage, and metastatic disease are associated with lower chances for survival (www.cancer.net).

MM is a multi-organ disease. In MM, the overgrowth of plasma cells in the bone marrow results in diminished normal hematopoiesis, leading to anemia, thromvocytopenia, and susceptibility to infections. Myeloma cells promote bone resorption by osteoclasts, leading to bone pain, bone loss, osteoporosis, fractions, and elevated blood calcium. Secretion of high level monoclonal immunoglobulins by myeloma cells leads to kidney damage and impaired kidney function. In addition, fractures of the vertebrae can cause elevated pressure on the nerve routes, causing neurologic symptoms, numbness tingling, pain, muscle weakness. MM is twice as prevalent in blacks as whites, and has a slight male predominance, with the median onset age is 66 years (Landgren O et al., Leukemia; Kyle R A et al., Mayo Clin Proc. 2003). An early abnormality leading to MM, termed monoclonal gammopathy of undetermined significance (MGUS), is an asymptomatic condition present in 3%-4% of the general population, which raises the risk of developing MM later in life by 1% per year (Kyle R. A et al., N Engl J Med. 2002 346.8 (2002): 564-569; Landgren O., et al., Blood. 2009 May 28; 113(22):5412-7). An intermediate stage condition leading up to the development of MM, smoldering multiple myeloma (SMM), is associated with 10% higher risk of progression to MM (Kyle R. A et al., N Engl J Med. 356.25 (2007): 2582-2590).

First line therapies of MM include combination regiments, often a combination therapy consisting of thalidomide, bortezomib and lenalidomide, and in some cases carfilzomib, pomalidomide and panobinostat. However, each of these se medications carries a risk of toxicity. For example, in one MM study the combination of lenalidomide and dexamethasone was associated with garage 3+ toxicity in almost all patients enrolled in the study, as well as early mortality, and venous embolism (Blood 105:4050-4053, 2005). Furthermore, frail or elderly patients, may not be able to tolerate the triple regiment, bringing down the chances of successful therapy. For such patients, alternative treatment approaches are needed. In eligible patients, high dose chemotherapy in combination with autologous stem cell transplant is practiced (Attal M. et al., N Engl J Med. 1996; Child J. A. et al., N Engl J Med. 2003). In some cases, a tandem ASCT is administered, aiming to improve chances of survival (Krishnan A et al., Lancet Oncol. 2011; Fermand J et al., Hematol J. 2003; 4(Suppl 1):S59). This approach, however, is associated with additional costs, medical risks and discomfort for the patients. If patients are not eligible for ASCT, however, their chances of recovery are low under currently available treatment options.

Treatment consolidation, and management of relapsed or refractory MM involves drug combinations, such as lenalidomide, pomalidomide, cyclophosphamide, prednisolone, which carry risk of treatment-related toxicities and are not curative.

Two monoclonal antibodies, daratumumab and SAR650984, targeting the CD38 molecule, have been used in relapsed and refractory MM (Sagar Lonial et J Clin Oncol. 2015; 33 (suppl; abstr LBA8512); Plesner T, Jeckert J et al., CCR 2014, DOI: 10.1158/1078-0432.CCR-14-0695; Front Immunol. 2018; 9:1228. doi:10.3389). A monoclonal antibody elotuzumab, targeting SLAMF7 (signaling lymphocytic activation molecule F7), has shown activity in relapsed MM when given is part of combination therapy (Lonial S, et al., N Engl J Med. 2015). However, better treatment options are necessary to improve success rate for relapsed or refractory disease, for the treatment of elderly of frail patients, and as an alternative to the currently accepted first-line therapies, in order to reduce side effects and improve efficacy.

B-cell maturation antigen (BCMA, CD269, TNFRSF17) is a marker of MM cells, and is expressed on early 100% MM tumor cells, while normal tissue expression is restricted to plasma cells and a subset of mature B-cells (Avery D T et al., J Clin Invest. 2003, 112(2)). In addition to MM, BCMA is expressed on a subset of lymphoma clinical samples, and in many lymphoma cell lines, including Raji Non-Hodgkin's lymphoma line (Thompson J S et al., Exp Med. 2000 Jul. 3; 192(1):129-35.; Rennert P et al., J Exp Med. 2000 Dec. 4; 192(11):1677-84).

CAR approaches targeting BCMA are superior to small molecule combination therapy because they may achieve better efficacy in eliminating BCMA-positive tumor cells and tumor stem cells, and because they avoid the toxicities associated with combination therapy. In addition, CAR T treatment may obviate the need for hematopoetic stem cell transplant, or a tandem transplant an and improve treatment's long-term tolerability, efficacy and survival.

Fully-human BCMA CARs represent an improvement over prior art because unique human ScFv sequences are used in the CAR design, as opposed to murine-derived ScFvs employed in CAR design elsewhere. Mouse-derived sequences carry the risk of immunogenicity, and may induce allergic or anaphylactic responses in patients, leading to CAR T elimination, or life-threatening anaphylaxis.

Chimeric Antigen Receptors (CARs) are hybrid molecules comprising three essential units: (1) an extracellular antigen-binding motif, (2) linking/transmembrane motifs, and (3) intracellular T-cell signaling motifs (Long A H, Haso W M, Orentas R J. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology. 2013; 2 (4):e23621). The antigen-binding motif of a CAR is commonly fashioned after an single chain Fragment variable (ScFv), the minimal binding domain of an immunoglobulin (Ig) molecule. Alternate antigen-binding motifs, such as receptor ligands (i.e., IL-13 has been engineered to bind tumor expressed IL-13 receptor), intact immune receptors, library-derived peptides, and innate immune system effector molecules (such as NKG2D) also have been engineered. Alternate cell targets for CAR expression (such as NK or gamma-delta T cells) are also under development (Brown C E et al. Clin Cancer Res. 2012; 18(8):2199-209; Lehner M et al. PLoS One. 2012; 7 (2):e31210). There remains significant work with regard to defining the most active T-cell population to transduce with CAR vectors, determining the optimal culture and expansion techniques, and defining the molecular details of the CAR protein structure itself.

The linking motifs of a CAR can be a relatively stable structural domain, such as the constant domain of IgG, or designed to be an extended flexible linker. Structural motifs, such as those derived from IgG constant domains, can be used to extend the ScFv binding domain away from the T-cell plasma membrane surface. This may be important for some tumor targets where the binding domain is particularly close to the tumor cell surface membrane (such as for the disialoganglioside GD2; Orentas et al., unpublished observations). To date, the signaling motifs used in CARs always include the CD3-ζ chain because this core motif is the key signal for T cell activation. The first reported second-generation CARs featured CD28 signaling domains and the CD28 transmembrane sequence. This motif was used in third-generation CARs containing CD137 (4-1BB) signaling motifs as well (Zhao Y et al. J Immunol. 2009; 183 (9): 5563-74). With the advent of new technology, the activation of T cells with beads linked to anti-CD3 and anti-CD28 antibody, and the presence of the canonical “signal 2” from CD28 was no longer required to be encoded by the CAR itself. Using bead activation, third-generation vectors were found to be not superior to second-generation vectors in in vitro assays, and they provided no clear benefit over second-generation vectors in mouse models of leukemia (Haso W, Lee D W, Shah N N, Stetler-Stevenson M, Yuan C M, Pastan I H, Dimitrov D S, Morgan R A, FitzGerald D J, Barrett D M, Wayne A S, Mackall C L, Orentas R J. Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia, Blood. 2013; 121 (7):1165-74; Kochenderfer J N et al. Blood. 2012; 119 (12):2709-20). This is borne out by the clinical success of CD19-specific CARS that are in a second generation CD28/CD3-ζ (Lee D W et al. American Society of Hematology Annual Meeting. New Orleans, La.; Dec. 7-10, 2013) and a CD137/CD3-ζ signaling format (Porter D L et al. N Engl J Med. 2011; 365 (8): 725-33). In addition to CD137, other tumor necrosis factor receptor superfamily members such as OX40 also are able to provide important persistence signals in CAR-transduced T cells (Yvon E et al. Clin Cancer Res. 2009; 15(18):5852-60). Equally important are the culture conditions under which the CAR T-cell populations were cultured.

Current challenges in the more widespread and effective adaptation of CAR therapy for cancer relate to a paucity of compelling targets. Creating binders to cell surface antigens is now readily achievable, but discovering a cell surface antigen that is specific for tumor while sparing normal tissues remains a formidable challenge. One potential way to imbue greater target cell specificity to CAR-expressing T cells is to use combinatorial CAR approaches. In one system, the CD3-ζ and CD28 signal units are split between two different CAR constructs expressed in the same cell; in another, two CARs are expressed in the same T cell, but one has a lower affinity and thus requires the alternate CAR to be engaged first for full activity of the second (Lanitis E et al. Cancer Immunol Res. 2013; 1(1):43-53; Kloss C C et al. Nat Biotechnol. 2013; 31(1):71-5). A second challenge for the generation of a single ScFv-based CAR as an immunotherapeutic agent is tumor cell heterogeneity. At least one group has developed a CAR strategy for glioblastoma whereby the effector cell population targets multiple antigens (HER2, IL-13Ra, EphA2) at the same time in the hope of avoiding the outgrowth of target antigen-negative populations. (Hegde M et al. Mol Ther. 2013; 21(11):2087-101).

T-cell-based immunotherapy has become a new frontier in synthetic biology; multiple promoters and gene products are envisioned to steer these highly potent cells to the tumor microenvironment, where T cells can both evade negative regulatory signals and mediate effective tumor killing. The elimination of unwanted T cells through the drug-induced dimerization of inducible caspase 9 constructs with AP1903 demonstrates one way in which a powerful switch that can control T-cell populations can be initiated pharmacologically (Di Stasi A et al. N Engl J Med. 2011; 365(18):1673-83). The creation of effector T-cell populations that are immune to the negative regulatory effects of transforming growth factor-β by the expression of a decoy receptor further demonstrates that degree to which effector T cells can be engineered for optimal anti-tumor activity (Foster A E et al. J Immunother. 2008; 31(5):500-5). Thus, while it appears that CARs can trigger T-cell activation in a manner similar to an endogenous T-cell receptor, a major impediment to the clinical application of this technology to date has been limited in vivo expansion of CAR+ T cells, rapid disappearance of the cells after infusion, and disappointing clinical activity. Accordingly, there is an urgent and long felt need in the art for discovering novel compositions and methods for treatment of MM using an approach that can exhibit specific and efficacious anti-tumor effect without the aforementioned short comings.

The present invention addresses these needs by providing CAR compositions and therapeutic methods that can be used to treat BCMA-positive cancers and other diseases and/or conditions. In particular, the present invention as disclosed and described herein provides CARs that may be used the treatment of BCMA-positive cancers, and which CARs contain BCMA antigen binding domains that exhibit a high surface expression on transduced T cells, exhibit a high degree of cytolysis and transduced T cell in vivo expansion and persistence.

SUMMARY

Novel anti-BCMA antibodies or antigen binding domains thereof and chimeric antigen receptors (CARs) that contain such BCMA antigen binding domains are provided herein, as well as host cells (e.g., T cells) expressing the receptors, and nucleic acid molecules encoding the receptors. CAR may consist either of a single molecule expressed on the effector cell surface, or a CAR comprised of an effector cell-expressed signaling module and a soluble targeting module, such as when the soluble targeting module binds to the cell-expressed signaling module, a complete functional CAR is formed. The CARs exhibit a high surface expression on transduced T cells, with a high degree of cytolysis and transduced T cell expansion and persistence in vivo. Methods of using the disclosed CARs, host cells, and nucleic acid molecules are also provided, for example, to treat a cancer in a subject.

Thus, in one aspect, an isolated polynucleotide encoding a human anti-BCMA antibody or a fragment thereof is provided comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 23, 25, 69, 71, 73, 75, and 77.

In one embodiment, an isolated polynucleotide encoding a fully human anti-BCMA antibody or a fragment thereof is provided, wherein the antibody or a fragment thereof comprises a fragment selected from the group consisting of an Fab fragment, an F(ab′)₂ fragment, an Fv fragment, and a single chain Fv (ScFv).

In one embodiment, an isolated polynucleotide encoding a fully human anti-BCMA antibody or a fragment thereof is provided, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78.

In one aspect, an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) is provided comprising, from N-terminus to C-terminus, at least one BCMA antigen binding domain encoded by a nucleotide sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 23, 25, 69, 71, 73, 75, and 77, at least one transmembrane domain, and at least one intracellular signaling domain.

In one embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded extracellular BCMA antigen binding domain comprises at least one single chain variable fragment of an antibody that binds to BCMA.

In another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded extracellular BCMA antigen binding domain comprises at least one heavy chain variable region of an antibody that binds to BCMA.

In another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded extracellular BCMA antigen binding domain comprises an ScFv.

In one embodiment, the targeting domain of the CAR is expressed separately in the form of monoclonal antibody, ScFv Fab, Fab′2 and is containing an antigen-targeting domain comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 23, 25, 69, 71, 73, 75, and 77, coupled to an additional binding tag or epitope, whereas the effector-cell expressed component of the CAR contains a binding domain specifically directed to bind the tag or epitope expressed on the soluble CAR module, such as specific binding on the soluble component of the CAR to the cell bound component of the CAR forms the full functional CAR structure.

In another embodiment, the targeting domain of the CAR is expressed separately in the form of a monoclonal antibody, ScFv Fab, Fab′2 and contains an antigen-targeting domain comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 23, 25, 69, 71, 73, 75, and 77, and an additional ScFv, whereas the effector-cell expressed component of the CAR contains a tag or epitope specifically reactive with the additional ScFv expressed on the soluble CAR module, such as specific binding on the soluble component of the CAR to the cell bound component of the CAR forms the full functional CAR structure.

In yet another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded CAR extracellular BCMA antigen binding domain further comprises at least one lipocalin-based antigen binding antigen (anticalins) that binds to BCMA.

In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA antigen binding domain is connected to the transmembrane domain by a linker domain.

In another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded BCMA extracellular antigen binding domain is preceded by a sequence encoding a leader or signal peptide.

In yet another embodiment, an isolated nucleic acid molecule encoding the CAR is provided comprising at least one BCMA antigen binding domain encoded by a nucleotide sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 23, 25, 69, 71, 73, 75, and 77, and wherein the CAR additionally encodes an extracellular antigen binding domain targets an antigen that includes, but is not limited to, CD19, CD20, CD22, ROR1, mesothelin, CD33, CD38, CD123 (IL3RA), CD138, GPC2, GPC3, FGFR4, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, NY-ESO-1 TCR, MAGE A3 TCR, or any combination thereof.

In certain embodiments, an isolated nucleic acid molecule encoding the CAR is provided wherein the additionally encoded extracellular antigen binding domain comprises an anti-CD19 ScFv antigen binding domain, an anti-CD20 ScFv antigen binding domain, an anti-CD22 ScFv antigen binding domain, an anti-ROR1 ScFv antigen binding domain, an anti-mesothelin ScFv antigen binding domain, an anti-CD33 ScFv antigen binding domain, an anti-CD38 ScFv antigen binding domain, an anti-CD123 (IL3RA) ScFv antigen binding domain, an anti-CD138 ScFv antigen binding domain, an anti-GPC2 ScFv antigen binding domain, an anti-GPC3 ScFv antigen binding domain, an anti-FGFR4 ScFv antigen binding domain, an anti-c-Met ScFv antigen binding domain, an anti-PMSA ScFv antigen binding domain, an anti-glycolipid F77 ScFv antigen binding domain, an anti-EGFRvIII ScFv antigen binding domain, an anti-GD-2 ScFv antigen binding domain, an anti-NY-ESO-1 TCR ScFv antigen binding domain, an anti-MAGE A3 TCR ScFv antigen binding domain, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, or any combination thereof.

In one aspect, the CARs provided herein further comprise a linker or spacer domain.

In one embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the extracellular BCMA antigen binding domain, the intracellular signaling domain, or both are connected to the transmembrane domain by a linker or spacer domain.

In one embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded linker domain is derived from the extracellular domain of CD8 or CD28, and is linked to a transmembrane domain.

In another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded CAR further comprises a transmembrane domain that comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or a combination thereof.

In yet another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded intracellular signaling domain further comprises a CD3 zeta intracellular domain.

In one embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded intracellular signaling domain is arranged on a C-terminal side relative to the CD3 zeta intracellular domain.

In another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded at least one intracellular signaling domain comprises a costimulatory domain, a primary signaling domain, or a combination thereof.

In further embodiments, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded at least one costimulatory domain comprises a functional signaling domain of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or a combination thereof.

In one embodiment, an isolated nucleic acid molecule encoding the CAR is provided that further contains a leader sequence or signal peptide wherein the leader or signal peptide nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 13, SEQ ID NO: 39, SEQ ID NO: 41, or SEQ ID NO: 43.

In yet another embodiment, an isolated nucleic acid molecule encoding the CAR is provided wherein the encoded leader sequence comprises the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 40, SEQ ID NO: 42, or SEQ ID NO: 44.

In one aspect, a chimeric antigen receptor (CAR) is provided herein comprising, from N-terminus to C-terminus, at least one BCMA antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling domain.

In one embodiment, a CAR is provided wherein the extracellular BCMA antigen binding domain comprises at least one single chain variable fragment of an antibody that binds to the antigen, or at least one heavy chain variable region of an antibody that binds to the antigen, or a combination thereof.

In another embodiment, a CAR is provided wherein the at least one transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or a combination thereof.

In some embodiments, the CAR is provided wherein CAR additionally encodes an extracellular antigen binding domain comprising CD19, CD20, CD22, ROR1, mesothelin, CD33, CD38, CD123 (IL3RA), CD138, GPC2, GPC3, FGFR4, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, NY-ESO-1 TCR, MAGE A3 TCR, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, or any combination thereof.

In one embodiment, the CAR is provided wherein the extracellular antigen binding domain additionally comprises an anti-CD19 ScFv antigen binding domain, an anti-CD20 ScFv antigen binding domain, an anti-CD22 ScFv antigen binding domain, an anti-ROR1 ScFv antigen binding domain, an anti-mesothelin ScFv antigen binding domain, an anti-CD33 ScFv antigen binding domain, an anti-CD38 ScFv antigen binding domain, an anti-CD123 (IL3RA) ScFv antigen binding domain, an anti-CD138 ScFv antigen binding domain, an anti-GPC2 ScFv antigen binding domain, an anti-GPC3 ScFv antigen binding domain, an anti-FGFR4 ScFv antigen binding domain, an anti-c-Met ScFv antigen binding domain, an anti-PMSA ScFv antigen binding domain, an anti-glycolipid F77 ScFv antigen binding domain, an anti-EGFRvIII ScFv antigen binding domain, an anti-GD-2 ScFv antigen binding domain, an anti-NY-ESo-1 TCR ScFv antigen binding domain, an anti-MAGE A3 TCR ScFv antigen binding domain, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, or any combination thereof.

In another embodiment, the CAR is provided wherein the extracellular antigen binding domain additionally comprises an immunoglobulin variable heavy chain only (VH) anti-CD19 antigen binding domain, an anti-CD20 VH antigen binding domain, an anti-CD22 VH antigen binding domain, an anti-ROR1 VH antigen binding domain, an anti-mesothelin VH antigen binding domain, an anti-CD33 VH antigen binding domain, an anti-CD38 VH antigen binding domain, an anti-CD123 (IL3RA) VH antigen binding domain, an anti-CD138 VH antigen binding domain, an anti-GPC2 VH antigen binding domain, an anti-GPC3 VH antigen binding domain, an anti-FGFR4 VH antigen binding domain, an anti-c-Met VH antigen binding domain, an anti-PMSA VH antigen binding domain, an anti-glycolipid F77 VH antigen binding domain, an anti-EGFRvIII VH antigen binding domain, an anti-GD-2 VH antigen binding domain, an anti-NY-ESO-1 TCR VH antigen binding domain, an anti-MAGE A3 TCR VH antigen binding domain, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, or any combination thereof.

In another embodiment, the CAR is provided wherein the extracellular antigen binding domain additionally comprises a protein or a peptide (P) sequence capable of specifically binding target antigen, which may be derived from a natural or a synthetic sequence comprising anti-CD19 P antigen binding domain, an anti-CD20 P antigen binding domain, an anti-CD22 P antigen binding domain, an anti-ROR1 P antigen binding domain, an anti-mesothelin P antigen binding domain, an anti-CD33 P antigen binding domain, an anti-CD38 P antigen binding domain, an anti-CD123 (IL3RA) P antigen binding domain, an anti-CD138 P antigen binding domain, an anti-BCMA (CD269) P antigen binding domain, an anti-GPC2 P antigen binding domain, an anti-GPC3 P antigen binding domain, an anti-FGFR4 P antigen binding domain, an anti-c-Met P antigen binding domain, an anti-PMSA P antigen binding domain, an anti-glycolipid F77 P antigen binding domain, an anti-EGFRvIII P antigen binding domain, an anti-GD-2 P antigen binding domain, an anti-NY-ESO-1 TCR P antigen binding domain, an anti-MAGE A3 TCR P antigen binding domain, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, or any combination thereof. In another embodiment, a CAR is provided wherein the at least one intracellular signaling domain comprises a costimulatory domain and a primary signaling domain.

In yet another embodiment, a CAR is provided wherein the at least one intracellular signaling domain comprises a costimulatory domain comprising a functional signaling domain of a protein selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or a combination thereof.

In one embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 87. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 88.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 89. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 90.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 91. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 92.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 93. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 94.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 95. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 96.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 97. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 98.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 99. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 100.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 101. In one embodiment, the nucleic acid sequence encodes a CAR comprising the amino acid sequence of SEQ ID NO: 102.

In one aspect, the CARs disclosed herein are modified to express or contain a detectable marker for use in diagnosis, monitoring, and/or predicting the treatment outcome such as progression free survival of cancer patients or for monitoring the progress of such treatment.

In one embodiment, the nucleic acid molecule encoding the disclosed CARS can be contained in a vector, such as a viral vector. The vector is a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpes virus vector, a measles virus vector, a lentivirus vector, adenoviral vector, or a retrovirus vector, or a combination thereof.

In certain embodiments, the vector further comprises a promoter wherein the promoter is an inducible promoter, a tissue specific promoter, a constitutive promoter, a suicide promoter or any combination thereof.

In yet another embodiment, the vector expressing the CAR can be further modified to include one or more operative elements to control the expression of CAR T cells, or to eliminate CAR-T cells by virtue of a suicide switch. The suicide switch can include, for example, an apoptosis inducing signaling cascade or a drug that induces cell death. In a preferred embodiment, the vector expressing the CAR can be further modified to express an enzyme such thymidine kinase (TK) or cytosine deaminase (CD).

In another aspect, host cells including the nucleic acid molecule encoding the CAR are also provided. In some embodiments, the host cell is a T cell, such as a primary T cell obtained from a subject. In one embodiment, the host cell is a CD8+ T cell.

In yet another aspect, a pharmaceutical composition is provided comprising an anti-tumor effective amount of a population of human T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one extracellular antigen binding domain comprising a BCMA antigen binding domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78; at least one linker domain; at least one transmembrane domain; and at least one intracellular signaling domain, wherein the T cells are T cells of a human having a cancer. The cancer includes, inter alia, a hematological cancer such as leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML), lymphoma (e.g., mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma) or multiple myeloma, or a combination thereof.

In one embodiment, a pharmaceutical composition is provided wherein the at least one transmembrane domain of the CAR contains a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, Mesothelin, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or a combination thereof.

In another embodiment, a pharmaceutical composition is provided wherein the human cancer includes an adult carcinoma comprising oral and pharynx cancer (tongue, mouth, pharynx, head and neck), digestive system cancers (esophagus, stomach, small intestine, colon, rectum, anus, liver, interhepatic bile duct, gallbladder, pancreas), respiratory system cancers (larynx, lung and bronchus), bones and joint cancers, soft tissue cancers, skin cancers (melanoma, basal and squamous cell carcinoma), pediatric tumors (neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma), tumors of the central nervous system (brain, astrocytoma, glioblastoma, glioma), and cancers of the breast, the genital system (uterine cervix, uterine corpus, ovary, vulva, vagina, prostate, testis, penis, endometrium), the urinary system (urinary bladder, kidney and renal pelvis, ureter), the eye and orbit, the endocrine system (thyroid), and the brain and other nervous system, or any combination thereof.

In yet another embodiment, a pharmaceutical composition is provided comprising an anti-tumor effective amount of a population of human T cells of a human having a cancer wherein the cancer is a refractory cancer non-responsive to one or more chemotherapeutic agents. The cancer includes hematopoietic cancer, myelodysplastic syndrome pancreatic cancer, head and neck cancer, cutaneous tumors, minimal residual disease (MRD) in multiple myeloma (MM), smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), adult and pediatric hematologic malignancies, including acute lymphoblastic leukemia (ALL), CLL (Chronic lymphocytic leukemia), non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Hodgkin's lymphoma (HL). chronic myelogenous leukemia (CML), lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, melanoma or other hematological cancer and solid tumors, or any combination thereof.

In another aspect, methods of making CAR-containing T cells (hereinafter “CAR-T cells”) are provided. The methods include transducing a T cell with a vector or nucleic acid molecule encoding a disclosed CAR that specifically binds BCMA, thereby making the CAR-T cell.

In yet another aspect, a method of generating a population of RNA-engineered cells is provided that comprises introducing an in vitro transcribed RNA or synthetic RNA of a nucleic acid molecule encoding a disclosed CAR into a cell of a subject, thereby generating a CAR cell.

In yet another aspect, a method for diagnosing a disease, disorder or condition associated with the expression of BCMA on a cell, is provided comprising a) contacting the cell with a human anti-BCMA antibody or fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78; and b) detecting the presence of BCMA wherein the presence of BCMA diagnoses for the disease, disorder or condition associated with the expression of BCMA.

In one embodiment, the disease, disorder or condition associated with the expression of BCMA is cancer including hematopoietic cancer, myelodysplastic syndrome pancreatic cancer, head and neck cancer, cutaneous tumors, minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adult B cell malignancies including, CLL (chronic lymphocytic leukemia), CML (chronic myelogenous leukemia), non-Hodgkin's lymphoma (NHL), pediatric B cell malignancies (including B lineage ALL (acute lymphocytic leukemia)), multiple myeloma lung cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, melanoma or other hematological cancer and solid tumors, or any combination thereof.

In another embodiment, a method of diagnosing, prognosing, or determining risk of a BCMA-related disease in a mammal, is provided comprising detecting the expression of BCMA in a sample derived from the mammal comprising: a) contacting the sample with a human anti-BCMA antibody or fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78; and b) detecting the presence of BCMA wherein the presence of BCMA diagnoses for a BCMA-related disease in the mammal.

In another embodiment, a method of inhibiting BCMA-dependent T cell inhibition, is provided comprising contacting a cell with a human anti-BCMA antibody or fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78. In one embodiment, the cell is selected from the group consisting of a BCMA-expressing tumor cell, a tumor-associated macrophage, and any combination thereof.

In another embodiment, a method of blocking T-cell inhibition mediated by a BCMA-expressing cell and altering the tumor microenvironment to inhibit tumor growth in a mammal, is provided comprising administering to the mammal an effective amount of a composition comprising an isolated anti-BCMA antibody or fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78. In one embodiment, the cell is selected from the group consisting of a BCMA-expressing tumor cell, a tumor-associated macrophage, and any combination thereof.

In another embodiment, a method of inhibiting, suppressing or preventing immunosuppression of an anti-tumor or anti-cancer immune response in a mammal, is provided comprising administering to the mammal an effective amount of a composition comprising an isolated anti-BCMA antibody or fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78. In one embodiment, the antibody or fragment thereof inhibits the interaction between a first cell with a T cell, wherein the first cell is selected from the group consisting of a BCMA-expressing tumor cell, a tumor-associated macrophage, and any combination thereof.

In another aspect, a method is provided for inducing an anti-tumor immunity in a mammal comprising administering to the mammal a therapeutically effective amount of a T cell transduced with vector or nucleic acid molecule encoding a disclosed CAR.

In another embodiment, a method of treating or preventing cancer in a mammal is provided comprising administering to the mammal one or more of the disclosed CARs, in an amount effective to treat or prevent cancer in the mammal. The method includes administering to the subject a therapeutically effective amount of host cells expressing a disclosed CAR that specifically binds BCMA and/or one or more of the aforementioned antigens, under conditions sufficient to form an immune complex of the antigen binding domain on the CAR and the extracellular domain of BCMA and/or one or more of the aforementioned antigens in the subject.

In yet another embodiment, a method is provided for treating a mammal having a disease, disorder or condition associated with an elevated expression of a tumor antigen, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR includes at least one extracellular BCMA antigen binding domain comprising the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78, or any combination thereof, at least one linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain, and wherein the T cells are T cells of the subject having cancer.

In yet another embodiment, a method is provided for treating cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one BCMA antigen binding domain comprising the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78, or any combination thereof, at least one linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain, wherein the T cells are T cells of the subject having cancer. In some embodiments of the aforementioned methods, the at least one transmembrane domain comprises a transmembrane the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, Mesothelin, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or a combination thereof.

In yet another embodiment, a method is provided for generating a persisting population of genetically engineered T cells in a human diagnosed with cancer. In one embodiment, the method comprises administering to a human a T cell genetically engineered to express a CAR wherein the CAR comprises at least one BCMA antigen binding domain comprising the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24, 26, 70, 72, 74, 76, and 78, or any combination thereof; at least one transmembrane domain; and at least one intracellular signaling domain wherein the persisting population of genetically engineered T cells, or the population of progeny of the T cells, persists in the human for at least one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration.

In one embodiment, the progeny T cells in the human comprise a memory T cell. In another embodiment, the T cell is an autologous T cell.

In all of the aspects and embodiments of methods described herein, any of the aforementioned cancers, diseases, disorders or conditions associated with an elevated expression of a tumor antigen that may be treated or prevented or ameliorated using one or more of the CARs disclosed herein,

In yet another aspect, a kit is provided for making a chimeric antigen receptor T-cell as described supra or for preventing, treating, or ameliorating any of the cancers, diseases, disorders or conditions associated with an elevated expression of a tumor antigen in a subject as described supra, comprising a container comprising any one of the nucleic acid molecules, vectors, host cells, or compositions disclosed supra or any combination thereof, and instructions for using the kit.

It will be understood that the CARs, host cells, nucleic acids, and methods are useful beyond the specific aspects and embodiments that are described in detail herein. The foregoing features and advantages of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the construction of CARs targeting BCMA. The anti-BCMA ScFv targeting domain was linked in frame to CD8 hinge and transmembrane domain, the 4-1BB (CD137) signaling domain and the CD3 zeta signaling domain.

FIG. 2 depicts surface expression of BCMA-targeting CAR T constructs on human primary T cells. CAR T expression was determined by flow cytometry. T cells were activated with Miltenyi Biotec TransAct™ CD3 CD28 reagent in the presence of IL-2, and transduced with LV as described in Materials and Methods. On culture day 8, viable transduced T cells (7-AAD negative) were assayed for CAR surface expression using the Protein L method (top panel) or the BCMA-Fc method (bottom panel). The CAR construct identifier (ScFv number) used in each transduction is listed above each figure. Bars represent the percentage of CAR T-positive populations in relation to non-transduced T cell control (UTD).

FIGS. 3A-C depict CAR T cytotoxicity in vitro. CARs are designated by their ScFv number, preceded by a prefix “BCMA”. Luciferase-based cytotoxicity assays were performed using, BCMA-positive tumor lines RPMI-8226 (FIG. 3A), and MM1.S (FIG. 3B), or BCMA-negative cell line 293T (FIG. 3C), stably transduced with firefly luciferase. Bars represent mean+SD values from three technical replicates.

FIGS. 4A-B depict surface expression of BCMA-targeting CAR T constructs on human primary T cells. T cells were isolated form a buffy coat via CD4+ CD8+ positive selection using Miltenyi cell isolation reagents. CAR T expression was determined by flow cytometry. T cells were activated with Miltenyi Biotec TransAct™ CD3 CD28 reagent in the presence of IL-2, and transduced with LV as described in Materials and Methods. On culture day 8, viable transduced T cells (7-AAD negative) were assayed for CAR surface expression using the BCMA-Fc method. CAR construct number is listed to the left of each figure. Expression of CAR T in CD8−(CD4+) and CD8+ cell population is shown in the left column (FIG. 4A), and the total CAR expression is shown in the histogram on the right (FIG. 4B). Bars on the right represent the percentage of CAR T-positive populations in relation to non-transduced T cell control (UTD, not shown).

FIGS. 5A-B depict the cytotoxicity of anti-BCMA CARs D0084, D0085, D0086, D0087, D0099, D0100 in vitro, in two separate donors. Luciferase-based cytotoxicity assays were performed using BCMA-positive tumor lines RPMI-8226, and MM1.S, or BCMA-negative cell line 293T, stably transduced with firefly luciferase. Bars represent mean+SD values from three technical replicates.

FIGS. 6A-G depict the superior functionality of the D100 BCMA CAR in comparison to the D085 BCMA CAR in a long-term in vitro co-incubation assay. (FIG. 6A) The structure of the BCMA CARs D100 and D085 includes an scFv CAR targeting domain linked to the CD8 extracellular and transmembrane domains, followed by the 4-1BB co-stimulatory molecule and the CD3 domain. (FIG. 6B) T-cells were transduced at various MOIs with lentiviral vectors harboring either the D100 or the D085 BCMA CAR constructs, and the cell surface expression of the CARs was assessed by flow cytometry. (FIG. 6C) In the long-term co-culture experiment, CAR T-cells were co-incubated with the target multiple myeloma cell line, MM1.S tagged with GFP, at an ETT ratio of 0.1. The co-culture was repeated for four rounds in the span of 20 days. The absolute counts of (FIG. 6D) T-cells and (FIG. 6E) target cells were assessed by flow cytometry at different time points during the four rounds of co-culture by quantifying the number of CD3+ cells and GFP+ cells, respectively. The absolute counts were determined by using CountBright Absolute Counting Beads. (FIG. 6F) The changes in the percentages of CAR+CD4+ and CD8+ at various timepoints during the long term co-culture were assessed by flow cytometry. (FIG. 6F) The production of IL-2, TNFα, and IFNγ in CD3+ cells was determined by intracellular staining and flow cytometric analysis on day 11 during the third round of co-culture (FIG. 6G).

FIGS. 7A-C depict in vivo evaluation of BCMA-targeting CAR Constructs. (FIG. 7A) Eight millions of RPMI-8226 cells were intradermally injected on the abdomen of NSG mice (all groups n=8, except untreated, n=5) and allowed to engraft for 17 days before the intravenous injection of five million/mouse CAR T-cells. The number of CAR T-cells that was infused was normalized based on CAR expression levels. On day 6, after T-cell infusion, 3 mice from each group were sacrificed for tumor harvest while the rest of the mice were monitored for (FIG. 7B) tumor growth and (FIG. 7C) survival.

FIGS. 8A-D depict in vitro characterization of CAR D153, incorporating the scFv sequence 4-1c. The scFv 4-1c was cloned into a CAR backbone comprised of CD8 extracellular and transmembrane domains, 4-1BB co-stimulatory domain, and CD3 activating domain, identical to that used in CARD100 and D085, as shown in FIG. 6A. (FIG. 8A) Lentiviral transduction efficiency of CAR D153, D100 and D085 in primary human T cells was measured by flow cytometry. (FIG. 8B) The cytotoxicity of anti-BCMA CARs D153, D100, D085, or non-transduced UTD control T cells in vitro. Luciferase-based cytotoxicity assays were performed using BCMA-positive tumor lines RPMI-8226, and MM1.S, stably transduced with firefly luciferase. (FIG. 8C). In vivo evaluation of BCMA-targeting CAR D153 as compared to BCMA CAR D100 in RPMI-8226 intradermal NSG xenograft model. (n=5) (FIG. 8D). Tumors were established for 17 days following intradermal injection of eight million RPMI-8226 cells per mouse. Tumor-bearing mice were distributed to groups with equal mean tumor volumes. Five million CAR T cells or UTD control were injected i.v., and tumor volume was recorded three times a week up to study day 40. Untreated—tumor only control.

FIGS. 9A-E depict the resistance to immunosuppressive TGF effects exhibited by the armored BCMA CAR incorporating the truncated TGFBRII dominant negative receptor. (FIG. 9A) The sequence of the extracellular binding and transmembrane domains of TGFBRII, but excluding the intracellular kinase domain, was cloned into the D100 BCMA CAR construct. A P2A element was utilized to allow for the separate co-expression of the BCMA CAR and the TGFBRII DN. (FIG. 9B) T-cells were transduced with lentiviral vectors containing either the D100 BCMA CAR construct or the armored BCMA CAR construct combining the D100 CAR with the TGFBRII DN element (D158) at MOI 10 and 80, respectively. The cell surface expression of the BCMA CAR (upper panel) and TGFBRII (lower panel) was assessed by flow cytometry. (FIG. 9C) In the long term co-culture experiment, CAR T-cells were co-incubated with the target cells, MM1.S-GFP, at an ETT ratio of 0.1, and the media was treated with 10 ng/ml of TGF-beta or remained untreated. When the target cells were eliminated on day 6, the co-culture was extended for a second round at an initial ETT ratio of 0.1. The absolute counts of (FIG. 9D) T-cells and (FIG. 9E) target cells at different time points during the long-term co-culture was assessed by quantifying the number of CD3+ and GFP+ cells via flow cytometry using absolute counting beads.

FIGS. 10A-H depict the superior efficacy of the armored BCMA CAR D158 incorporating the truncated TGFBRII dominant negative element in eradicating tumors in vivo. (FIG. 10A) Multiple myeloma cell lines, RPMI-8226 and MM1.S, were cultured for 4 days, and supernatants were collected and treated with 1M HCL to activate latent TGFβ, or the supernatants remained untreated. The presence of active TGFβ, in the supernatants was detected by ELISA. (FIG. 10B) NSG mice were intradermally injected on the abdomen with 8e6 RPMI-8226 cells (n=8 except untreated, n=5). On day 17 after tumor injection, 5e6 CAR+ T-cells were intravenously injected. The differences in CAR expression levels were normalized by adjusting the total number of infused T-cells. On day 7 after T-cell infusion, 3 mice from each group (except the untreated group) were sacrificed for tumor harvest, while the rest were monitored for (FIG. 10C) tumor progression and (FIG. 10D) survival. (FIG. 10E) The absolute counts of CD3+ cells, (FIG. 10F) the percentage of CD3+CAR+, (FIG. 10G) CD3+PD1+, and (FIG. 10H) CD3+CD45RO+ cells in the tumors on day 6 were determined by flow cytometry.

DETAILED DESCRIPTION Definitions

As used herein, the singular forms “a,” “an,” and “the,” refer to both the singular as well as plural, unless the context clearly indicates otherwise. For example, the term “an antigen” includes single or plural antigens and can be considered equivalent to the phrase “at least one antigen.” As used herein, the term “comprises” means “includes.” Thus, “comprising an antigen” means “including an antigen” without excluding other elements. The phrase “and/or” means “and” or “or.” It is further to be understood that any and all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. To facilitate review of the various embodiments, the following explanations of terms are provided:

The term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of .+−0.20% or in some instances .+−0.10%, or in some instances .+−0.5%, or in some instances .+−0.1%, or in some instances .+−0.0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

Unless otherwise noted, the technical terms herein are used according to conventional usage. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes VII, published by Oxford University Press, 1999; Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994; and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995; and other similar references.

The present disclosure provides for BCMA antibodies or fragments thereof as well as chimeric antigen receptors (CARs) having such BCMA antigen binding domains. The enhancement of the functional activity of the CAR directly relates to the enhancement of functional activity of the CAR-expressing T cell. As a result of one or more of these modifications, the CARs exhibit both a high degree of cytokine-induced cytolysis and cell surface expression on transduced T cells, along with an increased level of in vivo T cell expansion and persistence of the transduced CAR-expressing T cell.

The unique ability to combine functional moieties derived from different protein domains has been a key innovative feature of Chimeric Antigen Receptors (CARs). The choice of each of these protein domains is a key design feature, as is the way in which they are specifically combined. Each design domain is an essential component that can be used across different CAR platforms to engineer the function of lymphocytes. For example, the choice of the extracellular binding domain can make an otherwise ineffective CAR be effective.

The invariable framework components of the immunoglobulin-derived protein sequences used to create the extracellular antigen binding domain of a CAR can either be entirely neutral, or they can self-associate and drive the T cell to a state of metabolic exhaustion, thus making the therapeutic T cell expressing that CAR far less effective. This occurs independently of the antigen binding function of this CAR domain. Furthermore, the choice of the intracellular signaling domain(s) also can govern the activity and the durability of the therapeutic lymphocyte population used for immunotherapy. While the ability to bind target antigen and the ability to transmit an activation signal to the T cell through these extracellular and intracellular domains, respectively, are important CAR design aspects, what has also become apparent is that the choice of the source of the extracellular antigen binding fragments can have a significant effect on the efficacy of the CAR and thereby have a defining role for the function and clinical utility of the CAR.

Surprisingly and unexpectedly it has now been discovered that use of an entirely human antigen binding domain in a CAR, rather than using mouse-derived antigen binding fragments which are prone to induce anti-mouse immune response and CAR T elimination in a host (c.f., the UPenn-sponsored clinical trial using mouse derived SS1 ScFv sequence, NCT02159716), may also determine the functional activity of a CAR-expressing T cell.

The CARs disclosed herein are expressed at a high level in a cell. A cell expressing the CAR has a high in vivo proliferation rate, produces large amounts of cytokines, and has a high cytotoxic activity against a cell having, on its surface, a BCMA antigen to which a CAR binds. The use of a human extracellular BCMA antigen binding domain results in generation of a CAR that functions better in vivo, while avoiding the induction of anti-CAR immunity in the host immune response and the killing of the CAR T cell population. The CARs expressing the entirely human extracellular BCMA ScFv antigen binding domain exhibit superior activities/properties including i) prevention of poor CAR T persistence and function as seen with mouse-derived binding sequences; ii) lack of regional (i.e. intrapleural) delivery of the CAR to be efficacious; and iii) ability to generate CAR T cell designs based both on binders with high and low affinity to BCMA. This latter property allows investigators to better tune efficacy vs toxicity, and/or tissue specificity of the CAR T product, since lower-affinity binders may have higher specificity to tumors vs normal tissues due to higher expression of BCMA on tumors than normal tissue, which may prevent on-target off tumor toxicity and bystander cell killing.

What follows is a detailed description of the inventive CARs including a description of their extracellular BCMA antigen binding domain, the transmembrane domain and the intracellular domain, along with additional description of the CARs, antibodies and antigen binding fragments thereof, conjugates, nucleotides, expression, vectors, and host cells, methods of treatment, compositions, and kits employing the disclosed CARs.

A. Chimeric Antigen Receptors (CARs)

The CARs disclosed herein comprise at least one BCMA antigen binding domain capable of binding to BCMA, at least one transmembrane domain, and at least one intracellular domain.

A chimeric antigen receptor (CAR) is an artificially constructed hybrid protein or polypeptide containing the antigen binding domains of an antibody (e.g., single chain variable fragment (ScFv)) linked to T-cell signaling domains via the transmembrane domain. Characteristics of CARs include their ability to redirect T-cell specificity and reactivity toward a selected target in a non-MHC-restricted manner, and exploiting the antigen-binding properties of monoclonal antibodies. The non-MHC-restricted antigen recognition gives T cells expressing CARS the ability to recognize antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape. Moreover, when expressed in T-cells, CARS advantageously do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.

As disclosed herein, the intracellular T cell signaling domains of the CARs can include, for example, a T cell receptor signaling domain, a T cell costimulatory signaling domain, or both. The T cell receptor signaling domain refers to a portion of the CAR comprising the intracellular domain of a T cell receptor, such as, for example, and not by way of limitation, the intracellular portion of the CD3 zeta protein. The costimulatory signaling domain refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule, which is a cell surface molecule other than an antigen receptor or their ligands that are required for an efficient response of lymphocytes to antigen.

1. Extracellular Domain

In one embodiment, the CAR comprises a target-specific binding element otherwise referred to as an antigen binding domain or moiety. The choice of domain depends upon the type and number of ligands that define the surface of a target cell. For example, the antigen binding domain may be chosen to recognize a ligand that acts as a cell surface marker on target cells associated with a particular disease state. Thus examples of cell surface markers that may act as ligands for the antigen binding domain in the CAR include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells.

In one embodiment, the CAR can be engineered to target a tumor antigen of interest by way of engineering a desired antigen binding domain that specifically binds to an antigen on a tumor cell. Tumor antigens are proteins that are produced by tumor cells that elicit an immune response, particularly T-cell mediated immune responses. The selection of the antigen binding domain will depend on the particular type of cancer to be treated. Tumor antigens include, for example, a glioma-associated antigen, carcinoembryonic antigen (CEA), .beta.-human chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1 a, p53, prostein, PSMA, Her2/neu, survivin and telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrinB2, CD22, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor and BCMA. The tumor antigens disclosed herein are merely included by way of example. The list is not intended to be exclusive and further examples will be readily apparent to those of skill in the art.

In one embodiment, the tumor antigen comprises one or more antigenic cancer epitopes associated with a malignant tumor. Malignant tumors express a number of proteins that can serve as target antigens for an immune attack. These molecules include, but are not limited to, tissue-specific antigens such as MART-1, tyrosinase and GP 100 in melanoma and prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) in prostate cancer. Other target molecules belong to the group of transformation-related molecules such as the oncogene HER-2/Neu/ErbB-2. Yet another group of target antigens are onco-fetal antigens such as carcinoembryonic antigen (CEA). In B-cell lymphoma the tumor-specific idiotype immunoglobulin constitutes a truly tumor-specific immunoglobulin antigen that is unique to the individual tumor. B-cell differentiation antigens such as CD19, CD20 and CD37 are other candidates for target antigens in B-cell lymphoma. Some of these antigens (CEA, HER-2, CD19, CD20, idiotype) have been used as targets for passive immunotherapy with monoclonal antibodies with limited success.

In one preferred embodiment, the tumor antigen is BCMA and the tumors associated with expression of BCMA comprise lung mesothelioma, ovarian, and pancreatic cancers that express high levels of the extracellular protein BCMA, or any combination thereof.

The type of tumor antigen may also be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). A TSA is unique to tumor cells and does not occur on other cells in the body. A TAA is not unique to a tumor cell and instead is also expressed on a normal cell under conditions that fail to induce a state of immunologic tolerance to the antigen. The expression of the antigen on the tumor may occur under conditions that enable the immune system to respond to the antigen. TAAs may be antigens that are expressed on normal cells during fetal development when the immune system is immature and unable to respond or they may be antigens that are normally present at extremely low levels on normal cells but which are expressed at much higher levels on tumor cells.

Non-limiting examples of TSAs or TAAs include the following: Differentiation antigens such as MART-1/MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2 and tumor-specific multi-lineage antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15; overexpressed embryonic antigens such as CEA; overexpressed oncogenes and mutated tumor-suppressor genes such as p53, Ras, HER-2/neu; unique tumor antigens resulting from chromosomal translocations; such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, such as the Epstein Barr virus antigens EBVA and the human papillomavirus (HPV) antigens E6 and E7. Other large, protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, beta-Catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophilin C-associated protein, TAAL6, TAG72, TLP, and TPS.

In one embodiment, the antigen binding domain portion of the CAR targets an antigen that includes but is not limited to CD19, CD20, CD22, ROR1, CD33, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, MY-ESO-1 TCR, MAGE A3 TCR, and the like.

In a preferred embodiment, the antigen binding domain portion of the CAR targets the extracellular BCMA antigen.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 5 D0084 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 9, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 5 D0084 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 10, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 10.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 16 D0085 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 17, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 16 D0085 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 18, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 18.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 37 D0086 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 23, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 37 D0086 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 24, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 24.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 40 D0087 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 69, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 40 D0087 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 70, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 70.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 4-12 D0099 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 75, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 4-12 D0099 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 76, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 76.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular BCMA ScFv Clone 4-45 D0100 antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 77, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular BCMA ScFv Clone 4-45 D0100 antigen binding domain comprises an amino acid sequence of SEQ ID NO: 78, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 78.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular 4-1c VH antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 103, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular 4-1c VH antigen binding domain comprises an amino acid sequence of SEQ ID NO: 104, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 104.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular 4-1c VL antigen binding domain comprises a nucleotide sequence of SEQ ID NO: 105, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular 4-1c VL antigen binding domain comprises an amino acid sequence of SEQ ID NO: 106, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 106.

In one preferred embodiment, the isolated nucleic acid molecule encoding the extracellular TGFBRIIdn domain comprises a nucleotide sequence of SEQ ID NO: 109, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded extracellular TGFBRIIdn domain comprises an amino acid sequence of SEQ ID NO: 110, or an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 110.

The generation and binding characteristics of the specific BCMA ScFv antigen binding fragments described herein is shown in Example 1.

In the various embodiments of the BCMA-specific CARs disclosed herein, the general scheme is set forth in FIG. 1 and includes, from the N-terminus to the C-terminus, a signal or leader peptide, anti-BCMA ScFv, extracellular linker, CD8 transmembrane, 4-1BB, CD3 zeta, wherein the bolded text represents the cloning sites for linking domains.

In one embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 87, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 88.

In one embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 87, or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 88 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 89, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 90.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 89 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 90 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 91, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 92.

In another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 91 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 92 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 93, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 94.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 93 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 94 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 95, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 96.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 95 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 96 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof. In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 97, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 98.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 99, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 100.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 101, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 102.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 97 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 98 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 99 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 100 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

In yet another embodiment, the nucleic acid sequence encoding a CAR comprises the nucleic acid sequence of SEQ ID NO: 101 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and encodes the CAR comprising the amino acid sequence as set forth in SEQ ID NO: 102 or a sequence with 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.

The surface expression of anti-BCMA CARs incorporating immunoglobulin single chain fragment variable (ScFv) sequences reactive with BCMA antigen, is shown in Example 2 infra. The expression level for each ScFv—containing CAR was determined by flow cytometric analysis of LV-transduced T cells from healthy donors using a recombinant BCMA-Fc peptide, followed by anti-human Fc F(ab′)2 fragment conjugated to AF647, and detected in the APC channel, (c.f., Example 2, FIG. 2). Alternatively, CAR detection was performed using protein L-biotin conjugate, followed by Streptavidin-PE, with similar results (Example 2, FIG. 2). Further confirmation of CAR expression for constructs selected for further investigation was performed using the BCMA-Fc staining method (Example 2, FIG. 4). All anti-BCMA CAR constructs were readily detected on the surface of T cells, except for the sequence 15 CAR construct, demonstrating robust CAR expression. By contrast, no CAR expression was detected in the negative control non-transduced T cells (UTD), thus demonstrating the specificity of the detection method used (c.f., Example 2, FIG. 2, FIG. 4).

Without being intended to limit to any particular mechanism of action, it is believed that possible reasons for the enhanced therapeutic function associated with the exemplary CARs of the invention include, for example, and not by way of limitation, a) improved lateral movement within the plasma membrane allowing for more efficient signal transduction, b) superior location within plasma membrane microdomains, such as lipid rafts, and greater ability to interact with transmembrane signaling cascades associated with T cell activation, c) superior location within the plasma membrane by preferential movement away from dampening or down-modulatory interactions, such as less proximity to or interaction with phosphatases such as CD45, and d) superior assembly into T cell receptor signaling complexes (i.e. the immune synapse), or any combination thereof.

While the disclosure has been illustrated with an exemplary extracellular BCMA ScFv antigen binding domains, other nucleotide and/or amino acid variants within the BCMA variable ScFv antigen binding domains may be used to derive the BCMA antigen binding domains for use in the CARs described herein.

Depending on the desired antigen to be targeted, the CAR can be additionally engineered to include the appropriate antigen binding domain that is specific to the desired antigen target. For example, if CD19 is the desired antigen that is to be targeted, an antibody for CD19 can be used as the antigen bind domain incorporation into the CAR.

In one exemplary embodiment, the antigen binding domain portion of the CAR additionally targets CD19. Preferably, the antigen binding domain in the CAR is anti-CD19 ScFv, wherein the nucleic acid sequence of the anti-CD19 ScFv comprises the sequence set forth in SEQ ID NO: 37 In one embodiment, the anti-CD19 ScFv comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 30. In another embodiment, the anti-CD19 ScFv portion of the CAR comprises the amino acid sequence set forth in SEQ ID NO: 38.

In one aspect of the present invention, there is provided a CAR capable of binding to a non-TSA or non-TAA including, for example and not by way of limitation, an antigen derived from Retroviridae (e.g. human immunodeficiency viruses such as HIV-1 and HIV-LP), Picornaviridae (e.g. poliovirus, hepatitis A virus, enterovirus, human coxsackievirus, rhinovirus, and echovirus), rubella virus, coronavirus, vesicular stomatitis virus, rabies virus, Ebola virus, parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus, influenza virus, hepatitis B virus, parvovirus, Adenoviridae, Herpesviridae [e.g. type 1 and type 2 herpes simplex virus (HSV), varicella-zoster virus, cytomegalovirus (CMV), and herpes virus], Poxviridae (e.g. smallpox virus, vaccinia virus, and pox virus), or hepatitis C virus, or any combination thereof.

In another aspect of the present invention, there is provided a CAR capable of binding to an antigen derived from a bacterial strain of Staphylococci, Streptococcus, Escherichia coli, Pseudomonas, or Salmonella. Particularly, there is provided a CAR capable of binding to an antigen derived from an infectious bacterium, for example, Helicobacter pyloris, Legionella pneumophilia, a bacterial strain of Mycobacteria sps. (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, or M. gordonea), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitides, Listeria monocytogenes, Streptococcus pyogenes, Group A Streptococcus, Group B Streptococcus (Streptococcus agalactiae), Streptococcus pneumoniae, or Clostridium tetani, or a combination thereof

2. Transmembrane Domain

With respect to the transmembrane domain, the CAR comprises one or more transmembrane domains fused to the extracellular BCMA antigen binding domain of the CAR.

The transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.

Transmembrane regions of particular use in the CARs described herein may be derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, mesothelin, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, the transmembrane domain may be synthetic, in which case it will comprise predominantly hydrophobic residues such as leucine and valine. Preferably a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain. Optionally, a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR. A glycine-serine doublet provides a particularly suitable linker.

In one embodiment, the transmembrane domain that naturally is associated with one of the domains in the CAR is used in addition to the transmembrane domains described supra.

In some instances, the transmembrane domain can be selected by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.

In one embodiment, the transmembrane domain in the CAR of the invention is the CD8 transmembrane domain. In one embodiment, the CD8 transmembrane domain comprises the nucleic acid sequence of SEQ ID NO: 27. In one embodiment, the CD8 transmembrane domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 28. In another embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 28.

In one embodiment, the encoded transmembrane domain comprises an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 20, 10 or 5 modifications (e.g., substitutions) of an amino acid sequence of SEQ ID NO: 28, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO: 28.

In some instances, the transmembrane domain of the CAR comprises the CD8.alpha.hinge domain. In one embodiment, the CD8 hinge domain comprises the nucleic acid sequence of SEQ ID NO: 29. In one embodiment, the CD8 hinge domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 30. In another embodiment, the CD8 hinge domain comprises the amino acid sequence of SEQ ID NO: 30, or a sequence with 95-99% identify thereof.

In one embodiment, an isolated nucleic acid molecule is provided wherein the encoded linker domain is derived from the extracellular domain of CD8, and is linked to the transmembrane CD8 domain, the transmembrane CD28 domain, or a combination thereof.

In one embodiment, the transmembrane domain in the CAR of the invention is the TNFRSF19 transmembrane domain. In one embodiment, the TNFRSF19 transmembrane domain comprises the nucleic acid sequence of SEQ ID NO: 51. In one embodiment, the TNFRSF19 transmembrane domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 52. In another embodiment, the TNFRSF19 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 52.

In one embodiment, the encoded transmembrane domain comprises an amino acid sequence having at least one, two or three modifications (e.g., substitutions) but not more than 20, 10 or 5 modifications (e.g., substitutions) of an amino acid sequence of SEQ ID NO: 52, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO: 52.

3. Spacer Domain

In the CAR, a spacer domain, also termed hinge domain, can be arranged between the extracellular domain and the transmembrane domain, or between the intracellular domain and the transmembrane domain. The spacer domain means any oligopeptide or polypeptide that serves to link the transmembrane domain with the extracellular domain and/or the transmembrane domain with the intracellular domain. The spacer domain comprises up to 300 amino acids, preferably 10 to 100 amino acids, and most preferably 25 to 50 amino acids.

In several embodiments, the linker can include a spacer element, which, when present, increases the size of the linker such that the distance between the effector molecule or the detectable marker and the antibody or antigen binding fragment is increased. Exemplary spacers are known to the person of ordinary skill, and include those listed in U.S. Pat. Nos. 7,964,567, 498,298, 6,884,869, 6,323,315, 6,239,104, 6,034,065, 5,780,588, 5,665,860, 5,663,149, 5,635,483, 5,599,902, 5,554,725, 5,530,097, 5,521,284, 5,504,191, 5,410,024, 5,138,036, 5,076,973, 4,986,988, 4,978,744, 4,879,278, 4,816,444, and 4,486,414, as well as U.S. Pat. Pub. Nos. 20110212088 and 20110070248, each of which is incorporated by reference herein in its entirety.

The spacer domain preferably has a sequence that promotes binding of a CAR with an antigen and enhances signaling into a cell. Examples of an amino acid that is expected to promote the binding include cysteine, a charged amino acid, and serine and threonine in a potential glycosylation site, and these amino acids can be used as an amino acid constituting the spacer domain.

As the spacer domain, the entire or a part of amino acid numbers 118 to 178 (SEQ ID NO: 31) which is a hinge region of CD8.alpha. (NCBI RefSeq: NP.sub.—001759.3), amino acid numbers 135 to 195 of CD8.beta. (GenBank: AAA35664.1), amino acid numbers 315 to 396 of CD4 (NCBI RefSeq: NP.sub.—000607.1), or amino acid numbers 137 to 152 of CD28 (NCBI RefSeq: NP.sub.—006130.1) can be used. Also, as the spacer domain, a part of a constant region of an antibody H chain or L chain (CH1 region or CL region, for example, a peptide having an amino acid sequence shown in SEQ ID NO: 32) can be used. Further, the spacer domain may be an artificially synthesized sequence.

In addition, an entire or a part of amino acids comprising the constant region of a human IgG4 (UniProt ID: P01861), including CH1, (amino acid numbers 1-98), hinge, SEQ ID NO: 80, and the corresponding nucleotide SEQ ID NO: 79, (amino acid numbers 99-110), CH2, amino acid SEQ ID NO: 81 and corresponding nucleotide SEQ ID NO: 80, (amino acid numbers 111-220) and CH3, SEQ ID NO: 84 and corresponding nucleotide SEQ ID NO: 83, (amino acid numbers 221-327) or a combination thereof, such as IgG4 Hinge CH2 CH3 domain, SEQ ID NO: 86, and the corresponding nucleotide SEQ ID NO: 85, can be used.

In one embodiment, the spacer domain of the CAR comprises the TNFRSF19 hinge domain which comprises the nucleic acid sequence of SEQ ID NO: 53. In one embodiment, the TNFRSF19 hinge domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 54. In another embodiment, the TNFRSF19 hinge domain comprises the amino acid sequence of SEQ ID NO: 54, or a sequence with 95-99% identify thereof.

In one embodiment, the spacer domain of the CAR comprises the TNFRSF19 truncated hinge domain comprises the nucleic acid sequence of SEQ ID NO: 55. In one embodiment, the TNFRSF19 truncated hinge domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 56. In another embodiment, the TNFRSF19 truncated hinge domain comprises the amino acid sequence of SEQ ID NO: 56, or a sequence with 95-99% identify thereof.

In one embodiment, the TNFRSF19 hinge and transmembrane domains comprise the nucleic acid sequence of SEQ ID NO: 49. In one embodiment, the TNFRSF19 hinge and transmembrane domains comprise the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 50. In another embodiment, the TNFRSF19 hinge and transmembrane domains comprise the amino acid sequence of SEQ ID NO: 50, or a sequence with 95-99% identify thereof.

In one embodiment, a CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprising the nucleic acid sequence of SEQ ID NO: 57. In one embodiment, the CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 58. In another embodiment, the CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 58, or a sequence with 95-99% identify thereof.

Further, in the CAR, a signal peptide sequence, also termed leader peptide, can be linked to the N-terminus. The signal peptide sequence exists at the N-terminus of many secretory proteins and membrane proteins, and has a length of 15 to 30 amino acids. Since many of the protein molecules mentioned above as the intracellular domain have signal peptide sequences, the signal peptides can be used as a signal peptide for the CAR. In one embodiment, the signal peptide comprises the amino acid sequence shown in SEQ ID NO: 14).

In one embodiment, the CD8 alpha leader peptide, is comprising the nucleic acid sequence of SEQ ID NO: 43. In one embodiment, CD8 alpha leader peptide comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 44. In another embodiment, the CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 44, or a sequence with 95-99% identify thereof.

In another embodiment, the GMCSF leader peptide, is comprising the nucleic acid sequence of SEQ ID NO: 39. In one embodiment, the GMCSF leader peptide, comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 40. In another embodiment, the CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 40, or a sequence with 95-99% identify thereof.

In another embodiment, the TNFRSF19 leader peptide is comprising the nucleic acid sequence of SEQ ID NO: 41. In one embodiment, TNFRSF19 leader peptide, and CD8 alpha leader peptide comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 42. In another embodiment, the CD8a hinge domain is fused to a TNFRSF19 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 42, or a sequence with 95-99% identify thereof.

In one embodiment, a tag sequence encoding a truncated sequence of epidermal growth factor receptor (tEGFR) is comprising the nucleic acid sequence of SEQ ID NO: 67. In one embodiment, tEGFR comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 68. In another embodiment, the tEGFR tag comprises the amino acid sequence of SEQ ID NO: 68, or a sequence with 95-99% identify thereof.

In one embodiment, a furin recognition site and downstream T2A self-cleaving peptide sequence, designed for simultaneous bicistronic expression of the tag sequence and the CAR sequence, is comprising the nucleic acid sequence of SEQ ID NO: 65. In one embodiment, furin and T2A sequence comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 66. In another embodiment, the tEGFR tag comprises the amino acid sequence of SEQ ID NO: 66 or a sequence with 95-99% identify thereof.

In one embodiment, an upstream furin recognition site and T2A self-cleaving peptide sequence and a furin recognition downstream site, designed for simultaneous bicistronic expression of the tag sequence and the CAR sequence, is comprising the nucleic acid sequence of SEQ ID NO: 67. In one embodiment, furin and T2A sequence comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 68. In another embodiment, the tEGFR tag comprises the amino acid sequence of SEQ ID NO: 68 or a sequence with 95-99% identify thereof.

In one embodiment, the targeting domain of the CAR is expressed separately in the form of monoclonal antibody, ScFv Fab, Fab′2 and is containing at binding tag or epitope, whereas the effector-cell expressed component of the CAR contains a binding domain specifically directed to bind the tag or epitope expressed on the soluble CAR module, such as specific binding on the soluble component of the CAR to the cell bound component forms the full functional CAR structure.

4. Intracellular Domain

The cytoplasmic domain or otherwise the intracellular signaling domain of the CAR is responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR has been placed in. The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. Thus, the term “intracellular signaling domain” refers to the portion of a protein which transduces the effector function signal and directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector function signal.

Preferred examples of intracellular signaling domains for use in the CAR include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability.

It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary or co-stimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequence: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic signaling sequences).

Primary cytoplasmic signaling sequences regulate primary activation of the TCR complex either in a stimulatory way, or in an inhibitory way. Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs.

Examples of ITAM containing primary cytoplasmic signaling sequences that are of particular use in the CARs disclosed herein include those derived from TCR zeta (CD3 Zeta), FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. Specific, non-limiting examples, of the ITAM include peptides having sequences of amino acid numbers 51 to 164 of CD3.zeta. (NCBI RefSeq: NP.sub.—932170.1), amino acid numbers 45 to 86 of Fc.epsilon.RI.gamma. (NCBI RefSeq: NP.sub.—004097.1), amino acid numbers 201 to 244 of Fc.epsilon.RI.beta. (NCBI RefSeq: NP.sub.—000130.1), amino acid numbers 139 to 182 of CD3.gamma. (NCBI RefSeq: NP.sub.—000064.1), amino acid numbers 128 to 171 of CD3.delta. (NCBI RefSeq: NP.sub.—000723.1), amino acid numbers 153 to 207 of CD3. epsilon. (NCBI RefSeq: NP.sub.—000724.1), amino acid numbers 402 to 495 of CD5 (NCBI RefSeq: NP.sub.—055022.2), amino acid numbers 707 to 847 of 0022 (NCBI RefSeq: NP.sub.—001762.2), amino acid numbers 166 to 226 of CD79a (NCBI RefSeq: NP.sub.—001774.1), amino acid numbers 182 to 229 of CD79b (NCBI RefSeq: NP.sub.—000617.1), and amino acid numbers 177 to 252 of CD66d (NCBI RefSeq: NP.sub.—001806.2), and their variants having the same function as these peptides have. The amino acid number based on amino acid sequence information of NCBI RefSeq ID or GenBank described herein is numbered based on the full length of the precursor (comprising a signal peptide sequence etc.) of each protein. In one embodiment, the cytoplasmic signaling molecule in the CAR comprises a cytoplasmic signaling sequence derived from CD3 zeta.

In a preferred embodiment, the intracellular domain of the CAR can be designed to comprise the CD3-zeta signaling domain by itself or combined with any other desired cytoplasmic domain(s) useful in the context of the CAR. For example, the intracellular domain of the CAR can comprise a CD3 zeta chain portion and a costimulatory signaling region. The costimulatory signaling region refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or their ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such costimulatory molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83, and the like. Specific, non-limiting examples, of such costimulatory molecules include peptides having sequences of amino acid numbers 236 to 351 of CD2 (NCBI RefSeq: NP.sub.—001758.2), amino acid numbers 421 to 458 of CD4 (NCBI RefSeq: NP.sub.—000607.1), amino acid numbers 402 to 495 of CD5 (NCBI RefSeq: NP.sub.—055022.2), amino acid numbers 207 to 235 of CD8.alpha. (NCBI RefSeq: NP.sub.—001759.3), amino acid numbers 196 to 210 of CD83 (GenBank: AAA35664.1), amino acid numbers 181 to 220 of CD28 (NCBI RefSeq: NP.sub.—006130.1), amino acid numbers 214 to 255 of CD137 (4-1BB, NCBI RefSeq: NP.sub.—001552.2), amino acid numbers 241 to 277 of CD134 (OX40, NCBI RefSeq: NP.sub.—003318.1), and amino acid numbers 166 to 199 of ICOS (NCBI RefSeq: NP.sub.—036224.1), and their variants having the same function as these peptides have. Thus, while the disclosure herein is exemplified primarily with 4-1BB as the co-stimulatory signaling element, other costimulatory elements are within the scope of the disclosure.

The cytoplasmic signaling sequences within the cytoplasmic signaling portion of the CAR may be linked to each other in a random or specified order. Optionally, a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage. A glycine-serine doublet provides a particularly suitable linker.

In one embodiment, the intracellular domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD28. In another embodiment, the intracellular domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of 4-1BB. In yet another embodiment, the intracellular domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD28 and 4-1BB.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of 4-1BB and the signaling domain of CD3-zeta, wherein the signaling domain of 4-1BB comprises the nucleic acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 45, or SEQ ID NO: 59, respectively and the signaling domain of CD3-zeta comprises the nucleic acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 47, or SEQ ID NO: 61, respectively.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of 4-1BB and the signaling domain of CD3-zeta, wherein the signaling domain of 4-1BB comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 46, or SEQ ID NO: 60, respectively and the signaling domain of CD3-zeta comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 36, or SEQ ID NO: 48, or SEQ ID NO: 62.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of 4-1BB and the signaling domain of CD3-zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence set forth in SEQ ID NO: 34, SEQ ID NO: 46, or SEQ ID NO: 60, respectively and the signaling domain of CD3-zeta comprises the amino acid sequence set forth in SEQ ID NO: 36, SEQ ID NO: 48, or SEQ ID NO: 62, respectively.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of CD28 and the signaling domain of CD3-zeta, wherein the signaling domain of CD28 comprises the nucleic acid sequence set forth in SEQ ID NO: 45, or SEQ ID NO: 59, respectively, and the signaling domain of CD3-zeta comprises the nucleic acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 47, or SEQ ID NO: 61, respectively.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of CD28 and the signaling domain of CD3-zeta, wherein the signaling domain of CD28 comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO: 60, respectively and the signaling domain of CD3-zeta comprises the nucleic acid sequence that encodes the amino acid sequence of SEQ ID NO: 36, or SEQ ID NO: 48, or SEQ ID NO: 62.

In one embodiment, the intracellular domain in the CAR is designed to comprise the signaling domain of CD28 and the signaling domain of CD3-zeta, wherein the signaling domain of CD28 comprises the amino acid sequence set forth in SEQ ID NO: 46, or SEQ ID NO: 60, respectively and the signaling domain of CD3-zeta comprises the amino acid sequence set forth in SEQ ID NO: 36, SEQ ID NO: 48, or SEQ ID NO: 62, respectively.

5. Additional Description of CARs

Also expressly included within the scope of the invention are functional portions of the CARs disclosed herein. The term “functional portion” when used in reference to a CAR refers to any part or fragment of one or more of the CARs disclosed herein, which part or fragment retains the biological activity of the CAR of which it is a part (the parent CAR). Functional portions encompass, for example, those parts of a CAR that retain the ability to recognize target cells, or detect, treat, or prevent a disease, to a similar extent, the same extent, or to a higher extent, as the parent CAR. In reference to the parent CAR, the functional portion can comprise, for instance, about 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95%, or more, of the parent CAR.

The functional portion can comprise additional amino acids at the amino or carboxy terminus of the portion, or at both termini, which additional amino acids are not found in the amino acid sequence of the parent CAR. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, e.g., recognize target cells, detect cancer, treat or prevent cancer, etc. More desirably, the additional amino acids enhance the biological activity, as compared to the biological activity of the parent CAR.

Included in the scope of the disclosure are functional variants of the CARs disclosed herein. The term “functional variant” as used herein refers to a CAR, polypeptide, or protein having substantial or significant sequence identity or similarity to a parent CAR, which functional variant retains the biological activity of the CAR of which it is a variant. Functional variants encompass, for example, those variants of the CAR described herein (the parent CAR) that retain the ability to recognize target cells to a similar extent, the same extent, or to a higher extent, as the parent CAR. In reference to the parent CAR, the functional variant can, for instance, be at least about 30%, 50%, 75%, 80%, 90%, 98% or more identical in amino acid sequence to the parent CAR.

A functional variant can, for example, comprise the amino acid sequence of the parent CAR with at least one conservative amino acid substitution. Alternatively or additionally, the functional variants can comprise the amino acid sequence of the parent CAR with at least one non-conservative amino acid substitution. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the parent CAR.

Amino acid substitutions of the CARs are preferably conservative amino acid substitutions. Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and/or chemical properties is exchanged for another amino acid that has the same or similar chemical or physical properties. For instance, the conservative amino acid substitution can be an acidic/negatively charged polar amino acid substituted for another acidic/negatively charged polar amino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, He, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.), a basic/positively charged polar amino acid substituted for another basic/positively charged polar amino acid (e.g. Lys, His, Arg, etc.), an uncharged amino acid with a polar side chain substituted for another uncharged amino acid with a polar side chain (e.g., Asn, Gin, Ser, Thr, Tyr, etc.), an amino acid with a beta-branched side-chain substituted for another amino acid with a beta-branched side-chain (e.g., He, Thr, and Val), an amino acid with an aromatic side-chain substituted for another amino acid with an aromatic side chain (e.g., His, Phe, Trp, and Tyr), etc.

The CAR can consist essentially of the specified amino acid sequence or sequences described herein, such that other components, e.g., other amino acids, do not materially change the biological activity of the functional variant.

The CARs (including functional portions and functional variants) can be of any length, i.e., can comprise any number of amino acids, provided that the CARs (or functional portions or functional variants thereof) retain their biological activity, e.g., the ability to specifically bind to antigen, detect diseased cells in a mammal, or treat or prevent disease in a mammal, etc. For example, the CAR can be about 50 to about 5000 amino acids long, such as 50, 70, 75, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids in length.

The CARs (including functional portions and functional variants of the invention) can comprise synthetic amino acids in place of one or more naturally-occurring amino acids. Such synthetic amino acids are known in the art, and include, for example, aminocyclohexane carboxylic acid, norleucine, -amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, a-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N′-benzyl-N′-methyl-lysine, N′,N′-dibenzyl-lysine, 6-hydroxylysine, ornithine, -aminocyclopentane carboxylic acid, a-aminocyclohexane carboxylic acid, a-aminocycloheptane carboxylic acid, a-(2-amino-2-norbornane)-carboxylic acid, γ-diaminobutyric acid, β-diaminopropionic acid, homophenylalanine, and a-tert-butylglycine.

The CARs (including functional portions and functional variants) can be glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized via, e.g., a disulfide bridge, or converted into an acid addition salt and/or optionally dimerized or polymerized, or conjugated.

The CARs (including functional portions and functional variants thereof) can be obtained by methods known in the art. The CARs may be made by any suitable method of making polypeptides or proteins. Suitable methods of de novo synthesizing polypeptides and proteins are described in references, such as Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2000; Peptide and Protein Drug Analysis, ed. Reid, R., Marcel Dekker, Inc., 2000; Epitope Mapping, ed. Westwood et al., Oxford University Press, Oxford, United Kingdom, 2001; and U.S. Pat. No. 5,449,752. Also, polypeptides and proteins can be recombinantly produced using the nucleic acids described herein using standard recombinant methods. See, for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3^(rd) ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, N Y, 1994. Further, some of the CARs (including functional portions and functional variants thereof) can be isolated and/or purified from a source, such as a plant, a bacterium, an insect, a mammal, e.g., a rat, a human, etc. Methods of isolation and purification are well-known in the art. Alternatively, the CARs described herein (including functional portions and functional variants thereof) can be commercially synthesized by companies. In this respect, the CARs can be synthetic, recombinant, isolated, and/or purified.

B. Antibodies and Antigen Binding Fragments

One embodiment further provides a CAR, a T cell expressing a CAR, an antibody, or antigen binding domain or portion thereof, which specifically binds to one or more of the antigens disclosed herein. As used herein, a “T cell expressing a CAR,” or a “CAR T cell” means a T cell expressing a CAR, and has antigen specificity determined by, for example, the antibody-derived targeting domain of the CAR.

As used herein, and “antigen binding domain” can include an antibody and antigen binding fragments thereof. The term “antibody” is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multi-specific antibodies (e.g., bispecific antibodies), and antigen binding fragments thereof, so long as they exhibit the desired antigen-binding activity. Non-limiting examples of antibodies include, for example, intact immunoglobulins and variants and fragments thereof known in the art that retain binding affinity for the antigen.

A “monoclonal antibody” is an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. In some examples, a monoclonal antibody is an antibody produced by a single clone of B lymphocytes or by a cell into which nucleic acid encoding the light and heavy variable regions of the antibody of a single antibody (or an antigen binding fragment thereof) have been transfected, or a progeny thereof. In some examples monoclonal antibodies are isolated from a subject. Monoclonal antibodies can have conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. Exemplary methods of production of monoclonal antibodies are known, for example, see Harlow & Lane, Antibodies, A Laboratory Manual, 2^(nd) ed. Cold Spring Harbor Publications, New York (2013).

Typically, an immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable domain genes. There are two types of light chain, lambda (λ) and kappa (κ). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE.

Each heavy and light chain contains a constant region (or constant domain) and a variable region (or variable domain; see, e.g., Kindt et al. Kuby Immunology, 6^(th) ed., W.H. Freeman and Co., page 91 (2007).) In several embodiments, the heavy and the light chain variable regions combine to specifically bind the antigen. In additional embodiments, only the heavy chain variable region is required. For example, naturally occurring camelid antibodies consisting of a heavy chain only are functional and stable in the absence of light chain (see, e.g., Hamers-Casterman et al., Nature, 363:446-448, 1993; Sheriff et al., Nat. Struct. Biol., 3:733-736, 1996). References to “VH” or “VH” refer to the variable region of an antibody heavy chain, including that of an antigen binding fragment, such as Fv, ScFv, dsFv or Fab. References to “VL” or “VL” refer to the variable domain of an antibody light chain, including that of an Fv, ScFv, dsFv or Fab.

Light and heavy chain variable regions contain a “framework” region interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs” (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1991). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.

The CDRs are primarily responsible for binding to an epitope of an antigen. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (“Sequences of Proteins of Immunological Interest,” 5^(th) Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991; “Kabat” numbering scheme), Al-Lazikani et al., (JMB 273,927-948, 1997; “Chothia” numbering scheme), and Lefranc et al. (“IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Immunol., 27:55-77, 2003; “IMGT” numbering scheme). The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3 (from the N-terminus to C-terminus), and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is the CDR3 from the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found. Light chain CDRs are sometimes referred to as LCDR1, LCDR2, and LCDR3. Heavy chain CDRs are sometimes referred to as HCDR1, HCDR2, and HCDR3.

An “antigen binding fragment” is a portion of a full length antibody that retains the ability to specifically recognize the cognate antigen, as well as various combinations of such portions. Non-limiting examples of antigen binding fragments include Fv, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g. ScFv); and multi-specific antibodies formed from antibody fragments. Antibody fragments include antigen binding fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies (see, e.g., Kontermann and Dubel (Ed), Antibody Engineering, Vols. 1-2, 2^(nd) Ed., Springer Press, 2010).

A single-chain antibody (ScFv) is a genetically engineered molecule containing the VH and VL domains of one or more antibody(ies) linked by a suitable polypeptide linker as a genetically fused single chain molecule (see, for example, Bird et al., Science, 242:423 426, 1988; Huston et al., Proc. Natl. Acad. Sci., 85:5879 5883, 1988; Ahmad et al., Clin. Dev. Immunol., 2012, doi:10.1155/2012/980250; Marbry, Idrugs, 13:543-549, 2010). The intramolecular orientation of the VH-domain and the VL-domain in a ScFv, is typically not decisive for ScFvs. Thus, ScFvs with both possible arrangements (VH-domain-linker domain-VL-domain; VL-domain-linker domain-VH-domain) may be used.

In a dsFv, the heavy and light chain variable chains have been mutated to introduce a disulfide bond to stabilize the association of the chains. Diabodies also are included, which are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see, for example, Holliger et al., Proc. Natl. Acad. Sci., 90:6444 6448, 1993; Poljak et al., Structure, 2:1121 1123, 1994).

Antibodies also include genetically engineered forms such as chimeric antibodies (such as humanized murine antibodies) and heteroconjugate antibodies (such as bispecific antibodies). See also, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3^(rd) Ed., W.H. Freeman & Co., New York, 1997.

Non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly, or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Huse et al., Science 246:1275-1281 (1989), which is incorporated herein by reference. These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies, are well known to those skilled in the art (Winter and Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341:544-546 (1989); Harlow and Lane, supra, 1988; Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, 2d ed. (Oxford University Press 1995); each of which is incorporated herein by reference).

An “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. Antibody competition assays are known, and an exemplary competition assay is provided herein.

A “humanized” antibody or antigen binding fragment includes a human framework region and one or more CDRs from a non-human (such as a mouse, rat, or synthetic) antibody or antigen binding fragment. The non-human antibody or antigen binding fragment providing the CDRs is termed a “donor,” and the human antibody or antigen binding fragment providing the framework is termed an “acceptor.” In one embodiment, all the CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but if they are, they can be substantially identical to human immunoglobulin constant regions, such as at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized antibody or antigen binding fragment, except possibly the CDRs, are substantially identical to corresponding parts of natural human antibody sequences.

A “chimeric antibody” is an antibody which includes sequences derived from two different antibodies, which typically are of different species. In some examples, a chimeric antibody includes one or more CDRs and/or framework regions from one human antibody and CDRs and/or framework regions from another human antibody.

A “fully human antibody” or “human antibody” is an antibody which includes sequences from (or derived from) the human genome, and does not include sequence from another species. In some embodiments, a human antibody includes CDRs, framework regions, and (if present) an Fc region from (or derived from) the human genome. Human antibodies can be identified and isolated using technologies for creating antibodies based on sequences derived from the human genome, for example by phage display or using transgenic animals (see, e.g., Barbas et al. Phage display: A Laboratory Manuel. 1^(st) Ed. New York: Cold Spring Harbor Laboratory Press, 2004. Print.; Lonberg, Nat. Biotech., 23: 1117-1125, 2005; Lonenberg, Curr. Opin. Immunol., 20:450-459, 2008).

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a bispecific or bifunctional antibody has two different binding sites.

Methods of testing antibodies for the ability to bind to any functional portion of the CAR are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, and competitive inhibition assays (see, e.g., Janeway et al., infra, U.S. Patent Application Publication No. 2002/0197266 A1, and U.S. Pat. No. 7,338,929).

Also, a CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, can be modified to comprise a detectable label, such as, for instance, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and element particles (e.g., gold particles).

C. Conjugates

A CAR, a T cell expressing a CAR, or monoclonal antibodies, or antigen binding fragments thereof, specific for one or more of the antigens disclosed herein, can be conjugated to an agent, such as an effector molecule or detectable marker, using any number of means known to those of skill in the art. Both covalent and noncovalent attachment means may be used. Conjugates include, but are not limited to, molecules in which there is a covalent linkage of an effector molecule or a detectable marker to an antibody or antigen binding fragment that specifically binds one or more of the antigens disclosed herein. One of skill in the art will appreciate that various effector molecules and detectable markers can be used, including (but not limited to) chemotherapeutic agents, anti-angiogenic agents, toxins, radioactive agents such as ¹²⁵I, ³²P, ¹⁴C, ³H and ³⁵S and other labels, target moieties and ligands, etc.

The choice of a particular effector molecule or detectable marker depends on the particular target molecule or cell, and the desired biological effect. Thus, for example, the effector molecule can be a cytotoxin that is used to bring about the death of a particular target cell (such as a tumor cell).

The procedure for attaching an effector molecule or detectable marker to an antibody or antigen binding fragment varies according to the chemical structure of the effector. Polypeptides typically contain a variety of functional groups; such as carboxylic acid (COOH), free amine (—NH₂) or sulfhydryl (—SH) groups, which are available for reaction with a suitable functional group on an antibody to result in the binding of the effector molecule or detectable marker. Alternatively, the antibody or antigen binding fragment is derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of known linker molecules such as those available from Pierce Chemical Company, Rockford, Ill. The linker can be any molecule used to join the antibody or antigen binding fragment to the effector molecule or detectable marker. The linker is capable of forming covalent bonds to both the antibody or antigen binding fragment and to the effector molecule or detectable marker. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where the antibody or antigen binding fragment and the effector molecule or detectable marker are polypeptides, the linkers may be joined to the constituent amino acids through their side groups (such as through a disulfide linkage to cysteine) or to the alpha carbon amino and carboxyl groups of the terminal amino acids.

In several embodiments, the linker can include a spacer element, which, when present, increases the size of the linker such that the distance between the effector molecule or the detectable marker and the antibody or antigen binding fragment is increased. Exemplary spacers are known to the person of ordinary skill, and include those listed in U.S. Pat. Nos. 7,964,567, 498,298, 6,884,869, 6,323,315, 6,239,104, 6,034,065, 5,780,588, 5,665,860, 5,663,149, 5,635,483, 5,599,902, 5,554,725, 5,530,097, 5,521,284, 5,504,191, 5,410,024, 5,138,036, 5,076,973, 4,986,988, 4,978,744, 4,879,278, 4,816,444, and 4,486,414, as well as U.S. Pat. Pub. Nos. 20110212088 and 20110070248, each of which is incorporated by reference herein in its entirety.

In some embodiments, the linker is cleavable under intracellular conditions, such that cleavage of the linker releases the effector molecule or detectable marker from the antibody or antigen binding fragment in the intracellular environment. In yet other embodiments, the linker is not cleavable and the effector molecule or detectable marker is released, for example, by antibody degradation. In some embodiments, the linker is cleavable by a cleaving agent that is present in the intracellular environment (for example, within a lysosome or endosome or caveolea). The linker can be, for example, a peptide linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease. In some embodiments, the peptide linker is at least two amino acids long or at least three amino acids long. However, the linker can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long, such as 1-2, 1-3, 2-5, 3-10, 3-15, 1-5, 1-10, 1-15 amino acids long. Proteases can include cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives resulting in the release of active drug inside target cells (see, for example, Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). For example, a peptide linker that is cleavable by the thiol-dependent protease cathepsin-B, can be used (for example, a Phenylalanine-Leucine or a Glycine-Phenylalanine-Leucine-Glycine linker). Other examples of such linkers are described, for example, in U.S. Pat. No. 6,214,345, incorporated herein by reference. In a specific embodiment, the peptide linker cleavable by an intracellular protease is a Valine-Citruline linker or a Phenylalanine-Lysine linker (see, for example, U.S. Pat. No. 6,214,345, which describes the synthesis of doxorubicin with the Valine-Citruline linker).

In other embodiments, the cleavable linker is pH-sensitive, i.e., sensitive to hydrolysis at certain pH values. Typically, the pH-sensitive linker is hydrolyzable under acidic conditions. For example, an acid-labile linker that is hydrolyzable in the lysosome (for example, a hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, or the like) can be used. (See, for example, U.S. Pat. Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661.) Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the lysosome. In certain embodiments, the hydrolyzable linker is a thioether linker (such as, for example, a thioether attached to the therapeutic agent via an acylhydrazone bond (see, for example, U.S. Pat. No. 5,622,929).

In other embodiments, the linker is cleavable under reducing conditions (for example, a disulfide linker). A variety of disulfide linkers are known in the art, including, for example, those that can be formed using SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene)-, SPDB and SMPT. (See, for example, Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (C. W. Vogel ed., Oxford U. Press, 1987); Phillips et al., Cancer Res. 68:92809290, 2008). See also U.S. Pat. No. 4,880,935.)

In yet other specific embodiments, the linker is a malonate linker (Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1299-1304), or a 3′-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1305-12).

In yet other embodiments, the linker is not cleavable and the effector molecule or detectable marker is released by antibody degradation. (See U.S. Publication No. 2005/0238649 incorporated by reference herein in its entirety).

In several embodiments, the linker is resistant to cleavage in an extracellular environment. For example, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 3%, or no more than about 1% of the linkers, in a sample of conjugate, are cleaved when the conjugate is present in an extracellular environment (for example, in plasma). Whether or not a linker is resistant to cleavage in an extracellular environment can be determined, for example, by incubating the conjugate containing the linker of interest with plasma for a predetermined time period (for example, 2, 4, 8, 16, or 24 hours) and then quantitating the amount of free effector molecule or detectable marker present in the plasma. A variety of exemplary linkers that can be used in conjugates are described in WO 2004-010957, U.S. Publication No. 2006/0074008, U.S. Publication No. 20050238649, and U.S. Publication No. 2006/0024317, each of which is incorporated by reference herein in its entirety.

In several embodiments, conjugates of a CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, and one or more small molecule toxins, such as a calicheamicin, maytansinoids, dolastatins, auristatins, a trichothecene, and CC1065, and the derivatives of these toxins that have toxin activity, are provided.

Maytansine compounds suitable for use as maytansinoid toxin moieties are well known in the art, and can be isolated from natural sources according to known methods, produced using genetic engineering techniques (see Yu et al., (2002) PNAS 99:7968-7973), or maytansinol and maytansinol analogues prepared synthetically according to known methods. Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Pat. No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Pat. Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, each of which is incorporated herein by reference. Conjugates containing maytansinoids, methods of making same, and their therapeutic use are disclosed, for example, in U.S. Pat. Nos. 5,208,020; 5,416,064; 6,441,163 and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference.

Additional toxins can be employed with a CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof. Exemplary toxins include Pseudomonas exotoxin (PE), ricin, abrin, diphtheria toxin and subunits thereof, ribotoxin, ribonuclease, saporin, and calicheamicin, as well as botulinum toxins A through F. These toxins are well known in the art and many are readily available from commercial sources (for example, Sigma Chemical Company, St. Louis, Mo.). Contemplated toxins also include variants of the toxins (see, for example, see, U.S. Pat. Nos. 5,079,163 and 4,689,401).

Saporin is a toxin derived from Saponaria officinalis that disrupts protein synthesis by inactivating the 60S portion of the ribosomal complex (Stirpe et al., Bio/Technology, 10:405-412, 1992). However, the toxin has no mechanism for specific entry into cells, and therefore requires conjugation to an antibody or antigen binding fragment that recognizes a cell-surface protein that is internalized in order to be efficiently taken up by cells.

Diphtheria toxin is isolated from Corynebacterium diphtheriae. Typically, diphtheria toxin for use in immunotoxins is mutated to reduce or to eliminate non-specific toxicity. A mutant known as CRM107, which has full enzymatic activity but markedly reduced non-specific toxicity, has been known since the 1970's (Laird and Groman, J. Virol. 19:220, 1976), and has been used in human clinical trials. See, U.S. Pat. Nos. 5,792,458 and 5,208,021.

Ricin is the lectin RCA60 from Ricinus communis (Castor bean). For examples of ricin, see, U.S. Pat. Nos. 5,079,163 and 4,689,401. Ricinus communis agglutinin (RCA) occurs in two forms designated RCA60 and RCA120 according to their molecular weights of approximately 65 and 120 kD, respectively (Nicholson & Blaustein, J. Biochim. Biophys. Acta 266:543, 1972). The A chain is responsible for inactivating protein synthesis and killing cells. The B chain binds ricin to cell-surface galactose residues and facilitates transport of the A chain into the cytosol (Olsnes et al., Nature 249:627-631, 1974 and U.S. Pat. No. 3,060,165).

Ribonucleases have also been conjugated to targeting molecules for use as immunotoxins (see Suzuki et al., Nat. Biotech. 17:265-70, 1999). Exemplary ribotoxins such as α-sarcin and restrictocin are discussed in, for example Rathore et al., Gene 190:31-5, 1997; and Goyal and Batra, Biochem. 345 Pt 2:247-54, 2000. Calicheamicins were first isolated from Micromonospora echinospora and are members of the enediyne antitumor antibiotic family that cause double strand breaks in DNA that lead to apoptosis (see, for example Lee et al., J. Antibiot. 42:1070-87,1989). The drug is the toxic moiety of an immunotoxin in clinical trials (see, for example, Gillespie et al., Ann. Oncol. 11:735-41, 2000).

Abrin includes toxic lectins from Abrus precatorius. The toxic principles, abrin a, b, c, and d, have a molecular weight of from about 63 and 67 kD and are composed of two disulfide-linked polypeptide chains A and B. The A chain inhibits protein synthesis; the B chain (abrin-b) binds to D-galactose residues (see, Funatsu et al., Agr. Biol. Chem. 52:1095, 1988; and Olsnes, Methods Enzymol. 50:330-335, 1978).

A CAR, a T cell expressing a CAR, monoclonal antibodies, antigen binding fragments thereof, specific for one or more of the antigens disclosed herein, can also be conjugated with a detectable marker; for example, a detectable marker capable of detection by ELISA, spectrophotometry, flow cytometry, microscopy or diagnostic imaging techniques (such as computed tomography (CT), computed axial tomography (CAT) scans, magnetic resonance imaging (MRI), nuclear magnetic resonance imaging NMRI), magnetic resonance tomography (MTR), ultrasound, fiberoptic examination, and laparoscopic examination). Specific, non-limiting examples of detectable markers include fluorophores, chemiluminescent agents, enzymatic linkages, radioactive isotopes and heavy metals or compounds (for example super paramagnetic iron oxide nanocrystals for detection by MRI). For example, useful detectable markers include fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors and the like. Bioluminescent markers are also of use, such as luciferase, Green fluorescent protein (GFP), Yellow fluorescent protein (YFP). A CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, can also be conjugated with enzymes that are useful for detection, such as horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like. When a CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, is conjugated with a detectable enzyme, it can be detected by adding additional reagents that the enzyme uses to produce a reaction product that can be discerned. For example, when the agent horseradish peroxidase is present the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is visually detectable. A CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, may also be conjugated with biotin, and detected through indirect measurement of avidin or streptavidin binding. It should be noted that the avidin itself can be conjugated with an enzyme or a fluorescent label.

A CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, may be conjugated with a paramagnetic agent, such as gadolinium. Paramagnetic agents such as superparamagnetic iron oxide are also of use as labels. Antibodies can also be conjugated with lanthanides (such as europium and dysprosium), and manganese. An antibody or antigen binding fragment may also be labeled with a predetermined polypeptide epitopes recognized by a secondary reporter (such as leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags).

A CAR, a T cell expressing a CAR, an antibody, or antigen binding portion thereof, can also be conjugated with a radiolabeled amino acid. The radiolabel may be used for both diagnostic and therapeutic purposes. For instance, the radiolabel may be used to detect one or more of the antigens disclosed herein and antigen expressing cells by x-ray, emission spectra, or other diagnostic techniques. Further, the radiolabel may be used therapeutically as a toxin for treatment of tumors in a subject, for example for treatment of a neuroblastoma. Examples of labels for polypeptides include, but are not limited to, the following radioisotopes or radionucleotides: ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I.

Means of detecting such detectable markers are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted illumination. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.

D. Nucleotides, Expression, Vectors, and Host Cells

Further provided by an embodiment of the invention is a nucleic acid comprising a nucleotide sequence encoding any of the CARs, an antibody, or antigen binding portion thereof, described herein (including functional portions and functional variants thereof). The nucleic acids of the invention may comprise a nucleotide sequence encoding any of the leader sequences, antigen binding domains, transmembrane domains, and/or intracellular T cell signaling domains described herein.

In some embodiments, the nucleotide sequence may be codon-modified. Without being bound to a particular theory, it is believed that codon optimization of the nucleotide sequence increases the translation efficiency of the mRNA transcripts. Codon optimization of the nucleotide sequence may involve substituting a native codon for another codon that encodes the same amino acid, but can be translated by tRNA that is more readily available within a cell, thus increasing translation efficiency. Optimization of the nucleotide sequence may also reduce secondary mRNA structures that would interfere with translation, thus increasing translation efficiency.

In an embodiment of the invention, the nucleic acid may comprise a codon-modified nucleotide sequence that encodes the antigen binding domain of the inventive CAR. In another embodiment of the invention, the nucleic acid may comprise a codon-modified nucleotide sequence that encodes any of the CARs described herein (including functional portions and functional variants thereof).

“Nucleic acid” as used herein includes “polynucleotide,” “oligonucleotide,” and “nucleic acid molecule,” and generally means a polymer of DNA or RNA, which can be single-stranded or double-stranded, synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural or altered nucleotides, and which can contain a natural, non-natural or altered internucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. In some embodiments, the nucleic acid does not comprise any insertions, deletions, inversions, and/or substitutions. However, it may be suitable in some instances, as discussed herein, for the nucleic acid to comprise one or more insertions, deletions, inversions, and/or substitutions.

A recombinant nucleic acid may be one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques, such as those described in Sambrook et al., supra. The nucleic acids can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. See, for example, Sambrook et al., supra, and Ausubel et al., supra. For example, a nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides). Examples of modified nucleotides that can be used to generate the nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the invention can be purchased from companies, such as Integrated DNA Technologies (Coralville, Iowa, USA).

The nucleic acid can comprise any isolated or purified nucleotide sequence which encodes any of the CARs or functional portions or functional variants thereof. Alternatively, the nucleotide sequence can comprise a nucleotide sequence which is degenerate to any of the sequences or a combination of degenerate sequences.

An embodiment also provides an isolated or purified nucleic acid comprising a nucleotide sequence which is complementary to the nucleotide sequence of any of the nucleic acids described herein or a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of any of the nucleic acids described herein.

The nucleotide sequence which hybridizes under stringent conditions may hybridize under high stringency conditions. By “high stringency conditions” is meant that the nucleotide sequence specifically hybridizes to a target sequence (the nucleotide sequence of any of the nucleic acids described herein) in an amount that is detectably stronger than non-specific hybridization. High stringency conditions include conditions which would distinguish a polynucleotide with an exact complementary sequence, or one containing only a few scattered mismatches from a random sequence that happened to have a few small regions (e.g., 3-10 bases) that matched the nucleotide sequence. Such small regions of complementarily are more easily melted than a full-length complement of 14-17 or more bases, and high stringency hybridization makes them easily distinguishable. Relatively high stringency conditions would include, for example, low salt and/or high temperature conditions, such as provided by about 0.02-0.1 M NaCl or the equivalent, at temperatures of about 50-70° C. Such high stringency conditions tolerate little, if any, mismatch between the nucleotide sequence and the template or target strand, and are particularly suitable for detecting expression of any of the inventive CARs. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide.

Also provided is a nucleic acid comprising a nucleotide sequence that is at least about 70% or more, e.g., about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to any of the nucleic acids described herein.

In an embodiment, the nucleic acids can be incorporated into a recombinant expression vector. In this regard, an embodiment provides recombinant expression vectors comprising any of the nucleic acids. For purposes herein, the term “recombinant expression vector” means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors are not naturally-occurring as a whole.

However, parts of the vectors can be naturally-occurring. The recombinant expression vectors can comprise any type of nucleotides, including, but not limited to DNA and RNA, which can be single-stranded or double-stranded, synthesized or obtained in part from natural sources, and which can contain natural, non-natural or altered nucleotides. The recombinant expression vectors can comprise naturally-occurring or non-naturally-occurring internucleotide linkages, or both types of linkages. Preferably, the non-naturally occurring or altered nucleotides or internucleotide linkages do not hinder the transcription or replication of the vector.

In an embodiment, the recombinant expression vector can be any suitable recombinant expression vector, and can be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses. The vector can be selected from the group consisting of the pUC series (Fermentas Life Sciences, Glen Burnie, Md.), the pBluescript series (Stratagene, LaJolla, Calif.), the pET series (Novagen, Madison, Wis.), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, Calif.).

Bacteriophage vectors, such as λ{circumflex over (υ)}TIO, λ{circumflex over (υ)}TI 1, λZapII (Stratagene), EMBL4, and λNMI 149, also can be used. Examples of plant expression vectors include pBIO1, pBI101.2, pBHO1.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo (Clontech). The recombinant expression vector may be a viral vector, e.g., a retroviral vector or a lentiviral vector. A lentiviral vector is a vector derived from at least a portion of a lentivirus genome, including especially a self-inactivating lentiviral vector as provided in Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). Other examples of lentivirus vectors that may be used in the clinic, include, for example, and not by way of limitation, the LENTIVECTOR® gene delivery technology from Oxford BioMedica plc, the LENTIMAX™ vector system from Lentigen and the like. Nonclinical types of lentiviral vectors are also available and would be known to one skilled in the art.

A number of transfection techniques are generally known in the art (see, e.g., Graham et al., Virology, 52: 456-467 (1973); Sambrook et al., supra; Davis et al., Basic Methods in Molecular Biology, Elsevier (1986); and Chu et al, Gene, 13: 97 (1981).

Transfection methods include calcium phosphate co-precipitation (see, e.g., Graham et al., supra), direct micro injection into cultured cells (see, e.g., Capecchi, Cell, 22: 479-488 (1980)), electroporation (see, e.g., Shigekawa et al., BioTechniques, 6: 742-751 (1988)), liposome mediated gene transfer (see, e.g., Mannino et al., BioTechniques, 6: 682-690 (1988)), lipid mediated transduction (see, e.g., Feigner et al., Proc. Natl. Acad. Sci. USA, 84: 7413-7417 (1987)), and nucleic acid delivery using high velocity microprojectiles (see, e.g., Klein et al, Nature, 327: 70-73 (1987)).

In an embodiment, the recombinant expression vectors can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., supra, and Ausubel et al., supra. Constructs of expression vectors, which are circular or linear, can be prepared to contain a replication system functional in a prokaryotic or eukaryotic host cell. Replication systems can be derived, e.g., from ColE1, 2μ plasmid λ, SV40, bovine papilloma virus, and the like.

The recombinant expression vector may comprise regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host cell (e.g., bacterium, fungus, plant, or animal) into which the vector is to be introduced, as appropriate, and taking into consideration whether the vector is DNA- or RNA-based. The recombinant expression vector may comprise restriction sites to facilitate cloning.

The recombinant expression vector can include one or more marker genes, which allow for selection of transformed or transfected host cells. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like. Suitable marker genes for the inventive expression vectors include, for instance, neomycin/G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance genes.

The recombinant expression vector can comprise a native or nonnative promoter operably linked to the nucleotide sequence encoding the CAR (including functional portions and functional variants thereof), or to the nucleotide sequence which is complementary to or which hybridizes to the nucleotide sequence encoding the CAR. The selection of promoters, e.g., strong, weak, inducible, tissue-specific and developmental-specific, is within the ordinary skill of the artisan. Similarly, the combining of a nucleotide sequence with a promoter is also within the skill of the artisan. The promoter can be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, or a promoter found in the long-terminal repeat of the murine stem cell virus.

The recombinant expression vectors can be designed for either transient expression, for stable expression, or for both. Also, the recombinant expression vectors can be made for constitutive expression or for inducible expression.

Further, the recombinant expression vectors can be made to include a suicide gene. As used herein, the term “suicide gene” refers to a gene that causes the cell expressing the suicide gene to die. The suicide gene can be a gene that confers sensitivity to an agent, e.g., a drug, upon the cell in which the gene is expressed, and causes the cell to die when the cell is contacted with or exposed to the agent. Suicide genes are known in the art (see, for example, Suicide Gene Therapy: Methods and Reviews, Springer, Caroline J. (Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, UK), Humana Press, 2004) and include, for example, the Herpes Simplex Virus (HSV) thymidine kinase (TK) gene, cytosine daminase, purine nucleoside phosphorylase, and nitroreductase.

An embodiment further provides a host cell comprising any of the recombinant expression vectors described herein. As used herein, the term “host cell” refers to any type of cell that can contain the inventive recombinant expression vector. The host cell can be a eukaryotic cell, e.g., plant, animal, fungi, or algae, or can be a prokaryotic cell, e.g., bacteria or protozoa. The host cell can be a cultured cell or a primary cell, i.e., isolated directly from an organism, e.g., a human. The host cell can be an adherent cell or a suspended cell, i.e., a cell that grows in suspension. Suitable host cells are known in the art and include, for instance, DH5a E. coli cells, Chinese hamster ovarian cells, monkey VERO cells, COS cells, HEK293 cells, and the like. For purposes of amplifying or replicating the recombinant expression vector, the host cell may be a prokaryotic cell, e.g., a DH5a cell. For purposes of producing a recombinant CAR, the host cell may be a mammalian cell. The host cell may be a human cell. While the host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage, the host cell may be a peripheral blood lymphocyte (PBL) or a peripheral blood mononuclear cell (PBMC). The host cell may be a T cell.

For purposes herein, the T cell can be any T cell, such as a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupTl, etc., or a T cell obtained from a mammal. If obtained from a mammal, the T cell can be obtained from numerous sources, including but not limited to blood, bone marrow, lymph node, the thymus, or other tissues or fluids. T cells can also be enriched for or purified. The T cell may be a human T cell. The T cell may be a T cell isolated from a human. The T cell can be any type of T cell and can be of any developmental stage, including but not limited to, CD4⁺/CD8⁺ double positive T cells, CD4⁺ helper T cells, e.g., Th1 and Th2 cells, CD8⁺ T cells (e.g., cytotoxic T cells), tumor infiltrating cells, memory T cells, memory stem cells, i.e. Tscm, naive T cells, and the like. The T cell may be a CD8⁺ T cell or a CD4⁺ T cell.

In an embodiment, the CARs as described herein can be used in suitable non-T cells. Such cells are those with an immune-effector function, such as, for example, NK cells, and T-like cells generated from pluripotent stem cells.

Also provided by an embodiment is a population of cells comprising at least one host cell described herein. The population of cells can be a heterogeneous population comprising the host cell comprising any of the recombinant expression vectors described, in addition to at least one other cell, e.g., a host cell (e.g., a T cell), which does not comprise any of the recombinant expression vectors, or a cell other than a T cell, e.g., a B cell, a macrophage, a neutrophil, an erythrocyte, a hepatocyte, an endothelial cell, an epithelial cell, a muscle cell, a brain cell, etc. Alternatively, the population of cells can be a substantially homogeneous population, in which the population comprises mainly host cells (e.g., consisting essentially of) comprising the recombinant expression vector. The population also can be a clonal population of cells, in which all cells of the population are clones of a single host cell comprising a recombinant expression vector, such that all cells of the population comprise the recombinant expression vector. In one embodiment of the invention, the population of cells is a clonal population comprising host cells comprising a recombinant expression vector as described herein.

CARs (including functional portions and variants thereof), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and antibodies (including antigen binding portions thereof), can be isolated and/or purified. For example, a purified (or isolated) host cell preparation is one in which the host cell is more pure than cells in their natural environment within the body. Such host cells may be produced, for example, by standard purification techniques. In some embodiments, a preparation of a host cell is purified such that the host cell represents at least about 50%, for example at least about 70%, of the total cell content of the preparation. For example, the purity can be at least about 50%, can be greater than about 60%, about 70% or about 80%, or can be about 100%.

E. Methods of Treatment

It is contemplated that the CARs disclosed herein can be used in methods of treating or preventing a disease in a mammal. In this regard, an embodiment provides a method of treating or preventing cancer in a mammal, comprising administering to the mammal the CARs, the nucleic acids, the recombinant expression vectors, the host cells, the population of cells, the antibodies and/or the antigen binding portions thereof, and/or the pharmaceutical compositions in an amount effective to treat or prevent cancer in the mammal.

An embodiment further comprises lymphodepleting the mammal prior to administering the CARs disclosed herein. Examples of lymphodepletion include, but may not be limited to, nonmyeloablative lymphodepleting chemotherapy, myeloablative lymphodepleting chemotherapy, total body irradiation, etc.

For purposes of the methods, wherein host cells or populations of cells are administered, the cells can be cells that are allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal. As used herein, allogeneic means any material derived from a different animal of the same species as the individual to whom the material is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may be sufficiently unlike genetically to interact antigenically. As used herein, “autologous” means any material derived from the same individual to whom it is later to be re-introduced into the individual.

The mammal referred to herein can be any mammal. As used herein, the term “mammal” refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. The mammals may be from the order Carnivora, including Felines (cats) and Canines (dogs). The mammals may be from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). The mammals may be of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). Preferably, the mammal is a human.

With respect to the methods, the cancer can be any cancer, including any of acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bladder cancer (e.g., bladder carcinoma), bone cancer, brain cancer (e.g., medulloblastoma), breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma, gastrointestinal carcinoid tumor, head and neck cancer (e.g., head and neck squamous cell carcinoma), Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, leukemia, liquid tumors, liver cancer, lung cancer (e.g., non-small cell lung carcinoma and lung adenocarcinoma), lymphoma, mesothelioma, mastocytoma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia (ALL), and Burkitt's lymphoma, ovarian cancer, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, solid tumors, synovial sarcoma, gastric cancer, testicular cancer, thyroid cancer, and ureter cancer.

The terms “treat,” and “prevent” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the methods can provide any amount or any level of treatment or prevention of cancer in a mammal.

Furthermore, the treatment or prevention provided by the method can include treatment or prevention of one or more conditions or symptoms of the disease, e.g., cancer, being treated or prevented. Also, for purposes herein, “prevention” can encompass delaying the onset of the disease, or a symptom or condition thereof.

Another embodiment provides a method of detecting the presence of cancer in a mammal, comprising: (a) contacting a sample comprising one or more cells from the mammal with the CARs, the nucleic acids, the recombinant expression vectors, the host cells, the population of cells, the antibodies, and/or the antigen binding portions thereof, or the pharmaceutical compositions, thereby forming a complex, (b) and detecting the complex, wherein detection of the complex is indicative of the presence of cancer in the mammal.

The sample may be obtained by any suitable method, e.g., biopsy or necropsy. A biopsy is the removal of tissue and/or cells from an individual. Such removal may be to collect tissue and/or cells from the individual in order to perform experimentation on the removed tissue and/or cells. This experimentation may include experiments to determine if the individual has and/or is suffering from a certain condition or disease-state. The condition or disease may be, e.g., cancer.

With respect to an embodiment of the method of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal, the sample comprising cells of the mammal can be a sample comprising whole cells, lysates thereof, or a fraction of the whole cell lysates, e.g., a nuclear or cytoplasmic fraction, a whole protein fraction, or a nucleic acid fraction. If the sample comprises whole cells, the cells can be any cells of the mammal, e.g., the cells of any organ or tissue, including blood cells or endothelial cells.

The contacting can take place in vitro or in vivo with respect to the mammal. Preferably, the contacting is in vitro.

Also, detection of the complex can occur through any number of ways known in the art. For instance, the CARs disclosed herein, polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, or antibodies, or antigen binding portions thereof, described herein, can be labeled with a detectable label such as, for instance, a radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and element particles (e.g., gold particles) as disclosed supra.

Methods of testing a CAR for the ability to recognize target cells and for antigen specificity are known in the art. For instance, Clay et al., J. Immunol, 163: 507-513 (1999), teaches methods of measuring the release of cytokines (e.g., interferon-γ, granulocyte/monocyte colony stimulating factor (GM-CSF), tumor necrosis factor a (TNF-a) or interleukin 2 (IL-2)). In addition, CAR function can be evaluated by measurement of cellular cytotoxicity, as described in Zhao et al, J. Immunol, 174: 4415-4423 (2005).

Another embodiment provides for the use of the CARs, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and/or pharmaceutical compositions of the invention, for the treatment or prevention of a proliferative disorder, e.g., cancer, in a mammal. The cancer may be any of the cancers described herein.

Any method of administration can be used for the disclosed therapeutic agents, including local and systemic administration. For example, topical, oral, intravascular such as intravenous, intramuscular, intraperitoneal, intranasal, intradermal, intrathecal and subcutaneous administration can be used. The particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (for example the subject, the disease, the disease state involved, and whether the treatment is prophylactic). In cases in which more than one agent or composition is being administered, one or more routes of administration may be used; for example, a chemotherapeutic agent may be administered orally and an antibody or antigen binding fragment or conjugate or composition may be administered intravenously. Methods of administration include injection for which the CAR, CAR T Cell, conjugates, antibodies, antigen binding fragments, or compositions are provided in a nontoxic pharmaceutically acceptable carrier such as water, saline, Ringer's solution, dextrose solution, 5% human serum albumin, fixed oils, ethyl oleate, or liposomes. In some embodiments, local administration of the disclosed compounds can be used, for instance by applying the antibody or antigen binding fragment to a region of tissue from which a tumor has been removed, or a region suspected of being prone to tumor development. In some embodiments, sustained intra-tumoral (or near-tumoral) release of the pharmaceutical preparation that includes a therapeutically effective amount of the antibody or antigen binding fragment may be beneficial. In other examples, the conjugate is applied as an eye drop topically to the cornea, or intravitreally into the eye.

The disclosed therapeutic agents can be formulated in unit dosage form suitable for individual administration of precise dosages. In addition, the disclosed therapeutic agents may be administered in a single dose or in a multiple dose schedule. A multiple dose schedule is one in which a primary course of treatment may be with more than one separate dose, for instance 1-10 doses, followed by other doses given at subsequent time intervals as needed to maintain or reinforce the action of the compositions. Treatment can involve daily or multi-daily doses of compound(s) over a period of a few days to months, or even years. Thus, the dosage regime will also, at least in part, be determined based on the particular needs of the subject to be treated and will be dependent upon the judgment of the administering practitioner.

Typical dosages of the antibodies or conjugates can range from about 0.01 to about 30 mg/kg, such as from about 0.1 to about 10 mg/kg.

In particular examples, the subject is administered a therapeutic composition that includes one or more of the conjugates, antibodies, compositions, CARs, CAR T cells or additional agents, on a multiple daily dosing schedule, such as at least two consecutive days, 10 consecutive days, and so forth, for example for a period of weeks, months, or years. In one example, the subject is administered the conjugates, antibodies, compositions or additional agents for a period of at least 30 days, such as at least 2 months, at least 4 months, at least 6 months, at least 12 months, at least 24 months, or at least 36 months.

In some embodiments, the disclosed methods include providing surgery, radiation therapy, and/or chemotherapeutics to the subject in combination with a disclosed antibody, antigen binding fragment, conjugate, CAR or T cell expressing a CAR (for example, sequentially, substantially simultaneously, or simultaneously). Methods and therapeutic dosages of such agents and treatments are known to those skilled in the art, and can be determined by a skilled clinician. Preparation and dosing schedules for the additional agent may be used according to manufacturer's instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, (1992) Ed., M. C. Perry, Williams & Wilkins, Baltimore, Md.

In some embodiments, the combination therapy can include administration of a therapeutically effective amount of an additional cancer inhibitor to a subject. Non-limiting examples of additional therapeutic agents that can be used with the combination therapy include microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and RNA transcription inhibitors, antibodies, enzymes, enzyme inhibitors, gene regulators, and angiogenesis inhibitors. These agents (which are administered at a therapeutically effective amount) and treatments can be used alone or in combination. For example, any suitable anti-cancer or anti-angiogenic agent can be administered in combination with the CARS, CAR-T cells, antibodies, antigen binding fragment, or conjugates disclosed herein. Methods and therapeutic dosages of such agents are known to those skilled in the art, and can be determined by a skilled clinician.

Additional chemotherapeutic agents include, but are not limited to alkylating agents, such as nitrogen mustards (for example, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, and melphalan), nitrosoureas (for example, carmustine, fotemustine, lomustine, and streptozocin), platinum compounds (for example, carboplatin, cisplatin, oxaliplatin, and BBR3464), busulfan, dacarbazine, mechlorethamine, procarbazine, temozolomide, thiotepa, and uramustine; antimetabolites, such as folic acid (for example, methotrexate, pemetrexed, and raltitrexed), purine (for example, cladribine, clofarabine, fludarabine, mercaptopurine, and tioguanine), pyrimidine (for example, capecitabine), cytarabine, fluorouracil, and gemcitabine; plant alkaloids, such as Podophyllum (for example, etoposide, and teniposide), taxane (for example, docetaxel and paclitaxel), Vinca (for example, vinblastine, vincristine, vindesine, and vinorelbine); cytotoxic/antitumor antibiotics, such as anthracycline family members (for example, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin), bleomycin, rifampicin, hydroxyurea, and mitomycin; topoisomerase inhibitors, such as topotecan and irinotecan; monoclonal antibodies, such as alemtuzumab, bevacizumab, cetuximab, gemtuzumab, rituximab, panitumumab, pertuzumab, and trastuzumab; photosensitizers, such as aminolevulinic acid, methyl aminolevulinate, porfimer sodium, and verteporfin; and other agents, such as alitretinoin, altretamine, amsacrine, anagrelide, arsenic trioxide, asparaginase, axitinib, bexarotene, bevacizumab, bortezomib, celecoxib, denileukin diftitox, erlotinib, estramustine, gefitinib, hydroxycarbamide, imatinib, lapatinib, pazopanib, pentostatin, masoprocol, mitotane, pegaspargase, tamoxifen, sorafenib, sunitinib, vemurafinib, vandetanib, and tretinoin. Selection and therapeutic dosages of such agents are known to those skilled in the art, and can be determined by a skilled clinician.

The combination therapy may provide synergy and prove synergistic, that is, the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately. A synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation, a synergistic effect may be attained when the compounds are administered or delivered sequentially, for example by different injections in separate syringes. In general, during alternation, an effective dosage of each active ingredient is administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.

In one embodiment, an effective amount of an antibody or antigen binding fragment that specifically binds to one or more of the antigens disclosed herein or a conjugate thereof is administered to a subject having a tumor following anti-cancer treatment. After a sufficient amount of time has elapsed to allow for the administered antibody or antigen binding fragment or conjugate to form an immune complex with the antigen expressed on the respective cancer cell, the immune complex is detected. The presence (or absence) of the immune complex indicates the effectiveness of the treatment. For example, an increase in the immune complex compared to a control taken prior to the treatment indicates that the treatment is not effective, whereas a decrease in the immune complex compared to a control taken prior to the treatment indicates that the treatment is effective.

F. Biopharmaceutical Compositions

Biopharmaceutical or biologics compositions (hereinafter, “compositions”) are provided herein for use in gene therapy, immunotherapy and/or cell therapy that include one or more of the disclosed CARs, or T cells expressing a CAR, antibodies, antigen binding fragments, conjugates, CARs, or T cells expressing a CAR that specifically bind to one or more antigens disclosed herein, in a carrier (such as a pharmaceutically acceptable carrier). The compositions can be prepared in unit dosage forms for administration to a subject. The amount and timing of administration are at the discretion of the treating clinician to achieve the desired outcome. The compositions can be formulated for systemic (such as intravenous) or local (such as intra-tumor) administration. In one example, a disclosed CARs, or T cells expressing a CAR, antibody, antigen binding fragment, conjugate, is formulated for parenteral administration, such as intravenous administration. Compositions including a CAR, or T cell expressing a CAR, a conjugate, antibody or antigen binding fragment as disclosed herein are of use, for example, for the treatment and detection of a tumor, for example, and not by way of limitation, a neuroblastoma. In some examples, the compositions are useful for the treatment or detection of a carcinoma. The compositions including a CAR, or T cell expressing a CAR, a conjugate, antibody or antigen binding fragment as disclosed herein are also of use, for example, for the detection of pathological angiogenesis.

The compositions for administration can include a solution of the CAR, or T cell expressing a CAR, conjugate, antibody or antigen binding fragment dissolved in a pharmaceutically acceptable carrier, such as an aqueous carrier. A variety of aqueous carriers can be used, for example, buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, adjuvant agents, and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of a CAR, or T cell expressing a CAR, antibody or antigen binding fragment or conjugate in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the subject's needs. Actual methods of preparing such dosage forms for use in in gene therapy, immunotherapy and/or cell therapy are known, or will be apparent, to those skilled in the art.

A typical composition for intravenous administration includes about 0.01 to about 30 mg/kg of antibody or antigen binding fragment or conjugate per subject per day (or the corresponding dose of a CAR, or T cell expressing a CAR, conjugate including the antibody or antigen binding fragment). Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 19^(th) ed., Mack Publishing Company, Easton, Pa. (1995).

A CAR, or T cell expressing a CAR, antibodies, antigen binding fragments, or conjugates may be provided in lyophilized form and rehydrated with sterile water before administration, although they are also provided in sterile solutions of known concentration. The CARs, or T cells expressing a CAR, antibody or antigen binding fragment or conjugate solution is then added to an infusion bag containing 0.9% sodium chloride, USP, and in some cases administered at a dosage of from 0.5 to 15 mg/kg of body weight. Considerable experience is available in the art in the administration of antibody or antigen binding fragment and conjugate drugs; for example, antibody drugs have been marketed in the U.S. since the approval of R_(ITUXAN)® in 1997. A CAR, or T cell expressing a CAR, antibodies, antigen binding fragments and conjugates thereof can be administered by slow infusion, rather than in an intravenous push or bolus. In one example, a higher loading dose is administered, with subsequent, maintenance doses being administered at a lower level. For example, an initial loading dose of 4 mg/kg antibody or antigen binding fragment (or the corresponding dose of a conjugate including the antibody or antigen binding fragment) may be infused over a period of some 90 minutes, followed by weekly maintenance doses for 4-8 weeks of 2 mg/kg infused over a 30 minute period if the previous dose was well tolerated.

Controlled release parenteral formulations can be made as implants, oily injections, or as particulate systems. For a broad overview of protein delivery systems see, Banga, A. J., Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Technomic Publishing Company, Inc., Lancaster, Pa., (1995). Particulate systems include microspheres, microparticles, microcapsules, nanocapsules, nanospheres, and nanoparticles. Microcapsules contain the therapeutic protein, such as a cytotoxin or a drug, as a central core. In microspheres, the therapeutic is dispersed throughout the particle. Particles, microspheres, and microcapsules smaller than about 1 μm are generally referred to as nanoparticles, nanospheres, and nanocapsules, respectively. Capillaries have a diameter of approximately 5 μm so that only nanoparticles are administered intravenously. Microparticles are typically around 100 μm in diameter and are administered subcutaneously or intramuscularly. See, for example, Kreuter, J., Colloidal Drug Delivery Systems, J. Kreuter, ed., Marcel Dekker, Inc., New York, N.Y., pp. 219-342 (1994); and Tice & Tabibi, Treatise on Controlled Drug Delivery, A. Kydonieus, ed., Marcel Dekker, Inc. New York, N.Y., pp. 315-339, (1992).

Polymers can be used for ion-controlled release of the CARs, or T cells expressing a CAR, antibody or antigen binding fragment or conjugate compositions disclosed herein. Various degradable and nondegradable polymeric matrices for use in controlled drug delivery are known in the art (Langer, Accounts Chem. Res. 26:537-542, 1993). For example, the block copolymer, polaxamer 407, exists as a viscous yet mobile liquid at low temperatures but forms a semisolid gel at body temperature. It has been shown to be an effective vehicle for formulation and sustained delivery of recombinant interleukin-2 and urease (Johnston et al., Pharm. Res. 9:425-434, 1992; and Pec et al., J. Parent. Sci. Tech. 44(2):58-65, 1990). Alternatively, hydroxyapatite has been used as a microcarrier for controlled release of proteins (Ijntema et al., Int. J. Pharm. 112:215-224, 1994). In yet another aspect, liposomes are used for controlled release as well as drug targeting of the lipid-capsulated drug (Betageri et al., Liposome Drug Delivery Systems, Technomic Publishing Co., Inc., Lancaster, Pa. (1993)). Numerous additional systems for controlled delivery of therapeutic proteins are known (see U.S. Pat. Nos. 5,055,303; 5,188,837; 4,235,871; 4,501,728; 4,837,028; 4,957,735; 5,019,369; 5,055,303; 5,514,670; 5,413,797; 5,268,164; 5,004,697; 4,902,505; 5,506,206; 5,271,961; 5,254,342 and 5,534,496).

G. Kits

In one aspect, kits employing the CARs disclosed herein are also provided. For example, kits for treating a tumor in a subject, or making a CAR T cell that expresses one or more of the CARs disclosed herein. The kits will typically include a disclosed antibody, antigen binding fragment, conjugate, nucleic acid molecule, CAR or T cell expressing a CAR as disclosed herein. More than one of the disclosed antibodies, antigen binding fragments, conjugates, nucleic acid molecules, CARs or T cells expressing a CAR can be included in the kit.

The kit can include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container typically holds a composition including one or more of the disclosed antibodies, antigen binding fragments, conjugates, nucleic acid molecules, CARs or T cells expressing a CAR. In several embodiments the container may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). A label or package insert indicates that the composition is used for treating the particular condition.

The label or package insert typically will further include instructions for use of a disclosed antibodies, antigen binding fragments, conjugates, nucleic acid molecules, CARs or T cells expressing a CAR, for example, in a method of treating or preventing a tumor or of making a CAR T cell. The package insert typically includes instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. The instructional materials may be written, in an electronic form (such as a computer diskette or compact disk) or may be visual (such as video files). The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit may additionally contain means of detecting a label (such as enzyme substrates for enzymatic labels, filter sets to detect fluorescent labels, appropriate secondary labels such as a secondary antibody, or the like). The kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.

EXAMPLES

This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

Example 1 Derivation of Human BCMA-Specific Binders from a Fully Human Yeast Display Library Materials and Methods

A large yeast display human naive single chain variable fragment (ScFv) antibody library was used to isolate anti-human BCMA antibodies described herein. The library was constructed using a collection of human antibody gene repertoires from more than 60 individuals. Three rounds of magnetic-activated cell sorting (MACS) were performed to enrich human ScFv binders to the recombinant human BCMA (ectodomain)-Fc. For the first round of yeast library panning, the yeast display ScFv library (5×10¹⁰ cells) was incubated with 5 μg/ml BCMA-Fc in 15 ml PBSA (consisting of 0.1% Bovine Serum Albumin (BSA) in Dulbecco's phosphate-buffered saline (PBS) buffer), at room temperature on a rotator for 1.5 hours. After two times washing with 25 ml PBSA, the yeast library mix was incubated with 100 μL Protein G microbeads (Miltenyi Biotec) at room temperature on a rotator for 30 minutes. After one time washing, the library mix was resuspended in 50 ml of PBSA and loaded onto the MACS cell separation column (LS column). After three times washing with 10 ml PBSA. The yeast displayed ScFv binders to the column were then eluted two times with 2 ml PBSA. These eluted yeast cells were combined and then resuspended into 50 ml SDCAA medium (20 g D-glucose, 6.7 g BD Difco™ Yeast Nitrogen Base without Amino Acids, 5 g Bacto™ Casamino Acids, 5.4 g Na₂.HPO₄, and 8.56 g NaH₂PO₄.H₂O in 1 L water) and amplified with shaking at 225 rpm at 30° C. for 20 hours. The amplified pool was then induced in SGCAA medium (consisting of the same composition of SDCAA medium, but containing galactose instead of glucose), with shaking at 225 rpm at 30° C. for another 16 hours and used for next round of panning. The same process was repeated two more times to enrich the BCMA-Fc specific binders.

To further enrich the binders with higher affinity and better specificity, FACS based sorting was employed to isolate the strongest binders from the pool. The induced pool was incubated with 0.1 μg/ml of biotinylated BCMA-Fc at room temperature for 1 hour and then stained with Anti-c-Myc-Alexa 488 and Streptavidin-PE conjugates, the top 1% of the pool with the highest PE versus FITC signal was gated and sorted. The sorted pool was amplified in SDCAA medium and yeast plasmid DNA was extracted and transformed into bacterial for single clone DNA sequencing. 50 random clones were sequenced and 48 unique sequences were identified. 17 clones designated as MTB-1, MTB-2, MTB-3, MTB-4, MTB-5, MTB-14, MTB-15, MTB-16, MTB-25, MTB-28, MTB-37, MTB-39, MTB-40, MTB-49, MTB-50, MTB-4-12 and MTB-4-45 were cloned into CAR constructs for CAR-T function screening.

Example 2 Generation and Testing of BCMA-Targeting CAR T Constructs Incorporating Fully Human Binder ScFv Sequences

This Example 2 describes the creation of a CAR T cells targeting the tumor antigen BCMA for the treatment if MM and other BCMA-positive malignancies.

Schema of BCMA CAR design is shown in FIG. 1. Fully human ScFv binders targeting BCMA were linked in frame to CD8 hinge and transmembrane domain, 4-1BB costimulatory domain and CD3 zeta activation domain. CAR sequences were incorporated into third-generation lentiviral vectors and which were used in transduction of human primary T cells to generate the BCMA CAR T cells.

Table 1 below lists the BCMA CAR constructs built, designated by ScFv sequence used in CAR design in the left column, and the corresponding designation of the ScFv clone nomenclature in each construct in the right column.

TABLE 1 List of ScFv Clones used in CAR designs ScFv Sequence Designation ScFv Clone nomenclature sequence 1 MTB-1 sequence 2 MTB-2 sequence 3 MTB-3 sequence 4 MTB-4 sequence 5 MTB-5 sequence 14 MTB-14 sequence 15 MTB-15 sequence 16 MTB-16 sequence 25 MTB-25 sequence 28 MTB-28 sequence 37 MTB-37 sequence 39 MTB-39 sequence 40 MTB-40 sequence 49 MTB-49 sequence 50 MTB-50 sequence 4-12 MTB-4-12 sequence 4-45 MTB-4-45

The surface expression of anti-BCMA CARs incorporating single chain fragment variable (ScFv) sequences, is shown in FIG. 2. The expression level for each ScFv—containing CAR was determined by flow cytometric analysis of LV-transduced T cells from healthy donors using either Protein L detection method, or the BCMA—Fc method. In a Protein L detection method, CAR T cells and controls were stained in a two-step procedure with: step 1) protein L-biotin conjugate, followed by step 2) streptavidin—PE reagent. In a BCMA-Fc method, cells were stained with: step 1: BCMA-Fc peptide; followed by step 2: anti-Fc APC reagent. Results from both methods were taken into account when analyzing CAR expression. All CAR constructs were successfully expressed in human primary T cells, with the exception of CAR construct with ScFv sequence 15, which could not be detected by either of the staining methods (FIG. 2). Untransduced cells (UTD) were used as a negative staining control indicating the specificity of CAR T staining. Next, the cytolytic function of anti BCMA CARs was evaluated in a luciferase-based killing assay (FIG. 3).

CAR T cells were incubated with multiple myeloma BCMA-positive tumor lines RPMI-8226-luc, or MM1.S-luc, or with a BCMA-negative line 293T-luc, in order to control for non-specific CAR activation.

Effector CART cells and tumor cells were combined at effector to target (E:T) ratio of 5:1 or 10:1 in order to compare and contrast the potency of the different CAR constructs (FIG. 3). RPMI-8226 cells were most susceptible cell line to BCMA CAR-mediated tumor killing, with most CAR constructs achieving over 40% tumor lysis at the lowest E:T ratio of 5 (FIG. 3A), except for CARS containing ScFv sequence 1, sequence 2, sequence 15, or sequence 25, whereas the negative control untransduced T cells, the UTD group, caused no appreciable tumor lysis (FIG. 3A). In multiple myeloma MM1.S cells, which are less susceptible to cytolysis, strong killing function of CARs with ScFv sequence 5, sequence 16, sequence 37, and sequence 40 was observed, but not for the other constructs. The UTD group caused no appreciable tumor killing, indicating that the killing is CAR-specific (FIG. 3B). No killing of 293T cells, which lack the BCMA target antigen was seen, indicating the specificity of killing response (FIG. 3C).

Based on these results, CAR T constructs D0084, D0085, D0087, D0099, D0100, incorporating ScFv binder sequences 5, 16, 37, 40, 4-12, and 4-45, respectively, were used for further testing (Table 2).

TABLE 2 CAR Construct Numbers and the Corresponding ScFv sequences ScFv Sequence CAR Construct Number LTG Number Designation D0084 LTG2860 sequence 5 D0085 LTG2861 sequence 16 D0086 LTG2862 sequence 37 D0087 LTG2863 sequence 40 D0099 LTG2944 sequence 4-12 D0100 LTG2945 sequence 4-45

Next, expression of BCMA CAR constructs was evaluated by transduction of human CD4+CD8+ T cells at a fixed multiplicity of infection of 40 (FIG. 4). T cells were isolated from a human buffy coat product and transduced with lentiviral vectors encoding the CARs as described in Materials and Methods. CAR+ T cells were detected using BCMA-Fc peptide, followed by anti-Fc APC. Cells were counterstained with CD8 antibody-FL in order to confirm CAR expression among CD8+ and CD8− (CD4+) T cells. All constructs were expressed robustly, in CD4+ as well as CD8+ T cells. The total CAR expression frequencies ranged from 19.5% to 49.3% (FIG. 4).Data for one representative donor out of three transduction experiments is shown.

Then, CAR constructs D0084, D0085, D0087, D0099, D0100 were compared in terms of their tumor cytolytic capacity in a luciferase-based killing assay. Target lines stably expressing firefly luciferase were used, as above. CAR T cells from two separate donors are shown in order to demonstrate robustness and reproducibility of the results (FIG. 5).

Robust killing capacity of CARs D0084, D0085, D0087, D0099, D0100 was demonstrated in the BCMA-positive multiple myeloma cell lines MM1.S and RPMI-8226. No appreciable killing was observed in UTD negative control groups, indicating the dependence of the killing on CAR expression. Moreover, no killing was seen against BCMA-negative 293T cells, demonstrating that the killing is BCMA-dependent (FIG. 5).

Example 3 In Vivo Testing of BCMA-Targeting CAR T Constructs Incorporating Fully Human Binder ScFv Sequences

Example 3 describes long-term in vitro, and xenograft model in vivo evaluation of a CAR T cells targeting the tumor antigen BCMA for the treatment in multiple myeloma and other BCMA-positive malignancies. These testing modalities provide a more stringent environment for CAR T evaluation, and better approximate the conditions that CAR T cells may encounter in human patients.

Note: for clarity and brevity, in this and the following Examples, one zero was omitted form CAR construct names shown in Table 2. Therefore, CAR construct D0100 became D100, CAR construct D0085 became D085, etc.

Materials and Methods

T-Cell Transduction and Culture

Primary CD4 and CD8 T-cells were activated with TransAct (Miltenyi Biotec, Auburn Calif.) according to the manufacturer's protocol. The cells were cultured overnight at a density of 1e6 cells/ml in TexMACS media (Miltenyi Biotec) supplemented with 30 U/ml of recombinant human IL-2 (Miltenyi Biotec). After 18-24 hours, the T-cells were transduced with lentiviral vectors containing the CAR constructs. The T-cells were incubated with the lentiviral vectors for 2 days, and the cultures were subsequently washed and re-suspended in fresh TexMACS media with IL-2 and maintained at a density of 0.5e6 cells/ml. On day 6 or 7 after the start of T-cell culture, the cell surface expression of the CARs was assessed by flow cytometry.

Flow Cytometry Staining

To assess the cell surface expression of BCMA CARs, 0.5-1e6 CAR T-cells were resuspended in FACs buffer (Miltenyi Biotec's autoMACS Rinsing Solution+MACS BSA Stock Solution) and incubated with 0.5 ug of recombinant human BCMA Fc Chimera Protein (RNDsystems) for 20 mins at 4° C. Cells were washed twice and re-suspended in FACs buffer and incubated for 20 mins at 4° C. with anti-Fc-Alexa Fluor 647 at 1:200 dilution. Cells were again washed twice and resuspended in FACs buffer and incubated for 20 mins at 4° C. with anti-CD4-Vioblue or anti-CD8-Viogreen (Miltenyi Biotec) at 1:50 dilution and 7AAD at 1:20 dilution. Cells were subsequently washed and analyzed using the MACSQuant® Analyzer 10 flow cytometer (Miltenyi Biotec).

For exhaustion marker staining, CAR T-cells were resuspended in FACs buffer and incubated with anti-PD-1-Pevio770 (Miltenyi Biotec) and anti-LAG-3-APC (Biolegend) at 1:30 dilution. Memory markers were stained by incubating CAR T-cells with anti-CD45RO-Pevio770, anti-CD45RA-APC, and CD62L-PE (Miltenyi Biotec) at 1:30 dilution. For both exhaustion and memory staining panels, cells were additionally stained with CD8-Viogreen, CD3-Vioblue, and 7AAD. Cells were incubated with the antibodies for 20 mins at 4° C., and subsequently washed then acquired using the MACSQuant Analyzer 10 flow cytometer.

For intracellular cytokine staining, T-cells were incubated with target cells for 5-6 hours at 37° C. in the presence of Brefeldin A (BD Biosciences, CA). Cells were subsequently stained as previously described with cell surface markers CD8-Viogreen and CD3-Vioblue. After cell surface staining, cells were fixed and permeabilized with Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer's protocol. Cells were then stained with anti-IFN-gamma-APC, anti-TNF-APCvio770, and IL-2-PE (Miltenyi Biotec) at dilutions suggested by the manufacturer. After staining, cells were analyzed using the MACSQuant Analyzer 10 flow cytometer.

Long-Term Co-Culture

For the long term co-culture experiment, CAR T-cells were co-cultured with target cells, MM1.S or RPMI-8226 expressing GFP, at an ETT ratio of 0.1-0.3. The cells were cultured in 6-well plates with TexMACS media that was either treated with 10 ng/ml of human recombinant TGF-β (Miltenyi Biotec) or remained untreated. The co-culture was fed by adding TGF-β-treated media or untreated media every 2-3 days. The absolute counts of T-cells and target cells at different time points during the long-term co-culture was assessed by quantifying the number of CD3+ cells and GFP+ cells using flow cytometry. The absolute counts were determined by normalizing the number of acquired cells using CountBright Absolute Counting Beads (Molecular Probes). When less than 15% of the target cells remained, T-cells from the co-culture were added to fresh target cells at an ETT ratio of 0.1-0.3 to initiate the subsequent round of co-culture. Additional rounds of co-culture were done until the T-cells no longer proliferated.

In Vivo Tumor Model

Female 7 to 8-week old NSG mice (NOD.Cg-Prkdc^(scid)Il2rg^(tm1Wj)l/SzJ) from Jackson Laboratory (Bar Harbor, Me.) were intradermally injected on the abdomen with 8e6 RPMI-8226 cells. T-cells were intravenously injected after the tumors were allowed to engraft for 18-20 days and have reached volume sizes of >60 mm³ as measured via caliper. For groups receiving CAR T-cells, 5e6 CAR T-cells were infused, and the differences in CAR expression levels between groups were normalized by adjusting the number of total T-cells that was injected. The number of T-cells that was infused in the UTD group was the mean of the total T-cells that was injected in the CAR T-cell groups. On day 6-7 after T-cell infusion, 3-5 mice from each group (except the untreated group) were sacrificed for tumor harvest, while the rest were monitored for tumor progression and survival. Tumor sizes and body weights were measured every 2-3 days. Mice with tumor sizes reaching >1200 mm were sacrificed.

CAR constructs D100 and D085 were compared side-by side in a long-term co-incubation with targets in vitro. This assay facilitates long-term exposure of CAR-T cells to target antigens such as may occur in vivo and in the clinic, and may help identify critical differences in long-term function of CAR T cells. D100 and D085 CARs were comprised CD8 extracellular and transmembrane domain, 4-1BB/CD137 co-stimulation domain and CD3ζ activation domains, and differed only in the scFv sequence (FIG. 6A). Both CAR constructs achieved robust expression at MOI (multiplicity of infection) 10, 20, or 40. CAR T lines with similar CAR surface expression were chosen for the long term assay: 84.6% for D100, 81.5% for D085, (FIG. 6B).

CAR T and target cells were combined at the beginning of the first round of co-culture at E:T ratio of 0.1:1, then fresh target RPMI-8226 cells were spiked into the culture at the beginning of each consecutive round, to replace target cells which have been killed by CAR T cells, and maintain the desired E:T ratio (FIG. 6C). The BCMA CAR D100 demonstrated greater T cell expansion in the 1^(st), 3^(rd), and 4^(th) round of the long-term co-culture as compared to CAR D085 (FIG. 6D). In addition, CAR D100 mediated superior target cell killing in the long term, as seen in the 4^(th) co-culture round (FIG. 6E). Of note, in the course of the 20-day co-culture period, the percentage of CD8+T cell subsets of both CAR D085 and D100 continued to increase, whereas the percentage of CD4+T in CAR D085 and D100 populations decreased, especially at the later stages of co-incubation (FIG. 6F). This is to be expected, as CD8+T cells are known to dominate the later stages of the anti-tumor response. However, the percentage of both CD4+T and CD8+T subsets in CAR100 co-cultures with target cells remained higher than the respective T cell subsets in CAR085 (FIG. 6F). Finally, the production of inflammatory cytokines IL-2, and TNFa crucial for CAR T function, was greater in the CAR100 T cells, as compared to CAR085, whereas the levels of IFNγ were similar (FIG. 6G). Overall, the BCMA CAR D100 demonstrated superior target cell killing, expansion of CD4+T and CD8+T subsets, and cytokine elaboration, as compared to the BCMA CAR D085.

The in vivo anti-tumor function of BCMA CAR D085 and D100 were then evaluated in an RPMI-8226 intradermal xenograft mouse model. Mice were implanted with RPMI-8226 cells seventeen days prior to CAR T administration. Mice with established RPMI-8226 were treated with CAR T cells or untransduced cells (UTD) intravenously, and maintained for tumor progression analysis. Tumors were harvested from a subset of mice in each group six days after CAR administration, for CAR T function analysis (FIG. 7A). Tumor progression as recorded for a period of fifty days after tumor implant (FIG. 7B). Whereas both CAR D085 and CAR100 mediated tumor rejection in this xenograft model, the BCMA CAR D100 was more efficient and reduced tumor size to below the detection limit by study day 35, whereas in mice treated with CAR D085 tumors shrunk but were still detectable at the conclusion of the observation period (FIG. 7B). CAR D100 and CAR D085 both mediated 100% survival in this model, in contrast to untreated mice and the negative UTD control mice which have met sacrifice criteria (FIG. 7C). Therefore, CAR 100 was superior in anti-tumor function to CAR D085 in vivo, and showed no adverse toxicity.

An additional CAR candidate, CAR D153, was developed utilizing an scFv sequence 4-1c. The 4-1c scFv sequence was derived as described in Example 1. The 4-1c scFv sequence was incorporated into an identical CAR architecture to that used in CAR D100 and D085 as shown in FIG. 6A. Transduction of CAR D153 lentiviral vector into primary human T cells achieved comparable CAR expression levels to CAR D085 and CARD100 (FIG. 8A). Moreover, CAR D153 mediated potent lysis of BCMA-positive multiple myeloma target cell lines RPMI-8226 and MM1.S, similarly to CAR D100 and CARD085 (FIG. 8B). In the intradermal xenograft RPMI-8226 in vivo model (FIG. 7A), CAR D153 demonstrated potency equal or greater to that of the BCMA CAR D100 (FIG. 8C). Therefore, CAR D153 represents another highly efficient candidate for the treatment of BCMA-positive malignancies.

Example 4 Generation and Testing of an Armored BCMA CAR Incorporating a TGFβ Decoy Receptor for Improved CAR Potency in Suppressive Tumor Microenvironment

Example 4 describes the development and characterization of an armored BCMA CAR incorporating a TGFBRII DN, a dominant-negative form of the TGFβ receptor, for superior anti-tumor performance.

Materials and Methods

Generation of the TGFβRII Dominant Negative BCMA CAR

The sequence of the extracellular and transmembrane domains of the human TGFβRII (GenBank ID: AHI94914.1, amino acid residues 1-191), was cloned downstream of the BCMA D100 CAR. The CAR and the TGFβRII sequences were separated by a ribosome skip site (P2A), which was derived from the porcine teschovirus-1 polyprotein (AA 976-997, GenBank ID: CAB40546.1, mutated residue P977S). P2A is flanked on each side with a furin cleavage site (amino acids: RAKR). All DNA sequences were codone-optimized (IDT DNA, Coralville, Iowa).

Results

Clinical studies have revealed that resistance to BCMA CAR T therapy may emerge due to tumor-suppressive microenvironment, in part in the bone marrow. To better equip the BCMA CAR T cells for tumor-suppressive scenarios, the D100 CAR sequence has been combined with a decoy TGFβ receptor, to generate an armored BCMA CAR (FIG. 9A). The TGFBRII DN decoy receptor is comprised of the extracellular ligand binding domain and the transmembrane region of the TGFβRII, but lacks the intracellular signaling kinase domain of the TGF receptor. The BCMA CAR100 and the TGF decoy sequence were combined in a bicistronic expression cassette in a lentiviral vector backbone under the control of EF-1α promoter, to facilitate equal co-expression of both the CAR and the decoy receptor polyproteins in T cells (FIG. 9A). This armored BCMA CAR construct is termed D158. Successful transduction of the D158 construct into human primary T cells was achieved (FIG. 9B). To evaluate the armored BCMA CAR D158 function, an experimental co-culture with RPMI-8226 target cells was performed for two rounds of target addition (FIG. 9C). CAR D100, which shares the CAR sequence with the armored CAR construct D158, but lacks the armored decoy element, was included for comparison (FIG. 9D, 9E). A subset of co-cultures was treated with 10 ng/ml soluble TGF during co-incubation, to mimic the immunosuppressive tumor microenvironment. In both the first and the second round of co-incubation, the expansion of D100 BCMA CAR in the presence of soluble TGFβ was suppressed as compared to TGFβ-free culture. By contrast, the expansion of the armored BCMA CAR construct D158 remained unaffected by TGFβ addition (FIG. 9D). Subsequently, target cell counts remained similarly repressed between experimental groups in the first round of co-incubation, but have resurged in the second round in CAR 100 group spiked with soluble TGFβ, whereas the armored CAR maintained strong repression of tumor cells expansion regardless of TGFβ addition throughout the experiment (FIG. 9E). These findings demonstrate the protective effects of TGFβ armored BCMA CAR T cells in TGFβ-rich, T-cell suppressive tumor environment.

The sources of TGFβ in tumor microenvironment may include the tumor cells or the stromal cells, The RPMI-8226 multiple myeloma cells are capable of producing TGFβ in its inactive form (FIG. 10A), which may then be converted to its active form by other elements of tumor microenvironment in vivo.

The armored BCMA CAR D158 and the respective non-armored D100 BCMA CAR were evaluated in the RPMI-8226 intradermal xenograft model in vivo (FIG. 10B). Despite an unexpected anti-tumor effect observed in the mice treated with untransduced T cells (UTD), the armored CAR D158 demonstrated a superior tumor control as compared to the non-armored CAR version with same CAR sequence, D100 (FIG. 10C). Both the armored CAR D158 and the non-armored CAR D100 mediated 100% survival in this mouse model (FIG. 10D). In tumor tissue harvested six days after CAR administration, tumors of mice treated with the armored BCMA CAR D158 contained greater absolute T cell counts (FIG. 10E), and T cell percentage (FIG. 10F) than tumors of mice treated with the non-armored CAR D100. In addition, the armored CAR D158 mediated greater PD-1 expression on tumor-infiltrating lymphocytes (TIL) (FIG. 10G), and greater TIL memory cell fraction (FIG. 10H). These observations point to a stronger T cell activation and greater memory formation by the armored CAR D158, as compared to the non-armored CAR D100. Overall, the armored BCMA CAR D158 demonstrates a more potent anti-tumor activity in vivo as compared to the non-armored CAR D100, greater tumor infiltration, stronger activation and memory formation. All these features suggest a potential greater clinical benefit of the armored CAR D158.

Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications and patents (including during the prosecution of each issued patent; “application cited documents”), and each of the PCT and foreign applications or patents corresponding to and/or claiming priority from any of these applications and patents, and each of the documents cited or referenced in each of the application cited documents, are hereby expressly incorporated herein by reference, and may be employed in the practice of the invention. More generally, documents or references are cited in this text, either in a Reference List before the claims, or in the text itself; and, each of these documents or references (“herein cited references”), as well as each document or reference cited in each of the herein cited references (including any manufacturer's specifications, instructions, etc.), is hereby expressly incorporated herein by reference.

The foregoing description of some specific embodiments provides sufficient information that others can, by applying current knowledge, readily modify or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. In the drawings and the description, there have been disclosed exemplary embodiments and, although specific terms may have been employed, they are unless otherwise stated used in a generic and descriptive sense only and not for purposes of limitation, the scope of the claims therefore not being so limited. Moreover, one skilled in the art will appreciate that certain steps of the methods discussed herein may be sequenced in alternative order or steps may be combined. Therefore, it is intended that the appended claims not be limited to the particular embodiment disclosed herein. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments of the invention described herein. Such equivalents are encompassed by the following claims.

REFERENCE TO THE SEQUENCE LISTING

This application contains a Sequence Listing electronically submitted to the United States Patent and Trademark Office via a PDF file entitled “Sequence Listing”. The Sequence Listing is incorporated by reference.

SEQUENCES OF THE DISCLOSURE

The nucleic and amino acid sequences listed below are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:

nucleotide sequence of BCMA ScFv binder MTB-1 SEQ ID NO: 1 GAGGTGCAGCTGGTGGAGACTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGATGACACGGCTGTGTATTACTGTGCGAGAGATTGG GAGGGCTATGAGGGAGGGGTGAAATGGGGCCAGGGCACCCTGGTCACCGT CTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGAT CCCGAAATTGTGCTGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTAGG AGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATT TAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTAC GATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGG ATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATA TTGCAACATATTACTGTCAACAGTATGATAATCTCTCGTACACTTTTGGC CAGGGGACCAAGCTGGAGATCAAACGT amino acid sequence of BCMA ScFv binder MTB-1 SEQ ID NO: 2 EVQLVETGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARDW EGYEGGVKWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPSSLSASVG DRVTITCQASQDISNYLNVVYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTFTISSLQPEDIATYYCQQYDNLSYTFGQGTKLEIKR nucleotide sequence of BCMA ScFv binder MTB-2 SEQ ID NO: 3 GAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGA TGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGT ATTAATGGGAGTGGCGATAGAACATATTACGCAGACTCCGTGAAGGGCCG GTTCACCATCTCCAGAGACAATTCCAAGAACACGCTCTATCTGCAAATGA ACAGCCTGAGAGCCGAAGACACGGCCGTATATTACTGTGCGAACTATAAT TACGATGATAATAGTGGTTATGGCCTGGGCCAGGGAACCCTGGTCACCGT CTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGAT CCCAGTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAAAG ACGGCCAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTGCA CTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCATCTATGATG ATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCT GGGAACACAGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAAGC CGACTATTACTGTCAGGTGTGGGACAGTAGTAGTGATCATTGGGTGTTCG GCGGAGGGACCAAGGTCACCGTCCTAGGT amino acid sequence of BCMA ScFv binder MTB-2 SEQ ID NO: 4 EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVSG INGSGDRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANYN YDDNSGYGLGQGTLVTVSSGGGGSGGGGSGGGGSQSVLTQPPSVSVAPGK TARITCGGNNIGSKSVHWYQQKPGQAPVLVIYDDSDRPSGIPERFSGSNS GNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKVTVLG nucleotide sequence of BCMA ScFv binder MTB-3 SEQ ID NO: 5 GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCATCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGACGAC TACGGTGGTAACTCCGAGGGTGACTACTGGGGCCAGGGAACCCTGGTCAC CGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCG GATCCGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTGTGTCTCTA GGAGAGAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAACAG CTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCT ATGATGCATCCACGAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGT GGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCCTGAAGA TTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCACCTTCG GCCAAGGGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-3 SEQ ID NO: 6 EVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDD YGGNSEGDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSVSL GERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASTRATGIPARFSGS GSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of BCMA ScFv binder MTB-4 SEQ ID NO: 7 GAGGTGCAGCTGGTGGAGACTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGATGACACGGCTGTGTATTACTGTGCGAGAGATTGG GAGGGCTATGAGGGAGGGGTGAAATGGGGCCAGGGCACCCTGGTCACCGT CTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGAT CCGAAATTGTGCTGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGA GACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTT AAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACG ATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGA TCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATAT TGCAACATATTACTGTCAACAGTATGATAATCTCTCGTACACTTTTGGCC AGGGGACCAAGCTGGAGATCAAACGT amino acid sequence of BCMA ScFv binder MTB-4 SEQ ID NO: 8 EVQLVETGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARDW EGYEGGVKWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPSSLSASVG DRVTITCQASQDISNYLNVVYQQKPGKAPKLLIYDASNLETGVPSRFSGS GSGTDFTFTISSLQPEDIATYYCQQYDNLSYTFGQGTKLEIKR nucleotide sequence of BCMA ScFv binder MB-5 SEQ ID NO: 9 GAGGTCCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATTGG GCCGGGGATTGTACTAATGGCCAATGCGGCGTCTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCG GTGGTGGCGGATCCGAAATTGTGTTGACGCAGTCTCCACTCTCCCTGCCC GTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCT CCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAG GGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAA AATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAG CTCTACAAACTCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA CGT amino acid sequence of BCMA ScFv binder MTB-5 SEQ ID NO: 10 EVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDW AGDCTNGQCGVYVVGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPLSL PVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEI KR nucleotide sequence of BCMA ScFv binder MTB-14 SEQ ID NO: 11 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAGCGATGAC TACGGTGGTAACTCCGGGACTAGCTACTGGGGCCAGGGAACCCTGGTCAC CGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCG GATCCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA GGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTA TTTAAATTGGTATCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCT ACGATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGCAGT GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGA TTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCCGTGACGTTCG GCGGAGGGACCAAGCTGACCGTCCTAGGT amino acid sequence of BCMA ScFv binder MTB-14 SEQ ID NO: 12 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVSDD YGGNSGTSYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASV GDRVTITCQASQDISNYLNVVYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQSYSTPVTFGGGTKLTVLG nucleotide sequence of leader/signal peptide sequence SEQ ID NO: 13 atgctgctgctggtgaccagcctgctgctgtgcgaactgccgcatccggc gtbctgctgattccg amino acid sequence of leader/signal peptide sequence SEQ ID NO: 14 MLLLVTSLLLCELPHPAFLLIP nucleotide sequence of BCMA ScFv binder MTB-15 SEQ ID NO: 15 CAGGTGCAGCTGGTGGAGACCGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATTGG GATTGTACTGGTGGTGTATGCCCCCTTGGGGGCTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTG GTGGCGGATCCGACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCA TCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAG TGGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCC TGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGT GGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCC TGAAGATTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCA CCTTCGGCCAAGGGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-15 SEQ ID NO: 16 QVQLVETGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDW DCTGGVCPLGGWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSA SVGDRVTITCRASQSISGYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFS GSGSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of BCMA ScFv binder MTB-16 SEQ ID NO: 17 GAGGTCCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGACCTT AATGACTACGGTGACCCGCCCCCTTACTGGGGCCAGGGAACCCTGGTCAC CGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCG GATCCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA GGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTA TTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCT ACGATGCATCCAATTTGGAAACAGGGGTCTCATCAAGGTTCAGTGGCAGT GGATCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCCTGAAGA TTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCACCTTCG GCCAAGGGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-16 SEQ ID NO: 18 EVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDL NDYGDPPPYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASV GDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYDASNLETGVSSRFSGS GSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of BCMA ScFv binder MTB-25 SEQ ID NO: 19 GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCTC GAAATGACTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGG AGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCGAAATTG TGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCC TCCATATTTTGTAGGTCTAGTCAGAGTCTCCTGCATGAAAATGGATACAA CTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGA TCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGC AGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGA GGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACCCCTCGAACTT TTGGCCAGGGGACCAAGCTGGAAACCAAACGT amino acid sequence of BCMA ScFv binder MTB-25 SEQ ID NO: 20 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDL EMTDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPLSLPVTPGEPA SIFCRSSQSLLHENGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSG SGSGTDFTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKLETKR nucleotide sequence of BCMA ScFv binder MTB-28 SEQ ID NO: 21 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATTCG TATAGCAGCAGCGGGGACCCCCGGGCGTTCGACCCCTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCG GTGGTGGCGGATCCAATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAG TCTCCGGGGAAGACGGTAACCATCTCCTGCACCGGCAGCAGTGGCAGCAT TGCCAGCAACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGTGCCCCCT CCACTGTCATCTTTGAGGATAACCAAAGACCCTCTGGGGTCCCTGGTCGG TTCTCTGGCTCCGTCGACAGGTCCTCCAACTCTGCCTCCCTCACCATCTC TGGACTGAAGACTGAGGACGAGGCTGACTACTATTGTCAGTCTTATGATA GCAACAATCGGGGTCTGTTCGGCGGAGGGACCAAGGTCACCGTCCTAGGT amino acid sequence of BCMA ScFv binder MTB-28 SEQ ID NO: 22 QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDS YSSSGDPRAFDPWGQGTLVTVSSGGGGSGGGGSGGGGSNFMLTQPHSVSE SPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPSTVIFEDNQRPSGVPGR FSGSVDRSSNSASLTISGLKTEDEADYYCQSYDSNNRGLFGGGTKVTVLG nucleotide sequence of BCMA ScFv binder MTB-37 SEQ ID NO: 23 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATTGG GAATATAGTGGCTACGATGCCCACCCGGGGTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTG GCGGATCCGACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCT GTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAG TGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGA TCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGTGGC AGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCCTGA AGATTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCACCT TCGGCCAAGGGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-37 SEQ ID NO: 24 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDW EYSGYDAHPGWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSAS VGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSG SGSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of BCMA ScFv binder MTB-39 SEQ ID NO: 25 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGG GCTCGGAATGATTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGG AGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCAATTTTA TGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACC ATCTCCTGCACCCGCAGCAGTGGCAGCATTGCCAGCAACTATGTGCAGTG GTACCAGCAGCGCCCGGGCAGTGCCCCCACCACTGTGATCTATGAGGATA ACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGC TCCTCCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACTGAGGACGA GGCTGACTACTACTGTCAGACTTATGATGACAACAATCATGTCATTTTCG GCGGAGGGACCCAGCTCACCGTTTTAGGT amino acid sequence of BCMA ScFv binder MTB-39 SEQ ID NO: 26 EVQLVESGGGVVQPGGSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDG ARNDYWGQGTLVTVSSGGGGSGGGGSGGGGSNFMLTQPHSVSESPGKTVT ISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDS SSNSASLTISGLKTEDEADYYCQTYDDNNHVIFGGGTQLTVLG nucleotide sequence of DNA CD8 transmembrane domain SEQ ID NO: 27 atctacatctgggcgcccttggccgggacttgtggggtccttctcctgtc actggttatcaccctttactgc amino acid sequence of CD8 transmembrane domain SEQ ID NO: 28 Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys nucleotide sequence of DNA CD8 hinge domain SEQ ID NO: 29 accacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtc gcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcg cagtgcacacgagggggctggacttcgcctgtgat amino acid sequence of CD8 hinge domain SEQ ID NO: 30 Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr amino acid sequence of amino acid numbers 118 to 178 hinge region of CD8.alpha. (NCBI RefSeq: NP.sub.--001759.3) SEQ ID NO: 31 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu amino acid sequence of Human IgG CL sequence SEQ ID NO: 32 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser nucleotide sequence of DNA signaling domain of 4-1BB SEQ ID NO: 33 aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgag accagtacaaactactcaagaggaagatggctgtagctgccgatttccag aagaagaagaaggaggatgtgaactg amino acid sequence of signaling domain of 4-1BB SEQ ID NO: 34 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu nucleotide sequence of DNA signaling domain of CD3-zeta SEQ ID NO: 35 agagtgaagttcagcaggagcgcagacgcccccgcgtacaagcagggcca gaaccagctctataacgagctcaatctaggacgaagagaggagtacgatg ttttggacaagagacgtggccgggaccctgagatggggggaaagccgaga aggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagat ggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggca aggggcacgatggcctttaccagggtctcagtacagccaccaaggacacc tacgacgcccttcacatgcaggccctgccccctcgc amino acid sequence of CD3zeta SEQ ID NO: 36 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg nucleotide sequence of ScFv CD19 SEQ ID NO: 37 gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg gggaccaagc tggagatcac aggtggcggt ggctcgggcg gtggtgggtc gggtggcggc ggatctgagg tgaaactgca ggagtcagga cctggcctgg tggcgccctc acagagcctg tccgtcacat gcactgtctc aggggtctca ttacccgact atggtgtaag ctggattcgc cagcctccac gaaagggtct ggagtggctg ggagtaatat ggggtagtga aaccacatac tataattcag ctctcaaatc cagactgacc atcatcaagg acaactccaa gagccaagtt ttcttaaaaa tgaacagtct gcaaactgat gacacagcca tttactactg tgccaaacat tattactacg gtggtagcta tgctatggac tactggggcc aaggaacctc agtcaccgtc tcctca amino acid sequence of ScFv CD19 SEQ ID NO: 38 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser nucleotide sequence of GMCSF leader peptide SEQ ID NO: 39 ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGC GTTTCTGCTGATTCCG amino acid sequence of GMCSF leader peptide SEQ ID NO: 40 MLLLVTSLLLCELPHPAFLLIP nucleotide sequence of TNFRSF19 leader peptide SEQ ID NO: 41 GGCTCTGAAAGTGCTGTTGGAACAAGAAAAGACCTTCTTCACCTTGCTCG TGTTGCTGGGGTACCTGTCCTGCAAAGTCACCTGT amino acid sequence of TNFRSF19 leader peptide SEQ ID NO: 42 MALKVLLEQEKTFFTLLVLLGYLSCKVTC nucleotide sequence of CD8 alpha leader peptide SEQ ID NO: 43 atggcgctgccggtgaccgcgctgctgctgccgctggcgctgctgctgca tgcggcgcgcccg amino acid sequence of CD8 alpha leader peptide SEQ ID NO: 44 MALPVTALLLPLALLLHAARP nucleotide sequence of CD28 co-stimulatory domain SEQ ID NO: 45 CGGTCGAAGAGGTCCAGACTCTTGCACTCCGACTACATGAACATGACTCC TAGAAGGCCCGGACCCACTAGAAAGCACTACCAGCCGTACGCCCCTCCTC GGGATTTCGCCGCATACCGGTCC amino acid sequence of CD28 co-stimulatory domain SEQ ID NO: 46 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS nucleotide sequence of CD3 zeta activation domain SEQ ID NO: 47 AGAGTGAAGTTCAGCCGCTCAGCCGATGCACCGGCCTACCAGCAGGGACA GAACCAGCTCTACAACGAGCTCAACCTGGGTCGGCGGGAAGAATATGACG TGCTGGACAAACGGCGCGGCAGAGATCCGGAGATGGGGGGAAAGCCGAGG AGGAAGAACCCTCAAGAGGGCCTGTACAACGAACTGCAGAAGGACAAGAT GGCGGAAGCCTACTCCGAGATCGGCATGAAGGGAGAACGCCGGAGAGGGA AGGGTCATGACGGACTGTACCAGGGCCTGTCAACTGCCACTAAGGACACT TACGATGCGCTCCATATGCAAGCTTTGCCCCCGCGG amino acid sequence of CD3 zeta activation domain SEQ ID NO: 48 RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR nucleotide sequence of TNFRSF19 hinge and transmembrane domain (transmembrane domain underlined) SEQ ID NO: 49 GCGGCCGCGGTCGGATTCCAAGACATGGAATGCGTGCCCTGCGGCGACCC GCCACCTCCTTACGAGCCGCACTGCGCATCGAAGGTCAACCTCGTGAAGA TCGCGAGCACCGCGTCCTCACCCCGGGATACTGCTCTGGCCGCCGTGATT TGTTCCGCCTTGGCCACCGTGCTTCTGGCCCTGCTGATCCTCTGTGTGAT C amino acid sequence of TNFRSF19 hinge and transmembrane domain (transmembrane domain underlined) SEQ ID NO: 50 A A A V G F Q D M E C V P C G D P P P P Y E P H C A S K V N L V K I A S T A S S P R D T A L A A V I C S A L A T V L L A L L I L C V I nucleotide sequence of TNFRSF19 transmembrane domain SEQ ID NO: 51 GCCGCCGTGATTTGTTCCGCCTTGGCCACCGTGCTTCTGGCCCTGCTGAT CCTCTGTGTGATC amino acid sequence of TNFRSF19 transmembrane domain SEQ ID NO: 52 A A V I C S A L A T V L L A L L I L C V I nucleotide sequence of TNFRSF19 hinge domain SEQ ID NO: 53 GCGGCCGCGGTCGGATTCCAAGACATGGAATGCGTGCCCTGCGGCGACCC GCCACCTCCTTACGAGCCGCACTGCGCATCGAAGGTCAACCTCGTGAAGA TCGCGAGCACCGCGTCCTCACCCCGGGATACTGCTCTG amino acid sequence of TNFRSF19 hinge domain SEQ ID NO: 54 A A A V G F Q D M E C V P C G D P P P P Y E P H C A S K V N L V K I A S T A S S P R D T A L nucleotide sequence of truncated TNFRSF19 hinge domain SEQ ID NO: 55 TACGAGCCTCACTGCGCCAGCAAAGTCAACTTGGTGAAGATCGCGAGCAC TGCCTCGTCCCCTCGGGACACTGCTCTGGC amino acid sequence of truncated TNFRSF19 hinge domain SEQ ID NO: 56 YEPHCASKVNLVKIASTASSPRDTAL nucleotide sequence of CD8a hinge domain fused to TNFRSF19 transmembrane domain (transmembrane sequence underlined) SEQ ID NO: 57 GCGGCCGCGCCCGCCCCTCGGCCCCCGACTCCTGCCCCGACGATCGCTTC CCAACCTCTCTCGCTGCGCCCGGAAGCATGCCGGCCCGCCGCCGGTGGCG CTGTCCACACTCGCGGACTGGACTTTGATACCGCACTGGCGGCCGTGATC TGTAGCGCCCTGGCCACCGTGCTGCTGGCGCTGCTCATCCTTTGCGTGAT CTACTGCAAGCGGCAGCCTAGG amino acid sequence of CD8a hinge domain fused to TNFRSF19 transmembrane domain (transmembrane sequence underlined) SEQ ID NO: 58 A A A P A P R P P T P A P T I A S Q P L S L R P E A C R P A A G G A V H T R G L D F D T A L A A V I C S A L A T V L L A L L I L C V I Y C K R Q P R nucleotide sequence of CD28 co-stimulatory domain SEQ ID NO: 59 CGGTCGAAGAGGTCCAGACTCTTGCACTCCGACTACATGAACATGACTCC TAGAAGGCCCGGACCCACTAGAAAGCACTACCAGCCGTACGCCCCTCCTC GGGATTTCGCCGCATACCGGTCC amino acid sequence of CD28 co-stimulatory domain SEQ ID NO: 60 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS nucleotide sequence of CD3 zeta version 2 SEQ ID NO: 61 cgcgtgaaatttagccgcagcgcggatgcgccggcgtatcagcagggcca gaaccagctgtataacgaactgaacctgggccgccgcgaagaatatgatg tgctggataaacgccgcggccgcgatccggaaatgggcggcaaaccgcgc cgcaaaaacccgcaggaaggcctgtataacgaactgcagaaagataaaat ggcggaagcgtatagcgaaattggcatgaaaggcgaacgccgccgcggca aaggccatgatggcctgtatcagggcctgagcaccgcgaccaaagatacc tatgatgcgctgcatatgcaggcgctgccgccgcgc amino acid sequence of CD3 zeta version 2 SEQ ID NO: 62 R V K F S R S A D A P A Y Q Q G Q N Q L Y N E L N L G R R E E Y D V L D K R R G R D P E M G G K P R R K N P Q E G L Y N E L Q K D K M A E A Y S E I G M K G E R R R G K G H D G L Y Q G L S T A T K D T Y D A L H M Q A L P P R nucleotide sequence of Furin P2A Furin SEQ ID NO: 63 CGCGCGAAACGCAGCGGCAGCGGCGCGACCAACTTTAGCCTGCTGAAACA GGCGGGCGATGTGGAAGAAAACCCGGGCCCGCGAGCAAAGAGG amino acid sequence of Furin P2A Furin (furin sequence underlined) SEQ ID NO: 64 RAKRSGSGATNFSLLKQAGDVEENPGPRAKR nucleotide sequence of Furin T2A SEQ ID NO: 65 AGAGCTAAACGCTCTGGGTCTGGTGAAGGACGAGGTAGCCTTCTTACGTG CGGAGACGTGGAGGAAAACCCAGGACCC amino acid sequence of Furin T2A (furin sequence underlined) SEQ ID NO: 66 RAKRSGSGEGRGSLLTCGDVEENPGP nucleotide sequence of truncated EGFR (tEGFR) tag SEQ ID NO: 67 AGGAAGGTTTGCAATGGAATCGGTATAGGGGAGTTTAAGGATTCACTTAG CATAAACGCTACTAATATTAAACACTTCAAAAACTGTACGAGTATAAGTG GAGATCTTCACATTTTGCCGGTTGCATTCCGAGGCGATTCATTCACCCAC ACGCCACCGCTTGACCCACAAGAATTGGATATTCTTAAAACCGTTAAAGA AATAACGGGGTTTTTGCTCATTCAAGCGTGGCCAGAAAATCGCACTGACC TCCATGCTTTCGAGAACCTGGAGATTATAAGAGGACGAACTAAGCAGCAT GGTCAATTCTCCCTTGCTGTGGTCAGCCTGAACATCACCAGTCTTGGTTT GCGGTCCCTCAAGGAAATTTCAGATGGAGATGTCATCATAAGCGGCAACA AGAATTTGTGCTATGCAAATACCATAAACTGGAAAAAACTGTTTGGCACT TCCGGCCAGAAAACCAAGATTATTTCAAATCGGGGTGAGAACAGCTGCAA AGCCACCGGCCAGGTTTGTCATGCCTTGTGCTCTCCGGAAGGCTGTTGGG GGCCAGAACCCAGGGACTGCGTCAGTTGCAGAAACGTCTCAAGAGGCCGC GAATGCGTTGACAAGTGTAACCTCCTTGAGGGTGAGCCACGAGAGTTTGT TGAGAACAGCGAGTGTATACAATGTCACCCTGAATGTTTGCCCCAGGCTA TGAATATAACCTGCACAGGCCGCGGGCCTGATAACTGCATCCAGTGTGCT CATTACATAGATGGACCTCACTGTGTGAAAACCTGCCCGGCCGGAGTTAT GGGAGAAAACAACACTCTGGTGTGGAAATACGCTGATGCAGGCCACGTGT GCCACCTTTGTCACCCGAATTGTACATATGGGTGTACCGGTCCTGGACTT GAAGGTTGCCCTACCAATGGCCCTAAAATACCCAGTATCGCAACTGGCAT GGTAGGCGCTCTTCTCTTGCTCTTGGTAGTTGCTCTCGGCATAGGTCTTT TTATG amino acid sequence of truncated EGFR (tEGFR) tag SEQ ID NO: 68 RKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTH TPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQH GQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGT SGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGR ECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCA HYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGL EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFM nucleotide sequence of BCMA ScFv binder MTB-40 SEQ ID NO: 69 CAGGCGGCCGAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCC TGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTA GCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGG GTGGCATTTATACGGTATGATGGAAGTAATAAATACTACGCAGACTCCGT GAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCG AAAGAACCCCCCGAGTATTACTATGATAGTAGTGGTTATTCGTGGGGCCA GGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCG GTAGCGGTGGTGGCGGATCCGACATCCAGTTGACCCAGTCTCCATCCTCC CTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCA GGACATTGACACCTATTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCC CTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCTCATCA AGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAG TCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACTTACAGTC CCCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-40 SEQ ID NO: 70 QAAEVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA KEPPEYYYDSSGYSWGQGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSS LSASVGDRVTITCQASQDIDTYLNVVYQQKPGKAPKLLIYAASSLQSGVS SRFSGSGSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of BCMA ScFv binder MTB-49 SEQ ID NO: 71 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAGCGATGAC TACGGTGGTAACTCCGGGACTAGCTACTGGGGCCAGGGAACCCTGGTCAC CGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGCGGTAGCGGTGGTGGCG GATCCGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA GGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTA TTTAAATTGGTATCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCT ACGATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGCAGT GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGA TTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCCGTGACGTTCG GCGGAGGGACCAAGCTGACCGTCCTAGGT amino acid sequence of BCMA ScFv binder MTB-49 SEQ ID NO: 72 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVSDD YGGNSGTSYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASV GDRVTITCQASQDISNYLNVVYQQKPGKAPKLLIYDASNLETGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQSYSTPVTFGGGTKLTVLG nucleotide sequence of BCMA ScFv binder MTB-50 SEQ ID NO: 73 GAGGTGCAGCTGGTGCAGTCTGGGGGAGGTGTGGTACGGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACTTATGAAA TGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGCTTGCATAC ATTGGAGGTAGTGGTAGTCCCATATACTACGCAGACTCTGTGAGGGGCCG ATTCACCATCTCCAGAGACAACACCAAGAATTCACTATTTCTCCAAATGA GCAGCCTGAGAGCCGAGGACACCGCTGTTTACTATTGTGTGGAAGGGTGG TTTGACAAGTGGGGCCTGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGG CGGATCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCGACATCCAGTTGA CCCAGTCTCCATCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC ACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCA GAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATGCATCCAATTTGG AGACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTC ACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTG TCAACAGAGTTACAGTACCCCGTACACTTTTGGCCAGGGGACCAAGCTGG AAATCAAACGT amino acid sequence of BCMA ScFv binder MTB-50 SEQ ID NO: 74 EVQLVQSGGGVVRPGGSLRLSCAASGFTFSTYEMNWVRQAPGKGLEWLAY IGGSGSPIYYADSVRGRFTISRDNTKNSLFLQMSSLRAEDTAVYYCVEGW FDKWGLGTLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSTLSASVGDRVTI TCRASQSISSYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIKR nucleotide sequence of BCMA ScFv binder MTB-4-12 SEQ ID NO: 75 CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTACGTTA TACATTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCT ATATCGCATGATGGAAGCAATAAATACTACGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGA GCAGTCTGAGCGCTGAGGACACGGCTATGTATTACTGTGTGAAAACTAGT AGTGATTATTACTACGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTC CTCAGGAGGTGGCGGGTCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCC AGACTGTGGTGACTCAGGAGCCATCGTTCTCAGTGTCCCCTGGAGGGACA GTCACACTCACTTGTGGCTTGAGCTCTGGCTCAGTCTCTACTGGCAACTC CCCCACCTGGTACCAGCAGACCCCAGGCCAGGCTCCACGCACGCTCATCT ACAGCACAAACACTCGCTCTTCTGGGGTCCCTGATCGCTTCTCTGGCTCC ATCCTTGGGAACAAAGCTGCCCTCACCATCACGGGGGCCCAGGCAGATGA TGAATCTGATTATTACTGTGTGCTGTATATGGGTAGTGGCTATTGGGTGT TCGGCGGAGGGACCAAGGTCACCGTCCTAGGT amino acid sequence of BCMA ScFv binder MTB-4-12 SEQ ID NO: 76 QVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYVIHWVRQAPGKGLEWVAA ISHDGSNKYYADSVKGRFTISRDNSKNTLYLQMSSLSAEDTAMYYCVKTS SDYYYAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSFSVSPGGT VTLTCGLSSGSVSTGNSPTWYQQTPGQAPRTLIYSTNTRSSGVPDRFSGS ILGNKAALTITGAQADDESDYYCVLYMGSGYWVFGGGTKVTVLG nucleotide sequence of BCMA ScFv binder MTB-4-45 SEQ ID NO: 77 GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTC AGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTCCACCAGCTACTATA TGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATA ATCAACCCTAGTGGTGGTAGCACAAGCTACGCACAGAAGTTCCAGGGCAG AGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGA GCAGCTTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTG GGTGATGGCGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTC TTCAGGAGGTGGCGGGTCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCG ACATCCAGATGACCCAGTCTCTATCCTCCCTGTCTGCATCTGTAGGAGAC AGAGTCACCATCGCTTGCCGGGCAAGTCAGACCATTAGTAGGTATTTAAA TTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTG CATCCAGTTTGCAAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATCT GGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCCTGAAGATTTTGC AACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCACCTTCGGCCAAG GGACACGACTGGAGATTAAACGA amino acid sequence of BCMA ScFv binder MTB-4-45 SEQ ID NO: 78 EVQLVQSGAEVKKPGASVKVSCKASGYTSTSYYMHWVRQAPGQGLEWMGI INPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDL GDGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSLSSLSASVGD RVTIACRASQTISRYLNVVYQQKPGKAPKLLIYAASSLQSGVSSRFSGSG SGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQGTRLEIKR nucleotide sequence of human IgG4 hinge SEQ ID NO: 79 GAGAGCAAATACGGGCCGCCATGTCCCCCGTGTCCG amino acid sequence of human IgG4 hinge SEQ ID NO: 80 ESKYGPPCPPCP nucleotide sequence of human IgG4 CH2 domain SEQ ID NO: 81 GCACCACCAGTTGCTGGCCCTAGTGTCTTCTTGTTCCCTCCCAAGCCCAA AGACACCTTGATGATTTCCAGAACTCCTGAGGTTACCTGCGTTGTCGTAG ATGTTTCTCAGGAGGACCCAGAGGTCCAATTTAACTGGTACGTTGATGGG GTGGAAGTTCACAATGCGAAGACAAAGCCGCGGGAAGAACAATTTCAGTC CACTTACCGGGTTGTCAGCGTTCTGACGGTATTGCATCAAGACTGGCTTA ATGGAAAGGAATATAAGTGTAAGGTGTCCAACAAAGGTTTGCCGAGCAGT ATTGAGAAGACCATATCAAAGGCGAAG amino acid sequence of human IgG4 CH2 domain SEQ ID NO: 82 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS IEKTISKAK nucleotide sequence of human IgG4 CH3 domain SEQ ID NO: 83 GGGCAGCCGCGCGAGCCACAAGTTTACACTTTGCCGCCATCTCAAGAGGA AATGACTAAAAACCAGGTATCCTTGACATGCCTCGTAAAAGGATTTTATC CATCTGATATTGCTGTGGAATGGGAGTCTAACGGGCAGCCGGAAAATAAT TACAAAACTACACCACCTGTGCTCGATTCAGATGGAAGTTTCTTCCTTTA CAGTAGACTTACGGTGGACAAATCTAGGTGGCAGGAAGGGAATGTGTTTA GTTGTAGTGTAATGCACGAGGCACTTCATAACCACTATACACAGAAGTCA CTGAGTTTGAGTCTTGGCAAA amino acid sequence of human IgG4 CH3 domain SEQ ID NO: 84 GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKS LSLSLGK nucleotide sequence of human IgG4 hinge CH2 CH3 domain SEQ ID NO: 85 GAGAGCAAATACGGGCCGCCATGTCCCCCGTGTCCGGCACCACCAGTTGC TGGCCCTAGTGTCTTCTTGTTCCCTCCCAAGCCCAAAGACACCTTGATGA TTTCCAGAACTCCTGAGGTTACCTGCGTTGTCGTAGATGTTTCTCAGGAG GACCCAGAGGTCCAATTTAACTGGTACGTTGATGGGGTGGAAGTTCACAA TGCGAAGACAAAGCCGCGGGAAGAACAATTTCAGTCCACTTACCGGGTTG TCAGCGTTCTGACGGTATTGCATCAAGACTGGCTTAATGGAAAGGAATAT AAGTGTAAGGTGTCCAACAAAGGTTTGCCGAGCAGTATTGAGAAGACCAT ATCAAAGGCGAAGGGGCAGCCGCGCGAGCCACAAGTTTACACTTTGCCGC CATCTCAAGAGGAAATGACTAAAAACCAGGTATCCTTGACATGCCTCGTA AAAGGATTTTATCCATCTGATATTGCTGTGGAATGGGAGTCTAACGGGCA GCCGGAAAATAATTACAAAACTACACCACCTGTGCTCGATTCAGATGGAA GTTTCTTCCTTTACAGTAGACTTACGGTGGACAAATCTAGGTGGCAGGAA GGGAATGTGTTTAGTTGTAGTGTAATGCACGAGGCACTTCATAACCACTA TACACAGAAGTCACTGAGTTTGAGTCTTGGCAAA amino acid sequence of human IgG4 hinge CH2 CH3 domain SEQ ID NO: 86 ESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE DPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK nucleotide sequence of D0084 (Efla-BCMA sequence 5 CD8 BBz) SEQ ID NO: 87 ATGCTGCTGCTGGTGACCAGCCTGCTTCTGTGTGAACTGCCGCATCCGGC GTTTCTGCTGATTCCGGAGGTCCAGCTGGTGCAGTCTGGAGGAGGCGTGG TCCAGCCTGGTGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCATTTATACGGTATGATGGAAGTAATAAATACTATGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAGAGATTGGGCCGGGGATTGTACTAATGGCCAATGCGGCGTCT ACTGGGGACAGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGATCT GGTGGAGGCGGTAGCGGTGGTGGCGGATCCGAAATTGTGTTGACGCAGTC TCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCA GGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGG TACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTC TAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCA CAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTT TATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTTGGCCAGGGGAC CAAGCTGGAGATCAAACGTGCGGCCGCAACGACCACTCCTGCACCCCGCC CTCCGACTCCGGCCCCAACCATTGCCAGCCAGCCCCTGTCCCTGCGGCCG GAAGCCTGCAGACCGGCTGCCGGCGGAGCCGTCCATACCCGGGGACTGGA TTTCGCCTGCGATATCTATATCTGGGCACCACTCGCCGGAACCTGTGGAG TGCTGCTGCTGTCCCTTGTGATCACCCTGTACTGCAAGCGCGGACGGAAG AAACTCTTGTACATCTTCAAGCAGCCGTTCATGCGCCCTGTGCAAACCAC CCAAGAAGAGGACGGGTGCTCCTGCCGGTTCCCGGAAGAGGAAGAGGGCG GCTGCGAACTGCGCGTGAAGTTTTCCCGGTCCGCCGACGCTCCGGCGTAC CAGCAGGGGCAAAACCAGCTGTACAACGAACTTAACCTCGGTCGCCGGGA AGAATATGACGTGCTGGACAAGCGGCGGGGAAGAGATCCCGAGATGGGTG GAAAGCCGCGGCGGAAGAACCCTCAGGAGGGCTTGTACAACGAGCTGCAA AAGGACAAAATGGCCGAAGCCTACTCCGAGATTGGCATGAAGGGAGAGCG CAGACGCGGGAAGGGACACGATGGACTGTACCAGGGACTGTCAACCGCGA CTAAGGACACTTACGACGCCCTGCACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0084 (Efla-BCMA sequence 5 CD8 BBz) SEQ ID NO: 88 MLLLVTSLLLCELPHPAFLLIPEVQLVQSGGGVVQPGGSLRLSCAASGFT FSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCARDWAGDCTNGQCGVYWGQGTLVTVSSGGGGS GGGGSGGGGSEIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDW YLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGV YYCMQALQTPYTFGQGTKLEIKRAAATTTPAPRPPTPAPTIASQPLSLRP EACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRK KLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAY QQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0085 (Efla-BCMA sequence 16 CD8 BBz) SEQ ID NO: 89 ATGCTGCTGCTGGTGACCAGCCTGCTTCTGTGCGAACTGCCGCATCCGGC GTTTCTGTTGATTCCGGAGGTCCAGCTGGTGCAGTCTGGGGGAGGCGTGG TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCATTTATACGGTATGATGGAAGTAATAAATACTACGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAGAGACCTTAATGACTACGGTGACCCACCCCCTTACTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGATCTGGTGGAGGC GGTAGCGGTGGTGGCGGATCCGACATCCAGATGACCCAGTCTCCATCCTC CCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTC AGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCC CCTAAGCTCCTGATCTACGATGCATCCAATTTGGAAACAGGGGTCTCATC AAGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCA GTCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACTTACAGT CCCCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAGCGGC CGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCCAACCATTG CCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCCGGC GGAGCCGTCCATACCCGGGGACTGGATTTCGCCTGCGATATCTATATCTG GGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGATCA CCCTGTACTGCAAGCGCGGACGGAAGAAACTCTTGTACATCTTCAAGCAG CCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTCCTG CCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGTTTT CCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTGTAC AACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAAGCG GCGGGGAAGAGATCCCGAGATGGGTGGAAAGCCGCGGCGGAAGAACCCTC AGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCCTAC TCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGATGG ACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCCTGC ACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0085 (Efla-BCMA sequence 16 CD8 BBz) SEQ ID NO: 90 MLLLVTSLLLCELPHPAFLLIPEVQLVQSGGGVVQPGGSLRLSCAASGFT FSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCARDLNDYGDPPPYWGQGTLVTVSSGGGGSGGG GSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA PKLLIYDASNLETGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQTYS PPITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAG GAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQ PFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLY NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0086 (Efla-BCMA sequence 37 CD8 BBz) SEQ ID NO: 91 ATGCTGCTGCTGGTGACCAGCCTGCTTCTGTGCGAACTGCCGCATCCGGC GTTTCTGTTGATTCCGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGG TCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCATTTATACGGTATGATGGAAGTAATAAATACTATGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAAAGATTGGGAATATAGTGGATACGATGCACACCCGGGATGGG GTCAGGGAACCCTGGTCACCGTCTCTTCAGGAGGTGGTGGGTCTGGTGGA GGCGGTAGCGGTGGTGGCGGATCCGACATCCAGTTGACCCAGTCTCCATC CTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAA GTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAA GCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCC ATCAAGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCA GCAGTCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACTTAC AGTCCCCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAGC GGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCCAACCA TTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCC GGCGGAGCCGTCCATACCCGGGGACTGGATTTCGCCTGCGATATCTATAT CTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGA TCACCCTGTACTGCAAGCGCGGACGGAAGAAACTCTTGTACATCTTCAAG CAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTC CTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGT TTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTG TACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAA GCGGCGGGGAAGAGATCCCGAGATGGGTGGAAAGCCGCGGCGGAAGAACC CTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCC TACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGA TGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCC TGCACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0086 (Efla-BCMA sequence 37 CD8 BBz) SEQ ID NO: 92 MLLLVTSLLLCELPHPAFLLIPEVQLVESGGGLVKPGGSLRLSCAASGFT FSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKDWEYSGYDAHPGWGQGTLVTVSSGGGGSGG GGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGK APKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQQTY SPPITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAA GGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFK QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0087_LTG2092 (Efla-BCMA sequence 40 CD8 BBz) SEQ ID NO: 93 ATGCTGCTGCTGGTGACCAGCCTGCTTCTGTGCGAACTGCCGCATCCGGC GTTTCTTCTGATTCCGGAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGG TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCATTTATACGGTATGATGGAAGTAATAAATACTACGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAAAGAACCCCCCGAGTATTACTATGATAGTAGTGGTTATTCGT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGGTCTGGT GGAGGCGGTAGCGGTGGTGGCGGATCCGACATCCAGTTGACCCAGTCTCC ATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGG CGAGTCAGGACATTGACACCTATTTAAACTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGT CTCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCA TCAGCAGTCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACT TACAGTCCCCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACG AGCGGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCCAA CCATTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCT GCCGGCGGAGCCGTCCATACCCGGGGACTGGATTTCGCCTGCGATATCTA TATCTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTG TGATCACCCTGTACTGCAAGCGCGGACGGAAGAAACTCTTGTACATCTTC AAGCAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTG CTCCTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGA AGTTTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAG CTGTACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGA CAAGCGGCGGGGAAGAGATCCCGAGATGGGTGGAAAGCCGCGGCGGAAGA ACCCTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAA GCCTACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACA CGATGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACG CCCTGCACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0087_LTG2092 (Efla-BCMA sequence 40 CD8 BBz) SEQ ID NO: 94 MLLLVTSLLLCELPHPAFLLIPEVQLVQSGGGVVQPGGSLRLSCAASGFT FSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKEPPEYYYDSSGYSWGQGTLVTVSSGGGGSG GGGSGGGGSDIQLTQSPSSLSASVGDRVTITCQASQDIDTYLNWYQQKPG KAPKLLIYAASSLQSGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQT YSPPITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACRPA AGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIF KQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQ LYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0099_LTG2944 (Efla-BCMA sequence 4-12 CD8 BBz) SEQ ID NO: 95 ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGC GTTTCTGCTGATTCCGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGG TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACC TTCAGTAGTTACGTTATACATTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCAGCTATATCGCATGATGGAAGCAATAAATACTACGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTTCAAATGAGCAGTCTGAGCGCTGAGGACACGGCTATGTATTA CTGTGTGAAAACTAGTAGTGATTATTACTACGCCTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAGGAGGTGGCGGGTCTGGTGGAGGCGGTAGC GGTGGTGGCGGATCCCAGACTGTGGTGACTCAGGAGCCATCGTTCTCAGT GTCCCCTGGAGGGACAGTCACACTCACTTGTGGCTTGAGCTCTGGCTCAG TCTCTACTGGCAACTCCCCCACCTGGTACCAGCAGACCCCAGGCCAGGCT CCACGCACGCTCATCTACAGCACAAACACTCGCTCTTCTGGGGTCCCTGA TCGCTTCTCTGGCTCCATCCTTGGGAACAAAGCTGCCCTCACCATCACGG GGGCCCAGGCAGATGATGAATCTGATTATTACTGTGTGCTGTATATGGGT AGTGGCTATTGGGTGTTCGGCGGAGGGACCAAGGTCACCGTCCTAGGTGC GGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCCAACCA TTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCC GGCGGAGCCGTCCATACCCGGGGACTGGATTTCGCCTGCGATATCTATAT CTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGA TCACCCTGTACTGCAAGCGCGGACGGAAGAAACTCTTGTACATCTTCAAG CAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTC CTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGT TTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTG TACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAA GCGGCGGGGAAGAGATCCCGAGATGGGTGGAAAGCCGCGGCGGAAGAACC CTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCC TACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGA TGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCC TGCACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0099_LTG2944 (Efla-BCMA sequence 4-12 CD8 BBz) SEQ ID NO: 96 MLLLVTSLLLCELPHPAFLLIPQVQLVQSGGGVVQPGGSLRLSCAASGFT FSSYVIHWVRQAPGKGLEWVAAISHDGSNKYYADSVKGRFTISRDNSKNT LYLQMSSLSAEDTAMYYCVKTSSDYYYAYWGQGTLVTVSSGGGGSGGGGS GGGGSQTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTGNSPTWYQQTPGQA PRTLIYSTNTRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMG SGYWVFGGGTKVTVLGAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAA GGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFK QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0100_LTG2945 (Efla-BCMA sequence 4-45 CD8 BBz) SEQ ID NO: 97 ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGC GTTTCTGCTGATTCCGGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGA AGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACC TCCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCT TGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTACGCAC AGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACA GTCTACATGGAGCTGAGCAGCTTGAGATCTGAGGACACGGCCGTGTATTA CTGTGCGAGAGATTTGGGTGATGGCGCTTTTGATATCTGGGGCCAAGGGA CAATGGTCACCGTCTCTTCAGGAGGTGGCGGGTCTGGTGGAGGCGGTAGC GGTGGTGGCGGATCCGACATCCAGATGACCCAGTCTCTATCCTCCCTGTC TGCATCTGTAGGAGACAGAGTCACCATCGCTTGCCGGGCAAGTCAGACCA TTAGTAGGTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAG CTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCTCATCAAGGTT CAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGC AGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCG ATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAGCGGCCGCAAC GACCACTCCTGCACCCCGCCCTCCGACTCCGGCCCCAACCATTGCCAGCC AGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGACCGGCTGCCGGCGGAGCC GTCCATACCCGGGGACTGGATTTCGCCTGCGATATCTATATCTGGGCACC ACTCGCCGGAACCTGTGGAGTGCTGCTGCTGTCCCTTGTGATCACCCTGT ACTGCAAGCGCGGACGGAAGAAACTCTTGTACATCTTCAAGCAGCCGTTC ATGCGCCCTGTGCAAACCACCCAAGAAGAGGACGGGTGCTCCTGCCGGTT CCCGGAAGAGGAAGAGGGCGGCTGCGAACTGCGCGTGAAGTTTTCCCGGT CCGCCGACGCTCCGGCGTACCAGCAGGGGCAAAACCAGCTGTACAACGAA CTTAACCTCGGTCGCCGGGAAGAATATGACGTGCTGGACAAGCGGCGGGG AAGAGATCCCGAGATGGGTGGAAAGCCGCGGCGGAAGAACCCTCAGGAGG GCTTGTACAACGAGCTGCAAAAGGACAAAATGGCCGAAGCCTACTCCGAG ATTGGCATGAAGGGAGAGCGCAGACGCGGGAAGGGACACGATGGACTGTA CCAGGGACTGTCAACCGCGACTAAGGACACTTACGACGCCCTGCACATGC AGGCCCTGCCCCCGCGC amino acid sequence of D0100_LTG2945 (Efla-BCMA sequence 4-45 CD8BBz) SEQ ID NO: 98 MLLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGASVKVSCKASGYT STSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTST VYMELSSLRSEDTAVYYCARDLGDGAFDIWGQGTMVTVSSGGGGSGGGGS GGGGSDIQMTQSLSSLSASVGDRVTIACRASQTISRYLNWYQQKPGKAPK LLIYAASSLQSGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQTYSPP ITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D0153 (BCMA 4-1c CD8 BBz) SEQ ID NO: 99 ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGC GTTTCTGCTGATTCCGGAGGTGCAGCTGGTGGAGACCGGGGGAGGCGTGG TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCT GGAGTGGGTGGCATTTATACGGTATGATGGAAGTAATAAATACTACGCAG ACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACG CTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAAAGATTGGGATACGTATTACTATGATAGTAGTGGTTATGATC GGGCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGCGGG TCTGGTGGAGGCGGTAGCGGTGGTGGCGGATCCGACATCCAGATGACCCA GTCTCCCTCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTT GCCAGGCGAGTCAGGACATTAACAACTATTTAAATTGGTATCAGCAGAAA CCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAG TGGGGTCTCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTC TCACCATCAGCAGTCTGCAGCCTGAAGATTTTGCAACTTATTTCTGTCAA CAGACTTACAGTCCCCCGATCACCTTCGGCCAAGGGACACGACTGGAGAT TAAACGAGCGGCCGCAACGACCACTCCTGCACCCCGCCCTCCGACTCCGG CCCCAACCATTGCCAGCCAGCCCCTGTCCCTGCGGCCGGAAGCCTGCAGA CCGGCTGCCGGCGGAGCCGTCCATACCCGGGGACTGGATTTCGCCTGCGA TATCTATATCTGGGCACCACTCGCCGGAACCTGTGGAGTGCTGCTGCTGT CCCTTGTGATCACCCTGTACTGCAAGCGCGGACGGAAGAAACTCTTGTAC ATCTTCAAGCAGCCGTTCATGCGCCCTGTGCAAACCACCCAAGAAGAGGA CGGGTGCTCCTGCCGGTTCCCGGAAGAGGAAGAGGGCGGCTGCGAACTGC GCGTGAAGTTTTCCCGGTCCGCCGACGCTCCGGCGTACCAGCAGGGGCAA AACCAGCTGTACAACGAACTTAACCTCGGTCGCCGGGAAGAATATGACGT GCTGGACAAGCGGCGGGGAAGAGATCCCGAGATGGGTGGAAAGCCGCGGC GGAAGAACCCTCAGGAGGGCTTGTACAACGAGCTGCAAAAGGACAAAATG GCCGAAGCCTACTCCGAGATTGGCATGAAGGGAGAGCGCAGACGCGGGAA GGGACACGATGGACTGTACCAGGGACTGTCAACCGCGACTAAGGACACTT ACGACGCCCTGCACATGCAGGCCCTGCCCCCGCGC amino acid sequence of D0153 (BCMA 4-1c CD8 BBz) SEQ ID NO: 100 MLLLVTSLLLCELPHPAFLLIPEVQLVETGGGVVQPGGSLRLSCAASGFT FSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKDWDTYYYDSSGYDRAWGQGTLVTVSSGGGG SGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQK PGKAPKLLIYAASSLQSGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQ QTYSPPITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACR PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLY IFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR nucleotide sequence of D158 (BCMA 4-45 CD8 BBz 2A TGFBRIIdn) SEQ ID NO: 101 ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAACTGCCGCATCCGGC GTTTCTGCTGATTCCGGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGA AGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACC TCCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCT TGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTACGCAC AGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACA GTCTACATGGAGCTGAGCAGCTTGAGATCTGAGGACACGGCCGTGTATTA CTGTGCGAGAGATTTGGGTGATGGCGCTTTTGATATCTGGGGCCAAGGGA CAATGGTCACCGTCTCTTCAGGAGGTGGCGGGTCTGGTGGAGGCGGTAGC GGTGGTGGCGGATCCGACATCCAGATGACCCAGTCTCTATCCTCCCTGTC TGCATCTGTAGGAGACAGAGTCACCATCGCTTGCCGGGCAAGTCAGACCA TTAGTAGGTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAG CTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCTCATCAAGGTT CAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGTCTGC AGCCTGAAGATTTTGCAACTTATTTCTGTCAACAGACTTACAGTCCCCCG ATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAGCGGCCGCTAC CACAACCCCTGCGCCCCGGCCTCCTACCCCCGCACCCACGATTGCTTCTC AACCTCTTTCACTCCGACCTGAGGCTTGTAGACCTGCAGCCGGGGGTGCC GTCCACACACGGGGACTCGACTTCGCTTGTGATATATATATTTGGGCGCC CCTGGCCGGCACTTGTGGAGTTCTTTTGCTCTCTCTTGTTATCACATTGT ACTGCAAGCGAGGTAGGAAGAAATTGCTTTACATTTTTAAGCAGCCGTTC ATGCGACCAGTACAGACTACTCAAGAAGAAGATGGGTGCTCTTGTCGGTT CCCGGAAGAAGAAGAGGGTGGTTGCGAGTTGAGGGTGAAGTTCTCCCGCT CTGCCGACGCACCGGCATATCAGCAGGGACAAAACCAGCTCTACAACGAA TTGAACCTGGGTCGGCGGGAAGAATATGACGTGCTCGATAAGCGGCGGGG TCGCGACCCAGAAATGGGAGGCAAACCGCGCAGGAAAAATCCACAGGAGG GACTTTATAACGAACTTCAAAAGGATAAGATGGCAGAGGCATACAGCGAA ATCGGGATGAAAGGCGAGAGAAGAAGGGGGAAAGGGCACGATGGTCTTTA CCAGGGGCTTTCTACCGCGACGAAGGATACCTACGATGCTCTCCATATGC AAGCACTTCCTCCTAGACGGGCAAAGCGGGGCTCAGGGGCGACTAACTTT TCACTGTTGAAGCAGGCCGGGGATGTGGAGGAGAATCCTGGTCCTAGAGC TAAGCGAGTAGACATGGGAAGAGGGCTGCTCCGAGGCTTGTGGCCGTTGC ATATTGTATTGTGGACGCGGATAGCGAGTACAATCCCGCCTCACGTGCAA AAATCAGTTAATAACGACATGATCGTTACTGACAACAATGGCGCAGTTAA ATTTCCGCAGCTTTGTAAATTCTGTGATGTAAGATTTTCAACGTGCGATA ACCAGAAAAGCTGTATGTCCAACTGCAGCATCACATCAATCTGTGAAAAA CCCCAAGAGGTATGTGTGGCCGTCTGGCGAAAGAATGACGAAAATATCAC ACTGGAGACCGTTTGTCACGATCCTAAACTCCCTTATCATGACTTTATTC TGGAAGACGCAGCGTCACCGAAGTGTATAATGAAAGAGAAGAAGAAGCCT GGAGAGACGTTTTTCATGTGCAGTTGCTCCTCAGATGAGTGTAATGACAA CATCATTTTTTCCGAGGAGTACAATACGAGTAACCCAGACCTCCTGCTGG TTATTTTCCAGGTAACCGGCATCAGTTTGTTGCCCCCACTGGGTGTTGCA ATCAGTGTAATAATCATATTTTATTGTTACCGGGTGTGATAA amino acid sequence of D158 (BCMA 4-45 CD8 BBz 2A TGFBRIIdn) SEQ ID NO: 102 MLLLVTSLLLCELPHPAFLLIPEVQLVQSGAEVKKPGASVKVSCKASGYT STSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTST VYMELSSLRSEDTAVYYCARDLGDGAFDIWGQGTMVTVSSGGGGSGGGGS GGGGSDIQMTQSLSSLSASVGDRVTIACRASQTISRYLNWYQQKPGKAPK LLIYAASSLQSGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQTYSPP ITFGQGTRLEIKRAAATTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRAKRGSGATNF SLLKQAGDVEENPGPRAKRVDMGRGLLRGLWPLHIVLWTRIASTIPPHVQ KSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEK PQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKP GETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVA ISVIIIFYCYRV nucleotide sequence of Binder 4-1c VH SEQ ID NO: 103 GAGGTGCAGCTGGTGGAGACCGGGGGAGGCGTGGTCCAGCCTGGGGGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTT ATACGGTATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATTGG GATACGTATTACTATGATAGTAGTGGTTATGATCGGGCCTGGGGCCAGGG AACCCTGGTCACCGTCTCCTCA amino acid sequence of Binder 4-1c VH SEQ ID NO: 104 EVQLVETGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAF IRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDW DTYYYDSSGYDRAWGQGTLVTVSS nucleotide sequence of Binder 4-1c VL SEQ ID NO: 105 GACATCCAGATGACCCAGTCTCCCTCCTCCCTGTCTGCATCTGTAGGAGA CAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAACAACTATTTAA ATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT GCATCCAGTTTGCAAAGTGGGGTCTCATCAAGGTTCAGTGGCAGTGGATC TGGGACAGAGTTCACTCTCACCATCAGCAGTCTGCAGCCTGAAGATTTTG CAACTTATTTCTGTCAACAGACTTACAGTCCCCCGATCACCTTCGGCCAA GGGACACGACTGGAGATTAAACGAGC amino acid sequence of Binder 4-1c VL SEQ ID NO: 106 DIQMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQKPGKAPKLLIYA ASSLQSGVSSRFSGSGSGTEFTLTISSLQPEDFATYFCQQTYSPPITFGQ GTRLEIKR nucleotide sequence of Furin P2A Furin SEQ ID NO: 107 CGGGCAAAGCGGGGCTCAGGGGCGACTAACTTTTCACTGTTGAAGCAGGC CGGGGATGTGGAGGAGAATCCTGGTCCTAGAGCTAAGCGA amino acid sequence of Furin P2A Furin (furin cleavage sites underlined) SEQ ID NO: 108 RAKRGSGATNFSLLKQAGDVEENPGPRAKR nucleotide sequence of TGFBRIIdn SEQ ID NO: 109 ATGGGAAGAGGGCTGCTCCGAGGCTTGTGGCCGTTGCATATTGTATTGTG GACGCGGATAGCGAGTACAATCCCGCCTCACGTGCAAAAATCAGTTAATA ACGACATGATCGTTACTGACAACAATGGCGCAGTTAAATTTCCGCAGCTT TGTAAATTCTGTGATGTAAGATTTTCAACGTGCGATAACCAGAAAAGCTG TATGTCCAACTGCAGCATCACATCAATCTGTGAAAAACCCCAAGAGGTAT GTGTGGCCGTCTGGCGAAAGAATGACGAAAATATCACACTGGAGACCGTT TGTCACGATCCTAAACTCCCTTATCATGACTTTATTCTGGAAGACGCAGC GTCACCGAAGTGTATAATGAAAGAGAAGAAGAAGCCTGGAGAGACGTTTT TCATGTGCAGTTGCTCCTCAGATGAGTGTAATGACAACATCATTTTTTCC GAGGAGTACAATACGAGTAACCCAGACCTCCTGCTGGTTATTTTCCAGGT AACCGGCATCAGTTTGTTGCCCCCACTGGGTGTTGCAATCAGTGTAATAA TCATATTTTATTGTTACCGGGTG amino acid sequence of TGFBRIIdn SEQ ID NO: 110 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQL CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRV 

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO:
 78. 2.-13. (canceled)
 14. A chimeric antigen receptor (CAR) encoded by the isolated nucleic acid molecule of claim
 1. 15.-23. (canceled)
 24. A vector comprising a nucleic acid molecule of claim
 1. 25. The vector of claim 24, wherein the vector is selected from the group consisting of a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpes virus vector, a measles virus vector, a lentivirus vector, an adenoviral vector, a retrovirus vector, or a combination thereof.
 26. The vector of claim 24, further comprising a promoter.
 27. The vector of claim 26, wherein the promoter is an inducible promoter, a constitutive promoter, a tissue specific promoter, a suicide promoter or any combination thereof.
 28. A cell comprising the vector of claim
 24. 29. The cell of claim 28, wherein the cell is a T cell.
 30. The cell of claim 28, wherein the T cell is a CD8⁺ T cell.
 31. The cell of claim 28, wherein the cell is a human cell.
 32. A method of making a cell comprising transducing a T cell with a vector of claim
 24. 33. A method of generating a population of RNA-engineered cells comprising introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises a nucleic acid molecule of claim
 1. 34. A method of providing an anti-tumor immunity in a mammal comprising administering to the mammal an effective amount of a cell of claim
 28. 35. (canceled)
 36. A pharmaceutical composition comprising an anti-tumor effective amount of a population of human T cells, wherein the T cells comprise a nucleic acid sequence that encodes the chimeric antigen receptor (CAR) of claim 14, and wherein the T cells are T cells of a human having a cancer.
 37. (canceled)
 38. The pharmaceutical composition of claim 36, wherein the T cells are T cells of a human having a hematological cancer.
 39. The pharmaceutical composition of claim 38, wherein the hematological cancer is leukemia or lymphoma.
 40. The pharmaceutical composition of claim 39, wherein the leukemia is acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CIVIL), chronic lymphocytic leukemia (CLL), acute lymphoblastic T cell leukemia (T-ALL), or acute lymphoblastic B cell leukemia (B-ALL).
 41. The pharmaceutical composition of claim 39, wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
 42. The pharmaceutical composition of claim 38, wherein the hematological cancer is multiple myeloma.
 43. The pharmaceutical composition of claim 36, wherein the human cancer is an oral and pharynx cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric cancer, a cancer of the central nervous system a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system a cancer of the brain, or a combination thereof.
 44. A method of treating a mammal having a disease, disorder or condition associated with an elevated expression of a tumor antigen, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes the chimeric antigen receptor (CAR) of claim 14, wherein the T cells are T cells of the subject having cancer. 45.-46. (canceled)
 47. A process for producing a chimeric antigen receptor-expressing cell, the process comprising introducing the isolated nucleic acid of claim 1 into a cell.
 48. The process for producing a chimeric antigen receptor-expressing cell according to claim 47, wherein the cell is a T cell or a cell population containing a T cell. 